

APPENDIX

Appendix Table of Contents

List of Tables	2
Data and Methods	4
Data Sources	4
Unit of Analysis	4
Outcomes	5
Key Variables	8
Data Analysis	9
2010 Physician Quality Reporting System Appendix Tables	10
2010 eRx Incentive Program Appendix Tables	144

List of Tables

Table A1.	List of Individual Measure Numbers and Descriptions for the Physician Quality Reporting System (2010).	11
Table A2.	Distribution of Incentive Amounts by Specialty for the Physician Quality Reporting System (2010).	19
Table A3.	Potential Incentives and Participation Information by Specialty for the Physician Quality Reporting System (2010).	22
Table A4.	Eligible Professional Characteristics for the Physician Quality Reporting System (2010).	24
Table A5.	Number of Eligible Professionals by Specialty for the Physician Quality Reporting System (2007 to 2010).	26
Table A6.	Participation by Reporting Option for the Physician Quality Reporting System (2007 to 2010).	28
Table A7.	Eligible Professionals who Participated in the Physician Quality Reporting System, by Specialty (2007 to 2010).	29
Table A8.	Eligible Professionals who Participated by Reporting Individual Measures through the Claims Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).	32
Table A9.	Eligible Professionals who Participated by Reporting Measures Groups through the Claims Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).	35
Table A10.	Eligible Professionals who Participated by Reporting Individual Measures through the Registry Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).	38
Table A11.	Eligible Professionals who Participated by Reporting Measures Groups through the Registry Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).	41
Table A12.	Eligible Professionals, Participation, and Incentive Information for the Physician Quality Reporting System, by State (2010).	44
Table A13.	Submission Information for Individual Measures Submitted through the Claims Reporting Option for the Physician Quality Reporting System (2010).	46
Table A14.	Individual Measures Submitted through the Claims Reporting Option for the Physician Quality Reporting System Where More than 20% of Reported Instances did not Include the Necessary Diagnosis Code (2010).	57
Table A15.	Individual Measures Submitted through the Claims Reporting Option for the Physician Quality Reporting System Where More than 20% of Reported Instances did not Include the Necessary Procedure Code (2010).	58
Table A16.	Individual Measures Submitted through the Claims Reporting Option for the Physician Quality Reporting System Where More than 20% of Reported Instances were for a Patient that did not Meet the Necessary Age Range (2010).	59
Table A17.	Incentive Eligibility Information by Reporting Option for the Physician Quality Reporting System (2007 to 2010).	60
Table A18.	Eligible Professionals who Qualified for an Incentive from Individual Measures through the Claims Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).	61

Table A19.	Eligible Professionals who Qualified for an Incentive from Measures Groups through the Claims Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).	64
Table A20.	Eligible Professionals who Qualified for an Incentive from Individual Measures through the Registry Reporting Option by Specialty for the Physician Quality Reporting System (2007 to 2010).	67
Table A21.	Eligible Professionals who Qualified for an Incentive from Measures Groups through the Registry Reporting Option by Specialty for the Physician Quality Reporting System (2007 to 2010).	70
Table A22.	Eligible Professional Eligibility and Participation Information by Individual Measure for the Physician Quality Reporting System (2007 to 2010).	73
Table A23.	Reporting and Performance Information by Individual Measure for the Physician Quality Reporting System (2007 to 2010).	86
Table A24.	Eligible Professional Individual Measure Reporting Consistency Across Program Years for the Physician Quality Reporting System (2007 to 2010).	98
Table A25.	Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for 4 Years for the Physician Quality Reporting System (2007 to 2010).	111
Table A26.	Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for 3 Years for the Physician Quality Reporting System (2008 to 2010).	116
Table A27.	Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for 2 Years for the Physician Quality Reporting System (2009 to 2010).	123
Table A28.	Percent of Eligible Professionals who had at Least a 90% Performance Rate for Individual Measures in the Physician Quality Reporting System (2010).	133
Table A29.	Performance Information for Measures Reported by Practices Participating in the Group Practice Reporting Option for the Physician Quality Reporting System (2010).	142
Table A30.	Distribution of Incentive Amounts by Specialty for the eRx Incentive Program (2010).	145
Table A31.	Potential Incentives and Participation Information by Specialty for the eRx Incentive Program (2010).	148
Table A32.	Eligible Professional Information by Specialty for the eRx Incentive Program (2009 to 2010).	150
Table A33.	Eligible Professionals who Qualified for an Incentive from the eRx Incentive Program (2009 to 2010).	152
Table A34.	Eligible Professional Characteristics for the eRx Incentive Program (2010).	154
Table A35.	Eligible Professional Information by State for the eRx Incentive Program (2010).	156
Table A36.	Eligible Professionals who Successfully met Reporting Criteria but did not Qualify for an Incentive Because they did not have at Least 10% of their PFS Charges from Instances for the eRx Measure (i.e., Incentive Eligibility Threshold) for the eRx Incentive Program (2009 to 2010).	158

DATA AND METHODS

This section describes the data and methods used in the “2010 Physician Quality Reporting System and Electronic Prescribing (eRx) Incentive Program Reporting Experience Including Trends (2007-2011)” report.

Data Sources

The report used multiple sources of data: (1) Medicare Part B claims data, (2) data submitted by qualified registries, (3) data submitted from a qualified EHR vendor and (4) data submitted by practices that were approved to participate in the GPRO.

Claims data encompassed services within the respective program years and must have been processed by the last Friday in February of the following year to be included in analyses. For example, the 2010 program year—for both the Physician Quality Reporting System and the eRx Incentive Program—encompassed claims with service dates from January 1, 2010 through December 31, 2010 and processed no later than February 25, 2011. To provide preliminary information for the 2011 program year, the available information encompassed only service dates from January 1, 2011 through June 24, 2011 and processed no later than June 24, 2011. Similar to claims data, data collected from the registry, EHR, and GPRO reporting options aligns with the program year and must have been received by CMS by the established deadline, which has been near the end of March of the following year. For example, the 2010 program year encompassed services between January 1, 2010 and December 31, 2010; data submitted by registry or EHR had to be received no later than March 31, 2011 and GPROs submitted data no later than March 29, 2011. Therefore, no preliminary information was available for the 2011 program year from the registry, EHR, or GPRO methods; that is, preliminary information for the 2011 program year included claims information only.

Information on physician specialty and location were obtained from the National Plan and Provider Enumeration System (NPPES), which is publicly available data and downloadable from the CMS website.¹

Unit of Analysis

The most common unit of analysis for the Physician Quality Reporting System and eRx Incentive Program was the individual eligible professional. An eligible professional was defined by the National Provider Identifier number (NPI) within a billing unit (i.e., the taxpayer identification number [TIN]); the NPI was the *performing* NPI.² All analyses regarding individual eligibility, participation and incentive eligibility were performed at the NPI level within a TIN (referred to as TIN/NPI). Consequently, a single eligible professional could be

¹ http://nppes.viva-it.com/NPI_Files.html

² There are multiple NPIs associated with a service (performing, referring, and ordering); the performing NPI identifies the eligible professional who actually performed the service.

counted more than once if he/she worked for multiple practices (i.e., single NPI and more than one TIN).

An additional unit of analysis was at the group practice level, which was defined by a TIN. Practices that participated in the GPRO were analyzed at the practice (i.e., TIN) level. In addition to summarizing GPRO information at the TIN level, this report also aggregates information from individual eligible professionals to the practice (TIN) level for descriptive purposes. For these descriptions, a practice was defined as eligible, participated, or incentive eligible if at least one eligible professional associated with that practice was eligible, participated, or incentive eligible at the individual-level, respectively.

Certain sections of this report also described counts of individual eligible professionals within a practice that participated in the GPRO. For example, some tables and figures that describe results for individual eligible professionals also include the number of eligible professionals within participating GPROs; this is noted in the appropriate titles and footnotes. However, please note that not all of these individual eligible professionals necessarily participated in the program (that is, they might not have had an eligible instance).

Outcomes

The report summarized the following outcomes:

1. *Program eligibility.* A professional was defined as eligible to participate in the Physician Quality Reporting System or the eRx Incentive Program if he/she had at least one Medicare Part B physician fee schedule (PFS) professional services claim that contained the denominator criteria of the applicable quality measure for any Physician Quality Reporting System measure or the eRx measure, respectively. In addition, anyone who participated through the registry or EHR reporting options was defined as eligible to participate in the program—regardless of whether they had a qualifying claim—because eligibility information was not available from registry or EHR data. These reporting options can use clinical information to identify eligible instances on which to report that is not available in and therefore cannot be verified by claims information. Therefore, participation was used as a proxy for eligibility for these reporting options.

Eligible GPROs were practices (TINs) that applied and met requirements for participation. A practice could participate through the GPRO under the Physician Quality Reporting System and the eRx Incentive Program. However, a practice could not participate through the GPRO in the eRx Incentive Program alone; they were required to also participate in the Physician Quality Reporting System through the GPRO.³ A practice could participate in the Physician Quality Reporting System alone. Eligible professionals were not eligible to participate independently in the Physician Quality Reporting System or the eRx Incentive Program if they were associated with a GPRO that participated in that program.

³ There was one exception to this statement; several practices that were part of a pilot program participated through the GPRO in the eRx Incentive Program and not the Physician Quality Reporting System.

2. *Program participation.* Eligible professionals were defined as participating if they had a completely valid submission through claims or a valid submission from a qualified registry or EHR. To participate through the claims reporting option, eligible professionals submitted the specified quality data code(s) (QDC) for a given measure on a Medicare Part B professional services claim that met the denominator criteria for that measure. QDCs indicate that a specific quality action or outcome was or was not met, or that exclusion criteria for the measure were met. QDCs are entered as a procedure code on a line item on the claim. For example, a measure could require a specific combination of diagnosis, procedure codes, and beneficiary age to be an ‘eligible instance’ for a certain measure; to report the measure validly, the eligible professional had to submit the required QDC(s) on line items for that claim. If an eligible professional submitted only one valid QDC for a measure that required two QDCs, that instance did not count as participating. Please note, the program defined participation slightly differently in the 2007 and 2008 program years; an eligible professional was defined as participating in those years if they submitted any QDC for the measure.

To report measures groups through the claims reporting option, eligible professionals submitted a QDC indicating intent to submit measures group information on one claim during the reporting period. The eligible professional had to then report the specified QDCs for each measure in the specific measure group. Alternatively, an eligible professional could submit one ‘composite’ QDC specified for that measure group indicating that all quality actions in the measure group had been performed for that patient.

To report measures through the registry and EHR reporting options, eligible professionals submitted performance data for each measure—such as number of eligible instances (denominator), instances of quality service performed (numerator), number of performance exclusions, reporting rates and performance rates—in a file format specified by CMS.

A practice was defined as participating in the GPRO for the Physician Quality Reporting System if the practice submitted data on the GPRO quality measures for an assigned sample of patients through a web-based tool provided by CMS. A practice was defined as participating in the GPRO for the eRx Incentive Program if they had a valid submission of the eRx quality code through claims, or the required summary information through a registry or EHR.

3. *Incentive eligibility.* An individual eligible professional was defined as incentive eligible for the 2010 Physician Quality Reporting System if they met the criteria for incentive eligibility through at least one individual reporting option. The two basic criteria were:
 - a. 80% Method: An eligible professional could report at least 80% of eligible instances for at least 3 individual measures; this criterion applied to the individual measures methods for the claims, registry, and EHR methods. For the claims method only, an eligible professional could earn an incentive by reporting 1 or 2 measures (i.e., less than 3) in at least 80% of eligible instances if the MAV process was passed; the MAV process checked to ensure it was acceptable for an eligible professional to report less than 3 measures (e.g., only 1 or 2 measures

were applicable). In addition, an eligible professional could report all applicable measures on at least 80% of applicable Medicare Part B FFS patients for at least one measures group. For both the individual measures and measures groups reporting, eligible professionals could choose a 12-month reporting period (January 1, 2010 through December 31, 2010) or a 6-month reporting period (July 1, 2010 through December 31, 2010). Participants reporting individual measures via EHR used a 12-month reporting period.

- b. 30 Patient Method: An eligible professional could report at least one measures group for at least 30 patients; this criterion applied to the claims and registry options. The claims-based option required all Medicare Part B FFS patients, while for the registry options patients could include some, but not be exclusively, non-Medicare patients. Participants using the 30-patient method for the claims or registry options used a 12-month reporting period (January 1, 2010 through December 31, 2010).

A practice that participated in the GPRO for the 2010 Physician Quality Reporting System was defined as incentive eligible if they met the reporting criteria. The GPRO required a practice report on the first 411 preselected Medicare patients for each GPRO measure or on all eligible patients for a measure where fewer than 411 were available.

An eligible professional was defined as incentive eligible for the 2010 eRx Incentive Program if: 1) they correctly reported the eRx quality measure in at least 25 instances; and 2) during the reporting period, the allowed charges for Medicare Part B covered professional services furnished by the eligible professional for the codes that appear in the eRx quality measure denominator were at least 10% of the total allowed part B charges for all such covered professional services furnished by the eligible professional. A practice that participated in the GPRO for the 2010 eRx Incentive Program was defined as incentive eligible if: 1) they correctly reported at least 2,500 instances; and 2) during the reporting period, the allowed charges for Medicare Part B covered professional services furnished by the practice for the codes that appear in the eRx quality measure denominator were at least 10% of the total allowed part B charges for all such covered professional services furnished by the practice.

The above incentive eligibility criteria applied to the 2010 program year; criteria for preceding program years differed for some reporting options. For example, the 30 patient reporting option in the 2009 Physician Quality Reporting System required 30 consecutive patients. For the 2009 eRx Incentive Program, incentive eligibility required reporting of the eRx quality measure for at least 50% of eligible instances. Incentive eligibility for past program years was defined in accordance with the criteria established for those program years.

Finally, eligible professionals who met incentive eligibility criteria under the Physician Quality Reporting System but had no Medicare Part B Physician Fee Schedule charges had an incentive amount of \$0.00. For example, some eligible professionals who participated through a registry and reported at least 80% of eligible instances on at least 3 measures (i.e., met reporting criteria) were found to have no eligible Medicare claims. This was potentially caused by an eligible professional or the registry providing an

incorrect TIN or NPI. These professionals were not included in counts of eligible professionals who qualified for an incentive.

4. *Incentive amounts.* Eligible professionals (or group practice) who were incentive eligible qualified for an incentive payment that was a percentage of their estimated Medicare Part B PFS allowed charges for covered professional services furnished by the eligible professional (or group practice) during the reporting period. The applicable incentive percentage was 2% for the 2010 Physician Quality Reporting System and 2% for the 2010 eRx Incentive Program. The incentive percentages differed in previous program years. The incentive percentage was 2% for the Physician Quality Reporting System and the eRx Incentive Program in 2009 and 2010. The applicable percentage was 1.5% for the Physician Quality Reporting System in 2007 and 2008.
5. *Measure Performance.* For the Physician Quality Reporting System, performance on a measure was calculated as the number of times the eligible professional reported that the recommended quality action for that measure was performed (numerator), divided by the number of instances they could have performed the quality action (denominator), multiplied by 100. For example, under claims-based reporting options, the numerator was the number of times the eligible professional reported the measure-specific QDC indicating the quality action was met and the denominator was the number of eligible instances for that measure identified through claims. Instances that did not apply (i.e., reported as exclusions) were not included in the performance denominator. The following hierarchy was used if an eligible professional participated through more than one reporting option: EHR, claims, and then registry. Applying the hierarchy ensured only one performance rate for each measure for an eligible professional; information could not be combined across reporting methods.

Please note, multiple factors should be considered when interpreting performance trends. For example, there have been many changes within the Physician Quality Reporting System across program years that include changes in participation methods, measures, and the eligible professionals who participated. As a result, it is unclear the extent that any observed changes in performance were genuine or artifacts of the aforementioned changes.

Key Variables

The analysis examined outcomes by several eligible professional and practice characteristics.

- *Specialty (TIN/NPI level only).* The specialty for eligible professionals was obtained from the NPPES. Specialty in the NPPES was self-designated by the professionals and could contain multiple specialties for the same professional. The primary specialty was used in cases where it was designated by the professional. If there was no primary designation, the first specialty was selected to allow assigning of an eligible professional to a single specialty category. Some specialty codes were grouped for efficiency of data presentation.

- *Reporting Option (TIN and TIN/NPI levels)*. There were eleven individual reporting options for the 2010 Physician Quality Reporting System and three individual reporting options for the 2010 eRx Incentive Program. Additionally, practices could participate in the 2010 Physician Quality Reporting System and the 2010 eRx Incentive Program through the GPRO. Some analyses combined reporting options such as the time periods (e.g., 6- and 12-month methods).
- *State and Region*. The state for eligible professionals was obtained from NPPES. U.S. Census Bureau Regions were used.
- *Practice Size (TIN/NPI level only)*. This variable was the number of eligible professionals within the practice who were defined as eligible and therefore could have participated in the Physician Quality Reporting System or the eRx Incentive Program.
- *Beneficiary Volume (TIN and TIN/NPI levels)*. This variable was a unique count of Medicare beneficiaries who were identified as having an eligible claim for at least one Physician Quality Reporting System measure on which an eligible professional could have reported or who had at least one eligible claim on which an eligible professional could have reported the eRx measure for the eRx Incentive Program. Beneficiaries were identified by a health insurance claim (HIC) number. Beneficiary information was not available from the registry or EHR methods. Registry information was reported to CMS aggregated to individual eligible professionals and the patient identifier available in the EHR method was not linkable to the claims-based HIC number.
- *Eligible Measures (TIN/NPI level only)*. The number of measures the eligible professional could have reported (i.e., treated at least one beneficiary who qualified for the measure) was the sum of the count of individual measures identified as eligible in claims and the count of registry-only measures the eligible professional reported; eligibility information was not available for the registry or EHR options.

Data Analysis

Cross-tabulations were used to illustrate bivariate relationships between eligible professional or practice characteristics and the key outcomes of interest (e.g., eligibility, participation, and incentive eligibility). Tables commonly presented frequencies (i.e., counts) and percents. Note that summing counts across participation options or across tables do not equal unduplicated totals due to eligible professionals who participated in multiple options.

2010 PHYSICIAN QUALITY REPORTING SYSTEM APPENDIX TABLES

Table A1. List of Individual Measure Numbers and Descriptions for the Physician Quality Reporting System (2010).

Measure Number	Measure Description
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus ^c
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a
6	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ^{a, b}
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage

Measure Number	Measure Description
32	Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge ^{a, b}
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia
36	Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility ^b
47	Advance Care Plan
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy
53	Asthma: Pharmacologic Therapy
54	12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain
55	12-Lead Electrocardiogram (ECG) Performed for Syncope
56	Community-Acquired Pneumonia (CAP): Vital Signs
57	Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation
58	Community-Acquired Pneumonia (CAP): Assessment of Mental Status
59	Community-Acquired Pneumonia (CAP): Empiric Antibiotic
64	Asthma: Asthma Assessment

Measure Number	Measure Description
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use
66	Appropriate Testing for Children with Pharyngitis
67	Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
68	Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
69	Multiple Myeloma: Treatment with Bisphosphonates
70	Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol
79	End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD
81	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients ^{a, b}
82	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis ^{a, b}
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia ^a
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
85	Hepatitis C: HCV Genotype Testing Prior to Treatment
86	Hepatitis C: Antiviral Treatment Prescribed
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy
91	Acute Otitis Externa (AOE): Topical Therapy
92	Acute Otitis Externa (AOE): Pain Assessment
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use
94	Otitis Media with Effusion (OME): Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade

Measure Number	Measure Description
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy
106	Major Depressive Disorder (MDD): Diagnostic Evaluation
107	Major Depressive Disorder (MDD): Suicide Risk Assessment
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
109	Osteoarthritis (OA): Function and Pain Assessment
110	Preventive Care and Screening: Influenza Immunization for Patients \geq 50 Years Old
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
112	Preventive Care and Screening: Screening Mammography
113	Preventive Care and Screening: Colorectal Cancer Screening
114	Preventive Care and Screening: Inquiry Regarding Tobacco Use
115	Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) ^a
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients
121	Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)
122	Chronic Kidney Disease (CKD): Blood Pressure Management
123	Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation

Measure Number	Measure Description
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
130	Documentation and Verification of Current Medications in the Medical Record
131	Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up
134	Screening for Clinical Depression and Follow-Up Plan
135	Chronic Kidney Disease (CKD): Influenza Immunization
136	Melanoma: Follow-Up Aspects of Care ^a
137	Melanoma: Continuity of Care – Recall System ^a
138	Melanoma: Coordination of Care ^a
139	Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications
143	Oncology: Medical and Radiation – Pain Intensity Quantified ^a
144	Oncology: Medical and Radiation – Plan of Care for Pain ^a
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening ^c
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy
153	Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula
154	Falls: Risk Assessment
155	Falls: Plan of Care
156	Oncology: Radiation Dose Limits to Normal Tissues
157	Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage ^{a, b}

Measure Number	Measure Description
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis ^{a, b}
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy ^{a, b}
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy ^{a, b}
163	Diabetes Mellitus: Foot Exam
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation) ^{a, b, c}
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate ^{a, b, c}
166	Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA) ^{a, b, c}
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency ^{a, b, c}
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration ^{a, b, c}
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge ^{a, b}
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge ^{a, b}
171	Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling ^{a, b}
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening
175	Pediatric End Stage Renal Disease (ESRD): Influenza Immunization
176	Rheumatoid Arthritis (RA): Tuberculosis Screening
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
178	Rheumatoid Arthritis (RA): Functional Status Assessment
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
180	Rheumatoid Arthritis (RA): Glucocorticoid Management
181	Elder Maltreatment Screen and Follow-Up Plan
182	Functional Outcome Assessment in Chiropractic Care
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV

Measure Number	Measure Description
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
186	Wound Care: Use of Compression System in Patients with Venous Ulcers
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy ^a
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear
189	Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss
191	Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery ^a
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures ^{a, c}
193	Perioperative Temperature Management
194	Oncology: Cancer Stage Documented
195	Stenosis Measurement in Carotid Imaging Studies
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment ^a
197	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol ^a
198	Heart Failure: Left Ventricular Function (LVF) Assessment ^a
199	Heart Failure: Patient Education ^a
200	Heart Failure: Warfarin Therapy Patients with Atrial Fibrillation ^a
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control
202	Ischemic Vascular Disease (IVD): Complete Lipid Profile
203	Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea ^a
206	HIV/AIDS: Screening for High Risk Sexual Behaviors ^a
207	HIV/AIDS: Screening for Injection Drug Use ^a
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis ^a

Measure Number	Measure Description
209	Functional Communication Measure - Spoken Language Comprehension ^a
210	Functional Communication Measure - Attention ^a
211	Functional Communication Measure - Memory ^a
212	Functional Communication Measure - Motor Speech ^a
213	Functional Communication Measure - Reading ^a
214	Functional Communication Measure - Spoken Language Expression ^a
215	Functional Communication Measure - Writing ^a
216	Functional Communication Measure - Swallowing ^a

Notes for Table A1: ^a Measure was not reportable via claims (e.g., registry only) during the 2010 program year (Measures 5, 7, 8, 33, 81, 82, 83, 118, 136, 137, 138, 143, 144, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 174, 187, 191, 192, 196, 197, 198, 199, 200, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and 216). ^b Measure was not reportable via claims (e.g., registry only) during the 2009 program year (Measures 7, 33, 46, 81, 82, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171 and 174). ^c Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 146, 164, 165, 166, 167, 168 and 192).

Table A2. Distribution of Incentive Amounts by Specialty for the Physician Quality Reporting System (2010).

Specialty	Eligible Professionals who Qualified for Incentive	Incentive Amount					Percent of National Total
		Minimum	Maximum	Mean	Median	Total	
MD/DO	128,942	\$0.13	\$125,792.80	\$2,519.87	\$1,364.14	\$324,916,761.13	89.2%
Allergy/Immunology	262	\$5.25	\$13,114.03	\$1,131.69	\$653.33	\$296,502.68	0.1%
Anesthesiology	12,871	\$1.14	\$21,122.77	\$772.91	\$635.69	\$9,948,127.81	2.7%
Cardiology	6,798	\$0.49	\$62,655.15	\$6,582.86	\$5,642.26	\$44,750,285.16	12.3%
Colon/Rectal Surgery	148	\$59.05	\$6,403.08	\$2,230.43	\$1,887.04	\$330,104.21	0.1%
Critical Care	231	\$17.47	\$12,335.68	\$2,575.83	\$1,994.78	\$595,016.46	0.2%
Dermatology	1,451	\$3.51	\$71,512.06	\$7,462.06	\$4,910.12	\$10,827,445.24	3.0%
Emergency Medicine	27,772	\$1.24	\$16,106.34	\$1,186.53	\$970.65	\$32,952,408.21	9.0%
Endocrinology	1,041	\$3.92	\$11,508.49	\$1,733.09	\$1,224.67	\$1,804,151.21	0.5%
Family Practice	17,685	\$0.19	\$36,539.40	\$1,313.36	\$887.99	\$23,226,764.97	6.4%
Gastroenterology	1,616	\$3.35	\$16,382.05	\$2,751.65	\$2,390.54	\$4,446,665.97	1.2%
General Practice	346	\$1.40	\$16,404.17	\$1,450.77	\$837.04	\$501,965.11	0.1%
General Surgery	2,413	\$0.76	\$26,220.99	\$2,150.82	\$1,641.43	\$5,189,939.73	1.4%
Geriatrics	580	\$0.48	\$17,351.26	\$2,686.09	\$1,921.91	\$1,557,929.79	0.4%
Hand Surgery	174	\$18.83	\$9,658.05	\$2,296.73	\$1,840.24	\$399,631.71	0.1%
Infectious Disease	572	\$2.29	\$21,742.66	\$2,453.45	\$1,389.83	\$1,403,371.90	0.4%
Internal Medicine	15,844	\$0.19	\$34,604.87	\$2,226.27	\$1,537.27	\$35,273,041.06	9.7%
Interventional Radiologist	306	\$3.90	\$45,509.37	\$3,973.06	\$2,904.51	\$1,215,755.75	0.3%
Nephrology	1,894	\$1.28	\$56,972.10	\$6,270.47	\$5,638.90	\$11,876,279.49	3.3%
Neurology	1,238	\$1.30	\$22,757.71	\$1,934.16	\$1,350.80	\$2,394,486.37	0.7%
Neurosurgery	607	\$3.07	\$28,176.34	\$3,239.23	\$2,546.64	\$1,966,210.90	0.5%
Nuclear Medicine	123	\$27.80	\$28,619.59	\$3,224.12	\$1,504.15	\$396,567.07	0.1%
Obstetrics/Gynecology	2,083	\$0.55	\$11,361.82	\$542.32	\$226.82	\$1,129,652.22	0.3%
Oncology/Hematology	1,895	\$1.30	\$41,008.15	\$5,225.71	\$4,241.66	\$9,902,713.06	2.7%
Ophthalmology	5,216	\$0.49	\$81,073.27	\$7,750.95	\$6,182.11	\$40,428,951.96	11.1%

Specialty	Eligible Professionals who Qualified for Incentive	Incentive Amount					Percent of National Total
		Minimum	Maximum	Mean	Median	Total	
Oral/Maxillofacial Surgery	6	\$64.57	\$2,834.70	\$659.27	\$287.00	\$3,955.63	0.0%
Orthopedic Surgery	3,298	\$0.57	\$32,130.22	\$3,838.25	\$3,173.79	\$12,658,551.29	3.5%
Other MD/DO	879	\$1.35	\$21,336.57	\$2,176.22	\$1,285.52	\$1,912,900.63	0.5%
Otolaryngology	1,003	\$2.25	\$17,089.29	\$2,280.98	\$1,829.03	\$2,287,826.51	0.6%
Pathology	3,354	\$3.22	\$27,509.80	\$1,563.89	\$1,277.40	\$5,245,275.68	1.4%
Pediatrics	352	\$0.13	\$9,278.62	\$460.84	\$91.37	\$162,216.03	0.0%
Physical Medicine	505	\$14.05	\$22,292.46	\$2,445.89	\$1,683.20	\$1,235,176.47	0.3%
Plastic Surgery	250	\$0.77	\$13,239.22	\$1,432.96	\$923.18	\$358,240.61	0.1%
Psychiatry	425	\$1.30	\$7,242.37	\$599.35	\$290.17	\$254,724.98	0.1%
Pulmonary Disease	1,204	\$3.56	\$23,931.31	\$3,639.91	\$2,966.03	\$4,382,455.19	1.2%
Radiation Oncology	560	\$0.90	\$125,792.80	\$12,704.38	\$4,382.23	\$7,114,453.76	2.0%
Radiologist	9,461	\$0.60	\$119,863.60	\$2,811.39	\$2,104.63	\$26,598,572.06	7.3%
Rheumatology	994	\$1.28	\$52,826.61	\$3,515.70	\$2,640.73	\$3,494,602.22	1.0%
Thoracic/Cardiac Surgery	1,114	\$4.45	\$20,126.77	\$4,270.53	\$3,823.51	\$4,757,369.64	1.3%
Urology	1,752	\$1.28	\$43,990.58	\$4,583.05	\$3,912.59	\$8,029,511.27	2.2%
Vascular Surgery	619	\$1.93	\$55,944.96	\$5,827.08	\$4,599.21	\$3,606,961.11	1.0%
Other Eligible Professionals	39,838	\$0.15	\$119,022.49	\$986.14	\$370.48	\$39,285,987.66	10.8%
Agencies/Hospitals/Nursing and Treatment Facilities	159	\$4.45	\$17,639.70	\$1,363.81	\$536.82	\$216,845.01	0.1%
Audiologist	129	\$0.80	\$1,330.92	\$183.46	\$121.22	\$23,666.09	0.0%
Certified Nurse Midwives	79	\$0.56	\$526.41	\$29.38	\$10.68	\$2,320.65	0.0%
Chiropractor	215	\$0.48	\$2,320.74	\$343.61	\$202.70	\$73,877.20	0.0%
Clinical Nurse Specialists	142	\$1.66	\$4,655.39	\$444.79	\$261.06	\$63,160.75	0.0%
Counselor/Psychologist	272	\$1.59	\$14,010.28	\$580.62	\$225.40	\$157,928.85	0.0%
Dentist	15	\$30.07	\$2,531.71	\$331.41	\$88.29	\$4,971.15	0.0%
Dietitian/Nutritionist	134	\$0.84	\$859.66	\$100.22	\$63.45	\$13,429.02	0.0%
Nurse Anesthetist	9,549	\$0.86	\$3,149.39	\$380.94	\$295.98	\$3,637,642.59	1.0%
Nurse Practitioner	6,520	\$0.15	\$8,663.92	\$454.74	\$252.66	\$2,964,932.26	0.8%

Specialty	Eligible Professionals who Qualified for Incentive	Incentive Amount					Percent of National Total
		Minimum	Maximum	Mean	Median	Total	
Optometry	3,058	\$1.29	\$22,413.63	\$1,107.59	\$599.54	\$3,387,013.49	0.9%
Other Eligible Professional	6,263	\$0.79	\$119,022.49	\$3,089.80	\$1,400.79	\$19,351,424.62	5.3%
Physical/Occupational Therapy	3,342	\$1.44	\$14,421.50	\$1,157.46	\$741.16	\$3,868,240.38	1.1%
Physician Assistant	8,586	\$0.33	\$12,152.36	\$399.23	\$251.31	\$3,427,805.75	0.9%
Podiatrist	706	\$2.35	\$18,277.29	\$2,589.90	\$2,069.10	\$1,828,466.86	0.5%
Registered Nurse	525	\$0.80	\$11,124.86	\$444.85	\$268.16	\$233,544.63	0.1%
Social Worker	144	\$2.27	\$2,522.97	\$213.32	\$124.80	\$30,718.35	0.0%
<i>Unknown/Missing</i>	63	\$0.84	\$7,716.45	\$826.27	\$203.75	\$52,054.85	0.0%
Total (Unduplicated)	168,843	\$0.13	\$125,792.80	\$2,157.36	\$1,026.11	\$364,254,803.63	100.0%

Notes for Table A2: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A3. Potential Incentives and Participation Information by Specialty for the Physician Quality Reporting System (2010).

Specialty	Average Potential Incentive per Eligible Professional	% of Eligible Professionals who Participated
MD/DO	\$2,086.44	29.1%
Allergy/Immunology	\$1,087.52	11.0%
Anesthesiology	\$907.33	47.9%
Cardiology	\$5,292.12	36.7%
Colon/Rectal Surgery	\$2,227.57	25.1%
Critical Care	\$2,351.87	18.0%
Dermatology	\$4,760.73	16.9%
Emergency Medicine	\$1,071.12	65.6%
Endocrinology	\$1,645.09	27.0%
Family Practice	\$1,185.59	26.1%
Gastroenterology	\$2,748.47	21.8%
General Practice	\$1,136.40	8.4%
General Surgery	\$1,783.15	17.7%
Geriatrics	\$2,277.53	21.8%
Hand Surgery	\$2,032.84	16.2%
Infectious Disease	\$2,306.80	16.1%
Internal Medicine	\$1,994.27	24.6%
Interventional Radiologist	\$3,735.36	39.4%
Nephrology	\$4,922.29	30.0%
Neurology	\$1,990.20	16.6%
Neurosurgery	\$2,628.21	19.4%
Nuclear Medicine	\$2,992.97	23.8%
Obstetrics/Gynecology	\$389.08	11.6%
Oncology/Hematology	\$3,301.72	30.3%
Ophthalmology	\$5,303.49	43.1%
Oral/Maxillofacial Surgery	\$311.07	3.8%
Orthopedic Surgery	\$2,937.82	23.0%
Other MD/DO	\$1,827.48	16.0%
Otolaryngology	\$2,003.43	17.6%
Pathology	\$1,606.90	61.5%
Pediatrics	\$194.58	10.8%
Physical Medicine	\$2,236.53	10.0%
Plastic Surgery	\$1,230.27	8.5%
Psychiatry	\$704.03	2.7%
Pulmonary Disease	\$3,533.05	21.5%

Specialty	Average Potential Incentive per Eligible Professional	% of Eligible Professionals who Participated
Radiation Oncology	\$8,038.72	22.4%
Radiologist	\$2,654.21	40.2%
Rheumatology	\$2,420.38	33.7%
Thoracic/Cardiac Surgery	\$3,350.30	43.5%
Urology	\$3,670.38	31.3%
Vascular Surgery	\$4,564.45	29.4%
Other Eligible Professionals	\$797.52	15.9%
Agencies/Hospitals/Nursing and Treatment Facilities	\$3,487.99	8.7%
Audiologist	\$181.46	3.5%
Certified Nurse Midwives	\$21.47	10.7%
Chiropractor	\$307.25	1.2%
Clinical Nurse Specialists	\$424.42	10.7%
Counselor/Psychologist	\$420.62	1.7%
Dentist	\$191.97	0.9%
Dietitian/Nutritionist	\$80.32	8.1%
Nurse Anesthetist	\$377.74	34.7%
Nurse Practitioner	\$404.59	18.7%
Optometry	\$608.73	22.9%
Other Eligible Professional	\$2,615.13	21.5%
Physical/Occupational Therapy	\$1,111.69	16.1%
Physician Assistant	\$377.85	26.7%
Podiatrist	\$2,074.13	10.5%
Registered Nurse	\$406.92	20.4%
Social Worker	\$197.55	0.8%
<i>Unknown/Missing</i>	\$607.49	13.6%
Total (Unduplicated)	\$1,586.50	24.0%

Notes for Table A3: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A4. Eligible Professional Characteristics for the Physician Quality Reporting System (2010).

Characteristics	Eligible Professionals	Eligible Professionals who Participated		Eligible Professionals who Qualified for an Incentive	
		Count	% of Eligible Professionals	Count	% of Eligible Professionals who Participated
Reporting Option	--	--	--	--	--
Claims	1,017,664	201,567	19.8%	124,432	61.7%
Registry	1,017,664	56,214	5.5%	50,377	89.6%
EHR	1,017,664	14	0.0%	13	92.9%
Geography (Regions)	--	--	--	--	--
West	190,712	37,389	19.6%	26,064	69.7%
South	341,229	87,983	25.8%	60,474	68.7%
Midwest	237,450	67,473	28.4%	47,619	70.6%
Northeast	235,154	50,057	21.3%	33,857	67.6%
Other	12,139	1,110	9.1%	766	69.0%
Unknown	980	133	13.6%	63	47.4%
Number of Measures Eligible Professional was Eligible to Report	--	--	--	--	--
1 -5	266,851	64,031	24.0%	43,067	67.3%
6-15	244,859	51,299	21.0%	39,995	78.0%
16-30	251,089	51,228	20.4%	31,781	62.0%
>30	252,532	75,254	29.8%	53,921	71.7%
Unknown	2,333	2,333	100.0%	79	3.4%
Practice Size (# of NPIs)	--	--	--	--	--
1	222,651	11,420	5.1%	5,330	46.7%
2-4	130,705	18,130	13.9%	9,221	50.9%
5-10	114,489	24,037	21.0%	14,954	62.2%
>10	549,819	190,558	34.7%	139,338	73.1%

Characteristics	Eligible Professionals	Eligible Professionals who Participated		Eligible Professionals who Qualified for an Incentive	
		Count	% of Eligible Professionals	Count	% of Eligible Professionals who Participated
Beneficiary Volume	--	--	--	--	--
≤ 25	300,834	40,990	13.6%	31,846	77.7%
26 - 100	255,763	54,266	21.2%	37,516	69.1%
101 - 200	168,891	49,045	29.0%	33,531	68.4%
> 200	289,404	97,072	33.5%	65,833	67.8%
Unknown	2,772	2,772	100.0%	117	4.2%
Specialty	--	--	--	--	--
MD/DO	--	--	--	--	--
Primary Care	195,656	47,762	24.4%	34,227	71.7%
Surgery	60,680	12,793	21.1%	8,629	67.5%
Other Specialties	366,741	120,987	33.0%	86,086	71.2%
Other Eligible Professionals	--	--	--	--	--
Physicians	99,245	9,525	9.6%	3,994	41.9%
Physician Assistant	41,876	11,192	26.7%	8,586	76.7%
Nurses	96,848	24,514	25.3%	16,815	68.6%
Other Eligible Professionals	155,638	17,239	11.1%	10,443	60.6%
Unknown/Missing	980	133	13.6%	63	47.4%
Total (Unduplicated)	1,017,664	244,145	24.0%	168,843	69.2%

Notes for Table A4: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Sums across participation options do not equal totals due to participation in multiple options. (3) Results included the claims, registry and EHR reporting options.

Table A5. Number of Eligible Professionals by Specialty for the Physician Quality Reporting System (2007 to 2010).

Specialty	Eligible Professionals			
	2007	2008	2009	2010
MD/DO	477,381	601,733	621,051	623,077
Allergy/Immunology	3,092	3,520	3,463	3,418
Anesthesiology	15,043	40,727	42,360	42,125
Cardiology	20,124	22,799	23,287	23,768
Colon/Rectal Surgery	928	1,064	1,077	1,069
Critical Care	2,081	2,450	2,452	2,422
Dermatology	9,021	10,178	10,332	10,234
Emergency Medicine	40,030	48,171	49,508	49,278
Endocrinology	4,267	4,931	5,055	5,032
Family Practice	76,022	89,204	90,787	91,533
Gastroenterology	10,479	11,771	11,824	11,959
General Practice	4,974	5,904	5,759	5,883
General Surgery	18,089	21,445	21,871	21,595
Geriatrics	3,365	3,977	4,044	4,055
Hand Surgery	1,225	1,399	1,434	1,530
Infectious Disease	4,267	4,982	5,082	5,084
Internal Medicine	75,074	89,559	92,373	92,424
Interventional Radiologist	960	1,256	1,373	1,364
Nephrology	6,729	7,690	7,790	7,997
Neurology	9,861	11,959	12,434	12,286
Neurosurgery	3,865	4,501	4,541	4,452
Nuclear Medicine	262	383	713	703
Obstetrics/Gynecology	22,876	29,330	29,592	29,727
Oncology/Hematology	9,524	10,741	10,864	10,762
Ophthalmology	16,983	18,925	18,990	18,917
Oral/Maxillofacial Surgery	282	383	376	370
Orthopedic Surgery	17,931	20,441	20,644	20,662
Other MD/DO	5,758	7,801	8,143	8,978
Otolaryngology	7,385	8,307	8,448	8,374
Pathology	203	7,816	7,705	7,722
Pediatrics	2,083	5,464	5,840	5,816
Physical Medicine	6,150	7,498	7,680	7,859
Plastic Surgery	3,475	4,159	4,250	4,303
Psychiatry	22,366	29,695	30,273	30,269
Pulmonary Disease	7,617	8,716	8,763	9,100
Radiation Oncology	3,457	4,301	4,491	4,448
Radiologist	24,220	30,553	37,242	37,511

Specialty	Eligible Professionals			
	2007	2008	2009	2010
Rheumatology	3,688	4,167	4,207	4,116
Thoracic/Cardiac Surgery	3,033	3,526	3,576	3,543
Urology	8,006	9,078	9,380	9,233
Vascular Surgery	2,586	2,962	3,028	3,156
Other Eligible Professionals	207,814	359,132	383,690	393,607
Agencies/Hospitals/Nursing and Treatment Facilities	2,742	2,930	3,130	3,262
Audiologist	50	135	5,923	6,073
Certified Nurse Midwives	358	1,048	1,136	1,166
Chiropractor	119	48,351	47,362	47,494
Clinical Nurse Specialists	1,277	1,738	1,967	2,074
Counselor/Psychologist	20,366	30,409	31,189	31,287
Dentist	2,448	3,327	3,349	3,281
Dietitian/Nutritionist	1,419	2,225	2,303	2,298
Nurse Anesthetist	5,244	37,443	40,314	41,199
Nurse Practitioner	26,814	38,670	44,309	48,603
Optometry	24,675	29,440	29,979	31,028
Other Eligible Professional	35,211	43,196	46,537	43,711
Physical/Occupational Therapy	27,219	35,927	37,794	39,769
Physician Assistant	25,856	35,443	38,638	41,876
Podiatrist	15,690	17,892	17,408	17,442
Registered Nurse	1,763	3,744	4,176	3,806
Social Worker	16,563	27,214	28,176	29,238
<i>Unknown/Missing</i>	3,134	3,331	2,092	980
Total (Unduplicated)	688,329	964,196	1,006,833	1,017,664

Notes for Table A5: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A6. Participation by Reporting Option for the Physician Quality Reporting System (2007 to 2010).

Reporting Options	2007		2008		2009		2010	
	Eligible Professionals who Participated	% of Eligible Professionals	Eligible Professionals who Participated	% of Eligible Professionals	Eligible Professionals who Participated	% of Eligible Professionals	Eligible Professionals who Participated	% of Eligible Professionals
Eligible Professionals	--	--	--	--	--	--	--	--
Claims	--	--	--	--	--	--	--	--
Individual Measures	103,710	15.1%	144,972	15.0%	185,154	18.4%	200,517	19.7%
Measures Groups	N/A	N/A	1,410	0.2%	3,649	0.36%	4,151	0.4%
Registry	--	--	--	--	--	--	--	--
Individual Measures	N/A	N/A	8,653	0.9%	22,750	2.3%	39,255	3.9%
Measures Groups	N/A	N/A	3,167	0.3%	10,356	1.03%	17,133	1.7%
EHR	N/A	N/A	N/A	N/A	N/A	N/A	14	0.0%
Total (Unduplicated)	103,710	15.1%	153,839	16.0%	210,559	20.9%	244,145	24.0%

Notes for Table A6: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Sums across participation options do not equal totals due to participation in multiple options. (3) Results included the claims, registry, and EHR options. (4) The measures groups reporting option was not available in the 2007 program year. (5) The EHR option was not available before the 2010 program year.

Table A7. Eligible Professionals who Participated in the Physician Quality Reporting System, by Specialty (2007 to 2010).

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
MD/DO	80,044	16.8%	117,080	19.5%	157,194	25.3%	181,542	29.1%
Allergy/Immunology	48	1.6%	170	4.8%	313	9.0%	376	11.0%
Anesthesiology	9,524	63.3%	12,941	31.8%	17,485	41.3%	20,157	47.9%
Cardiology	4,143	20.6%	5,194	22.8%	7,083	30.4%	8,729	36.7%
Colon/Rectal Surgery	128	13.8%	169	15.9%	243	22.6%	268	25.1%
Critical Care	188	9.0%	247	10.1%	362	14.8%	437	18.0%
Dermatology	1,548	17.2%	291	2.9%	2,104	20.4%	1,725	16.9%
Emergency Medicine	20,918	52.3%	28,839	59.9%	31,215	63.1%	32,327	65.6%
Endocrinology	514	12.1%	857	17.4%	1,291	25.5%	1,359	27.0%
Family Practice	8,298	10.9%	15,143	17.0%	20,551	22.6%	23,926	26.1%
Gastroenterology	1,082	10.3%	949	8.1%	1,805	15.3%	2,612	21.8%
General Practice	129	2.6%	237	4.0%	387	6.7%	493	8.4%
General Surgery	1,563	8.6%	2,310	10.8%	3,142	14.4%	3,819	17.7%
Geriatrics	371	11.0%	582	14.6%	770	19.0%	882	21.8%
Hand Surgery	66	5.4%	110	7.9%	168	11.7%	248	16.2%
Infectious Disease	97	2.3%	264	5.3%	595	11.7%	816	16.1%
Internal Medicine	8,758	11.7%	13,906	15.5%	19,206	20.8%	22,715	24.6%
Interventional Radiologist	160	16.7%	251	20.0%	448	32.6%	537	39.4%
Nephrology	1,100	16.4%	1,278	16.6%	1,984	25.5%	2,395	30.0%
Neurology	599	6.1%	1,003	8.4%	1,580	12.7%	2,037	16.6%
Neurosurgery	293	7.6%	513	11.4%	721	15.9%	864	19.4%
Nuclear Medicine	33	12.6%	41	10.7%	117	16.4%	167	23.8%
Obstetrics/Gynecology	643	2.8%	1,343	4.6%	2,558	8.6%	3,453	11.6%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Oncology/Hematology	2,269	23.8%	2,372	22.1%	3,066	28.2%	3,258	30.3%
Ophthalmology	5,140	30.3%	5,891	31.1%	7,363	38.8%	8,144	43.1%
Oral/Maxillofacial Surgery	0	0.0%	7	1.8%	13	3.5%	14	3.8%
Orthopedic Surgery	1,889	10.5%	2,527	12.4%	4,013	19.4%	4,746	23.0%
Other MD/DO	485	8.4%	802	10.3%	1,087	13.4%	1,438	16.0%
Otolaryngology	163	2.2%	424	5.1%	1,060	12.6%	1,477	17.6%
Pathology	7	3.5%	4,207	53.8%	4,539	58.9%	4,749	61.5%
Pediatrics	125	6.0%	266	4.9%	499	8.5%	628	10.8%
Physical Medicine	188	3.1%	394	5.3%	645	8.4%	789	10.0%
Plastic Surgery	76	2.2%	127	3.1%	296	7.0%	365	8.5%
Psychiatry	156	0.7%	329	1.1%	686	2.3%	825	2.7%
Pulmonary Disease	705	9.3%	1,072	12.3%	1,475	16.8%	1,958	21.5%
Radiation Oncology	519	15.0%	820	19.1%	919	20.5%	995	22.4%
Radiologist	5,525	22.8%	7,484	24.5%	11,889	31.9%	15,071	40.2%
Rheumatology	372	10.1%	567	13.6%	1,152	27.4%	1,386	33.7%
Thoracic/Cardiac Surgery	920	30.3%	1,136	32.2%	1,419	39.7%	1,540	43.5%
Urology	920	11.5%	1,468	16.2%	2,174	23.2%	2,888	31.3%
Vascular Surgery	382	14.8%	549	18.5%	771	25.5%	929	29.4%
Other Eligible Professionals	23,479	11.3%	36,596	10.2%	53,029	13.8%	62,470	15.9%
Agencies/Hospitals/Nursing and Treatment Facilities	110	4.0%	162	5.5%	228	7.3%	283	8.7%
Audiologist	1	2.0%	13	9.6%	138	2.3%	212	3.5%
Certified Nurse Midwives	10	2.8%	45	4.3%	101	8.9%	125	10.7%
Chiropractor	3	2.5%	291	0.6%	477	1.0%	563	1.2%
Clinical Nurse Specialists	59	4.6%	140	8.1%	187	9.5%	221	10.7%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Counselor/Psychologist	73	0.4%	272	0.9%	494	1.6%	534	1.7%
Dentist	4	0.2%	9	0.3%	22	0.7%	29	0.9%
Dietitian/Nutritionist	94	6.6%	143	6.4%	190	8.3%	187	8.1%
Nurse Anesthetist	5,028	95.9%	7,831	20.9%	11,800	29.3%	14,294	34.7%
Nurse Practitioner	2,866	10.7%	5,042	13.0%	7,391	16.7%	9,097	18.7%
Optometry	4,116	16.7%	4,862	16.5%	5,925	19.8%	7,110	22.9%
Other Eligible Professional	3,583	10.2%	4,997	11.6%	8,535	18.3%	9,410	21.5%
Physical/Occupational Therapy	3,304	12.1%	4,936	13.7%	5,770	15.3%	6,391	16.1%
Physician Assistant	3,895	15.1%	6,968	19.7%	9,599	24.8%	11,192	26.7%
Podiatrist	106	0.7%	331	1.9%	1,175	6.8%	1,823	10.5%
Registered Nurse	197	11.2%	404	10.8%	724	17.3%	777	20.4%
Social Worker	30	0.2%	150	0.6%	273	1.0%	222	0.8%
Unknown/Missing	187	6.0%	163	4.9%	336	16.1%	133	13.6%
Total (Unduplicated)	103,710	15.1%	153,839	16.0%	210,559	20.9%	244,145	24.0%

Notes for Table A7: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A8. Eligible Professionals who Participated by Reporting Individual Measures through the Claims Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
MD/DO	80,044	16.8%	109,647	18.2%	135,778	21.9%	145,047	23.3%
Allergy/Immunology	48	1.6%	101	2.9%	191	5.5%	232	6.8%
Anesthesiology	9,524	63.3%	12,923	31.7%	17,372	41.0%	20,040	47.6%
Cardiology	4,143	20.6%	4,951	21.7%	5,756	24.7%	5,331	22.4%
Colon/Rectal Surgery	128	13.8%	159	14.9%	192	17.8%	213	19.9%
Critical Care	188	9.0%	231	9.4%	319	13.0%	353	14.6%
Dermatology	1,548	17.2%	206	2.0%	1,878	18.2%	538	5.3%
Emergency Medicine	20,918	52.3%	28,727	59.6%	31,000	62.6%	32,030	65.0%
Endocrinology	514	12.1%	747	15.2%	899	17.8%	866	17.2%
Family Practice	8,298	10.9%	12,193	13.7%	14,557	16.0%	14,778	16.1%
Gastroenterology	1,082	10.3%	830	7.1%	1,414	12.0%	1,820	15.2%
General Practice	129	2.6%	219	3.7%	308	5.4%	370	6.3%
General Surgery	1,563	8.6%	2,166	10.1%	2,593	11.9%	2,879	13.3%
Geriatrics	371	11.0%	511	12.9%	562	13.9%	569	14.0%
Hand Surgery	66	5.4%	101	7.2%	139	9.7%	186	12.2%
Infectious Disease	97	2.3%	224	4.5%	383	7.5%	452	8.9%
Internal Medicine	8,758	11.7%	12,084	13.5%	14,231	15.4%	14,427	15.6%
Interventional Radiologist	160	16.7%	245	19.5%	433	31.5%	522	38.3%
Nephrology	1,100	16.4%	1,140	14.8%	1,157	14.9%	1,050	13.1%
Neurology	599	6.1%	906	7.6%	1,241	10.0%	1,484	12.1%
Neurosurgery	293	7.6%	475	10.6%	590	13.0%	634	14.2%
Nuclear Medicine	33	12.6%	39	10.2%	110	15.4%	138	19.6%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Obstetrics/Gynecology	643	2.8%	1,050	3.6%	1,771	6.0%	2,238	7.5%
Oncology/Hematology	2,269	23.8%	2,300	21.4%	2,629	24.2%	2,649	24.6%
Ophthalmology	5,140	30.3%	5,799	30.6%	7,044	37.1%	7,555	39.9%
Oral/Maxillofacial Surgery	0	0.0%	6	1.6%	13	3.5%	12	3.2%
Orthopedic Surgery	1,889	10.5%	2,370	11.6%	3,321	16.1%	3,687	17.8%
Other MD/DO	485	8.4%	723	9.3%	908	11.2%	1,037	11.6%
Otolaryngology	163	2.2%	344	4.1%	778	9.2%	905	10.8%
Pathology	7	3.5%	4,200	53.7%	4,529	58.8%	4,733	61.3%
Pediatrics	125	6.0%	206	3.8%	319	5.5%	302	5.2%
Physical Medicine	188	3.1%	374	5.0%	505	6.6%	553	7.0%
Plastic Surgery	76	2.2%	102	2.5%	202	4.8%	246	5.7%
Psychiatry	156	0.7%	285	1.0%	540	1.8%	674	2.2%
Pulmonary Disease	705	9.3%	964	11.1%	1,184	13.5%	1,433	15.8%
Radiation Oncology	519	15.0%	800	18.6%	789	17.6%	755	17.0%
Radiologist	5,525	22.8%	7,455	24.4%	11,730	31.5%	14,554	38.8%
Rheumatology	372	10.1%	505	12.1%	721	17.1%	789	19.2%
Thoracic/Cardiac Surgery	920	30.3%	1,120	31.8%	1,079	30.2%	1,037	29.3%
Urology	920	11.5%	1,334	14.7%	1,744	18.6%	2,252	24.4%
Vascular Surgery	382	14.8%	532	18.0%	647	21.4%	724	22.9%
Other Eligible Professionals	23,479	11.3%	35,171	9.8%	49,086	12.8%	55,378	14.1%
Agencies/Hospitals/Nursing and Treatment Facilities	110	4.0%	158	5.4%	203	6.5%	233	7.1%
Audiologist	1	2.0%	0	0.0%	112	1.9%	171	2.8%
Certified Nurse Midwives	10	2.8%	32	3.1%	67	5.9%	72	6.2%
Chiropractor	3	2.5%	289	0.6%	460	1.0%	546	1.2%
Clinical Nurse Specialists	59	4.6%	126	7.3%	157	8.0%	179	8.6%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Counselor/Psychologist	73	0.4%	250	0.8%	413	1.3%	461	1.5%
Dentist	4	0.2%	8	0.2%	16	0.5%	20	0.6%
Dietitian/Nutritionist	94	6.6%	133	6.0%	149	6.5%	136	5.9%
Nurse Anesthetist	5,028	95.9%	7,831	20.9%	11,781	29.2%	14,274	34.7%
Nurse Practitioner	2,866	10.7%	4,541	11.7%	6,064	13.7%	6,721	13.8%
Optometry	4,116	16.7%	4,834	16.4%	5,837	19.5%	6,949	22.4%
Other Eligible Professional	3,583	10.2%	4,827	11.2%	7,655	16.5%	7,595	17.4%
Physical/Occupational Therapy	3,304	12.1%	4,907	13.7%	5,693	15.1%	6,081	15.3%
Physician Assistant	3,895	15.1%	6,454	18.2%	8,623	22.3%	9,529	22.8%
Podiatrist	106	0.7%	278	1.6%	970	5.6%	1,499	8.6%
Registered Nurse	197	11.2%	389	10.4%	677	16.2%	707	18.6%
Social Worker	30	0.2%	114	0.4%	209	0.7%	205	0.7%
<i>Unknown/Missing</i>	187	6.0%	154	4.6%	290	13.9%	92	9.4%
Total (Unduplicated)	103,710	15.1%	144,972	15.0%	185,154	18.4%	200,517	19.7%

Notes for Table A8: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims reporting option only.

Table A9. Eligible Professionals who Participated by Reporting Measures Groups through the Claims Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
MD/DO	N/A	N/A	1,311	0.2%	3,155	0.5%	3,487	0.6%
Allergy/Immunology	N/A	N/A	1	0.0%	4	0.1%	N/A	N/A
Anesthesiology	N/A	N/A	N/A	N/A	37	0.1%	38	0.1%
Cardiology	N/A	N/A	22	0.1%	42	0.2%	559	2.4%
Colon/Rectal Surgery	N/A	N/A	N/A	N/A	8	0.7%	16	1.5%
Critical Care	N/A	N/A	1	0.0%	9	0.4%	5	0.2%
Dermatology	N/A	N/A	5	0.1%	6	0.1%	12	0.1%
Emergency Medicine	N/A	N/A	1	0.0%	6	0.0%	47	0.1%
Endocrinology	N/A	N/A	37	0.8%	71	1.4%	50	1.0%
Family Practice	N/A	N/A	495	0.6%	928	1.0%	759	0.8%
Gastroenterology	N/A	N/A	15	0.1%	29	0.3%	18	0.2%
General Practice	N/A	N/A	2	0.0%	14	0.2%	12	0.2%
General Surgery	N/A	N/A	11	0.1%	145	0.7%	140	0.7%
Geriatrics	N/A	N/A	20	0.5%	31	0.8%	36	0.9%
Hand Surgery	N/A	N/A	N/A	N/A	3	0.2%	4	0.3%
Infectious Disease	N/A	N/A	3	0.1%	2	0.0%	2	0.0%
Internal Medicine	N/A	N/A	479	0.5%	997	1.1%	895	1.0%
Interventional Radiologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nephrology	N/A	N/A	87	1.1%	117	1.5%	91	1.1%
Neurology	N/A	N/A	15	0.1%	19	0.2%	10	0.1%
Neurosurgery	N/A	N/A	5	0.1%	59	1.3%	71	1.6%
Nuclear Medicine	N/A	N/A	N/A	N/A	N/A	N/A	1	0.1%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Obstetrics/Gynecology	N/A	N/A	9	0.0%	41	0.1%	29	0.1%
Oncology/Hematology	N/A	N/A	17	0.2%	22	0.2%	24	0.2%
Ophthalmology	N/A	N/A	21	0.1%	16	0.1%	1	0.0%
Oral/Maxillofacial Surgery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Orthopedic Surgery	N/A	N/A	5	0.0%	245	1.2%	285	1.4%
Other MD/DO	N/A	N/A	4	0.1%	46	0.6%	41	0.5%
Otolaryngology	N/A	N/A	7	0.1%	6	0.1%	4	0.1%
Pathology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pediatrics	N/A	N/A	2	0.0%	2	0.0%	2	0.0%
Physical Medicine	N/A	N/A	11	0.2%	28	0.4%	45	0.6%
Plastic Surgery	N/A	N/A	N/A	N/A	3	0.1%	N/A	N/A
Psychiatry	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pulmonary Disease	N/A	N/A	12	0.1%	24	0.3%	34	0.4%
Radiation Oncology	N/A	N/A	N/A	N/A	4	0.1%	N/A	N/A
Radiologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Rheumatology	N/A	N/A	5	0.1%	149	3.5%	204	5.0%
Thoracic/Cardiac Surgery	N/A	N/A	N/A	N/A	9	0.3%	9	0.3%
Urology	N/A	N/A	13	0.1%	17	0.2%	30	0.3%
Vascular Surgery	N/A	N/A	6	0.2%	16	0.5%	13	0.4%
Other Eligible Professionals	N/A	N/A	99	0.0%	490	0.1%	664	0.2%
Agencies/Hospitals/Nursing and Treatment Facilities	N/A	N/A	2	0.1%	2	0.1%	1	0.0%
Audiologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Certified Nurse Midwives	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chiropractor	N/A	N/A	N/A	N/A	11	0.0%	N/A	N/A
Clinical Nurse Specialists	N/A	N/A	N/A	N/A	3	0.2%	9	0.4%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Counselor/Psychologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dentist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dietitian/Nutritionist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nurse Anesthetist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nurse Practitioner	N/A	N/A	48	0.1%	164	0.4%	153	0.3%
Optometry	N/A	N/A	N/A	N/A	20	0.1%	N/A	N/A
Other Eligible Professional	N/A	N/A	33	0.1%	152	0.3%	222	0.5%
Physical/Occupational Therapy	N/A	N/A	N/A	N/A	N/A	N/A	158	0.4%
Physician Assistant	N/A	N/A	12	0.0%	113	0.3%	109	0.3%
Podiatrist	N/A	N/A	1	0.0%	19	0.1%	7	0.0%
Registered Nurse	N/A	N/A	3	0.1%	6	0.1%	5	0.1%
Social Worker	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>Unknown/Missing</i>	N/A	N/A	N/A	N/A	4	0.2%	N/A	N/A
Total (Unduplicated)	N/A	N/A	1,410	0.2%	3,649	0.4%	4,151	0.4%

Notes for Table A9: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the measures group claims reporting option only. (3) The measures groups reporting option was not available in the 2007 program year.

Table A10. Eligible Professionals who Participated by Reporting Individual Measures through the Registry Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
MD/DO	N/A	N/A	7,087	1.2%	19,054	3.1%	32,532	5.2%
Allergy/Immunology	N/A	N/A	30	0.9%	81	2.3%	105	3.1%
Anesthesiology	N/A	N/A	19	0.1%	112	0.3%	172	0.4%
Cardiology	N/A	N/A	334	1.5%	1,358	5.8%	2,199	9.3%
Colon/Rectal Surgery	N/A	N/A	10	0.9%	27	2.5%	51	4.8%
Critical Care	N/A	N/A	23	0.9%	43	1.8%	83	3.4%
Dermatology	N/A	N/A	88	0.9%	257	2.5%	1,311	12.8%
Emergency Medicine	N/A	N/A	137	0.3%	366	0.7%	475	1.0%
Endocrinology	N/A	N/A	117	2.4%	383	7.6%	467	9.3%
Family Practice	N/A	N/A	2,264	2.5%	4,509	5.0%	7,059	7.7%
Gastroenterology	N/A	N/A	112	1.0%	337	2.9%	613	5.1%
General Practice	N/A	N/A	4	0.1%	50	0.9%	80	1.4%
General Surgery	N/A	N/A	185	0.9%	557	2.6%	881	4.1%
Geriatrics	N/A	N/A	60	1.5%	192	4.8%	268	6.6%
Hand Surgery	N/A	N/A	8	0.6%	23	1.6%	62	4.1%
Infectious Disease	N/A	N/A	43	0.9%	219	4.3%	346	6.8%
Internal Medicine	N/A	N/A	1,785	2.0%	4,505	4.9%	7,239	7.8%
Interventional Radiologist	N/A	N/A	7	0.6%	26	1.9%	50	3.7%
Nephrology	N/A	N/A	70	0.9%	269	3.5%	397	5.0%
Neurology	N/A	N/A	119	1.0%	387	3.1%	627	5.1%
Neurosurgery	N/A	N/A	50	1.1%	139	3.1%	203	4.6%
Nuclear Medicine	N/A	N/A	2	0.5%	14	2.0%	26	3.7%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Obstetrics/Gynecology	N/A	N/A	309	1.1%	833	2.8%	1,276	4.3%
Oncology/Hematology	N/A	N/A	84	0.8%	328	3.0%	655	6.1%
Ophthalmology	N/A	N/A	148	0.8%	441	2.3%	1,061	5.6%
Oral/Maxillofacial Surgery	N/A	N/A	1	0.3%	N/A	N/A	2	0.5%
Orthopedic Surgery	N/A	N/A	284	1.4%	563	2.7%	842	4.1%
Other MD/DO	N/A	N/A	87	1.1%	140	1.7%	372	4.1%
Otolaryngology	N/A	N/A	82	1.0%	227	2.7%	490	5.9%
Pathology	N/A	N/A	7	0.1%	13	0.2%	29	0.4%
Pediatrics	N/A	N/A	64	1.2%	193	3.3%	348	6.0%
Physical Medicine	N/A	N/A	22	0.3%	98	1.3%	182	2.3%
Plastic Surgery	N/A	N/A	26	0.6%	90	2.1%	114	2.7%
Psychiatry	N/A	N/A	47	0.2%	176	0.6%	184	0.6%
Pulmonary Disease	N/A	N/A	99	1.1%	254	2.9%	471	5.2%
Radiation Oncology	N/A	N/A	23	0.5%	212	4.7%	327	7.4%
Radiologist	N/A	N/A	72	0.2%	383	1.0%	1,710	4.6%
Rheumatology	N/A	N/A	69	1.7%	218	5.2%	289	7.0%
Thoracic/Cardiac Surgery	N/A	N/A	34	1.0%	493	13.8%	647	18.3%
Urology	N/A	N/A	135	1.5%	399	4.3%	626	6.8%
Vascular Surgery	N/A	N/A	27	0.9%	139	4.6%	193	6.1%
Other Eligible Professionals	N/A	N/A	1,558	0.4%	3,660	1.0%	6,699	1.7%
Agencies/Hospitals/Nursing and Treatment Facilities	N/A	N/A	5	0.2%	14	0.5%	42	1.3%
Audiologist	N/A	N/A	13	9.6%	32	0.5%	60	1.0%
Certified Nurse Midwives	N/A	N/A	14	1.3%	34	3.0%	53	4.6%
Chiropractor	N/A	N/A	3	0.0%	12	0.0%	11	0.0%
Clinical Nurse Specialists	N/A	N/A	20	1.2%	30	1.5%	47	2.3%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Counselor/Psychologist	N/A	N/A	25	0.1%	106	0.3%	98	0.3%
Dentist	N/A	N/A	1	0.0%	4	0.1%	11	0.3%
Dietitian/Nutritionist	N/A	N/A	11	0.5%	46	2.0%	54	2.4%
Nurse Anesthetist	N/A	N/A	N/A	N/A	19	0.1%	17	0.0%
Nurse Practitioner	N/A	N/A	577	1.5%	1,261	2.9%	2,237	4.6%
Optometry	N/A	N/A	46	0.2%	100	0.3%	215	0.7%
Other Eligible Professional	N/A	N/A	135	0.3%	632	1.4%	1,332	3.1%
Physical/Occupational Therapy	N/A	N/A	41	0.1%	142	0.4%	446	1.1%
Physician Assistant	N/A	N/A	555	1.6%	942	2.4%	1,714	4.1%
Podiatrist	N/A	N/A	56	0.3%	154	0.9%	260	1.5%
Registered Nurse	N/A	N/A	19	0.5%	47	1.1%	67	1.8%
Social Worker	N/A	N/A	37	0.1%	85	0.3%	35	0.1%
<i>Unknown/Missing</i>	N/A	N/A	8	0.2%	36	1.7%	24	2.5%
Total (Unduplicated)	N/A	N/A	8,653	0.9%	22,750	2.3%	39,255	3.9%

Notes for Table A10: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the individual measures registry reporting option only.

Table A11. Eligible Professionals who Participated by Reporting Measures Groups through the Registry Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
MD/DO	N/A	N/A	2,983	0.5%	9,135	1.5%	15,006	2.4%
Allergy/Immunology	N/A	N/A	41	1.2%	64	1.9%	70	2.1%
Anesthesiology	N/A	N/A	3	0.0%	34	0.1%	31	0.1%
Cardiology	N/A	N/A	92	0.4%	651	2.8%	2,279	9.6%
Colon/Rectal Surgery	N/A	N/A	2	0.2%	42	3.9%	31	2.9%
Critical Care	N/A	N/A	7	0.3%	16	0.7%	26	1.1%
Dermatology	N/A	N/A	4	0.0%	63	0.6%	48	0.5%
Emergency Medicine	N/A	N/A	13	0.0%	28	0.1%	61	0.1%
Endocrinology	N/A	N/A	43	0.9%	130	2.6%	182	3.6%
Family Practice	N/A	N/A	1,480	1.7%	2,891	3.2%	4,042	4.4%
Gastroenterology	N/A	N/A	28	0.2%	141	1.2%	340	2.8%
General Practice	N/A	N/A	17	0.3%	40	0.7%	77	1.3%
General Surgery	N/A	N/A	15	0.1%	156	0.7%	350	1.6%
Geriatrics	N/A	N/A	43	1.1%	99	2.5%	150	3.7%
Hand Surgery	N/A	N/A	1	0.1%	10	0.7%	24	1.6%
Infectious Disease	N/A	N/A	5	0.1%	47	0.9%	89	1.8%
Internal Medicine	N/A	N/A	786	0.9%	1,961	2.1%	3,045	3.3%
Interventional Radiologist	N/A	N/A	N/A	N/A	N/A	N/A	1	0.1%
Nephrology	N/A	N/A	145	1.9%	755	9.7%	1,164	14.6%
Neurology	N/A	N/A	20	0.2%	93	0.8%	85	0.7%
Neurosurgery	N/A	N/A	4	0.1%	34	0.8%	67	1.5%
Nuclear Medicine	N/A	N/A	N/A	N/A	1	0.1%	15	2.1%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Obstetrics/Gynecology	N/A	N/A	31	0.1%	143	0.5%	226	0.8%
Oncology/Hematology	N/A	N/A	30	0.3%	242	2.2%	336	3.1%
Ophthalmology	N/A	N/A	17	0.1%	133	0.7%	191	1.0%
Oral/Maxillofacial Surgery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Orthopedic Surgery	N/A	N/A	15	0.1%	355	1.7%	571	2.8%
Other MD/DO	N/A	N/A	4	0.1%	51	0.6%	98	1.1%
Otolaryngology	N/A	N/A	21	0.3%	147	1.7%	233	2.8%
Pathology	N/A	N/A	N/A	N/A	1	0.0%	N/A	N/A
Pediatrics	N/A	N/A	N/A	N/A	14	0.2%	16	0.3%
Physical Medicine	N/A	N/A	3	0.0%	60	0.8%	74	0.9%
Plastic Surgery	N/A	N/A	1	0.0%	22	0.5%	18	0.4%
Psychiatry	N/A	N/A	N/A	N/A	8	0.0%	11	0.0%
Pulmonary Disease	N/A	N/A	52	0.6%	138	1.6%	224	2.5%
Radiation Oncology	N/A	N/A	N/A	N/A	30	0.7%	26	0.6%
Radiologist	N/A	N/A	1	0.0%	10	0.0%	2	0.0%
Rheumatology	N/A	N/A	14	0.3%	266	6.3%	370	9.0%
Thoracic/Cardiac Surgery	N/A	N/A	4	0.1%	29	0.8%	56	1.6%
Urology	N/A	N/A	30	0.3%	195	2.1%	303	3.3%
Vascular Surgery	N/A	N/A	11	0.4%	35	1.2%	74	2.3%
Other Eligible Professionals	N/A	N/A	183	0.1%	1,210	0.3%	2,108	0.5%
Agencies/Hospitals/Nursing and Treatment Facilities	N/A	N/A	N/A	N/A	15	0.5%	22	0.7%
Audiologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Certified Nurse Midwives	N/A	N/A	N/A	N/A	2	0.2%	4	0.3%
Chiropractor	N/A	N/A	N/A	N/A	4	0.0%	9	0.0%
Clinical Nurse Specialists	N/A	N/A	1	0.1%	12	0.6%	7	0.3%

Specialty	Eligible Professionals who Participated							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals	Count	% of Eligible Professionals
Counselor/Psychologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dentist	N/A	N/A	N/A	N/A	3	0.1%	N/A	N/A
Dietitian/Nutritionist	N/A	N/A	N/A	N/A	2	0.1%	5	0.2%
Nurse Anesthetist	N/A	N/A	N/A	N/A	N/A	N/A	11	0.0%
Nurse Practitioner	N/A	N/A	55	0.1%	344	0.8%	598	1.2%
Optometry	N/A	N/A	4	0.0%	44	0.2%	63	0.2%
Other Eligible Professional	N/A	N/A	81	0.2%	480	1.0%	866	2.0%
Physical/Occupational Therapy	N/A	N/A	N/A	N/A	5	0.0%	58	0.2%
Physician Assistant	N/A	N/A	36	0.1%	214	0.6%	311	0.7%
Podiatrist	N/A	N/A	4	0.0%	79	0.5%	144	0.8%
Registered Nurse	N/A	N/A	2	0.1%	6	0.1%	10	0.3%
Social Worker	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>Unknown/Missing</i>	N/A	N/A	1	0.0%	11	0.5%	19	1.9%
Total (Unduplicated)	N/A	N/A	3,167	0.3%	10,356	1.0%	17,133	1.7%

Notes for Table A11: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the registry option only. (3) The measures groups reporting option was not available in the 2007 program year.

Table A12. Eligible Professionals, Participation, and Incentive Information for the Physician Quality Reporting System, by State (2010).

State or Territory	Eligible Professionals	Eligible Professionals who Participated	% of Eligible Professionals	Eligible Professionals who Qualified for an Incentive	% of Eligible Professionals who Participated
Alaska	2,475	232	9.4%	154	66.4%
Alabama	13,794	3,315	24.0%	2,224	67.1%
Arkansas	8,111	2,027	25.0%	1,516	74.8%
Arizona	19,147	3,634	19.0%	2,378	65.4%
California	84,188	15,755	18.7%	10,789	68.5%
Colorado	15,842	3,546	22.4%	2,443	68.9%
Connecticut	16,189	3,438	21.2%	2,099	61.1%
<i>District of Columbia</i>	3,390	772	22.8%	642	83.2%
Delaware	3,503	959	27.4%	694	72.4%
Florida	59,741	15,400	25.8%	10,885	70.7%
Georgia	26,196	7,596	29.0%	5,095	67.1%
Hawaii	3,866	534	13.8%	393	73.6%
Iowa	9,731	2,528	26.0%	1,782	70.5%
Idaho	5,071	1,164	23.0%	852	73.2%
Illinois	41,737	11,449	27.4%	7,890	68.9%
Indiana	21,516	6,443	30.0%	4,147	64.4%
Kansas	10,245	2,161	21.1%	1,338	61.9%
Kentucky	14,723	3,372	22.9%	2,187	64.9%
Louisiana	14,691	3,292	22.4%	2,347	71.3%
Massachusetts	36,256	8,827	24.4%	6,274	71.1%
Maryland	21,522	4,571	21.2%	3,086	67.5%
Maine	7,387	1,888	25.6%	1,274	67.5%
Michigan	37,673	10,209	27.1%	7,443	72.9%
Minnesota	20,722	5,876	28.4%	4,208	71.6%
Missouri	20,850	6,040	29.0%	4,169	69.0%
Mississippi	7,204	1,400	19.4%	1,098	78.4%
Montana	3,667	589	16.1%	414	70.3%
North Carolina	32,108	10,826	33.7%	7,401	68.4%
North Dakota	2,422	371	15.3%	255	68.7%
Nebraska	7,100	1,552	21.9%	1,000	64.4%
New Hampshire	4,968	1,000	20.1%	694	69.4%
New Jersey	33,717	6,755	20.0%	4,598	68.1%
New Mexico	5,487	1,019	18.6%	755	74.1%
Nevada	6,277	1,255	20.0%	788	62.8%
New York	83,227	13,772	16.6%	9,151	66.5%

State or Territory	Eligible Professionals	Eligible Professionals who Participated	% of Eligible Professionals	Eligible Professionals who Qualified for an Incentive	% of Eligible Professionals who Participated
Ohio	40,244	11,933	29.7%	8,052	67.5%
Oklahoma	10,929	1,967	18.0%	1,174	59.7%
Oregon	12,388	2,872	23.2%	2,240	78.0%
Pennsylvania	51,202	14,091	27.5%	9,719	69.0%
Rhode Island	4,851	1,063	21.9%	593	55.8%
South Carolina	13,667	2,980	21.8%	2,246	75.4%
South Dakota	3,476	956	27.5%	657	68.7%
Tennessee	22,412	5,825	26.0%	3,983	68.4%
Texas	59,179	15,186	25.7%	10,266	67.6%
Utah	7,010	1,783	25.4%	1,329	74.5%
Virginia	23,595	6,868	29.1%	4,726	68.8%
Vermont	2,325	223	9.6%	149	66.8%
Washington	23,474	4,758	20.3%	3,404	71.5%
Wisconsin	21,734	7,955	36.6%	6,678	84.0%
West Virginia	6,464	1,627	25.2%	904	55.6%
Wyoming	1,820	248	13.6%	125	50.4%
Other	7,171	110	1.5%	72	65.5%
<i>Unknown/Missing</i>	980	133	13.6%	63	47.4%
Total (Unduplicated)	1,017,664	244,145	24.0%	168,843	69.2%

Notes for Table A12: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A13. Submission Information for Individual Measures Submitted through the Claims Reporting Option for the Physician Quality Reporting System (2010).

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#1 Hemoglobin A1c Poor Control	324,650	19,167	5.9%	9,649	50.3%	61.6%
#2 Low Density Lipoprotein Control	324,650	18,070	5.6%	9,236	51.1%	61.8%
#3 High Blood Pressure Control	324,650	18,044	5.6%	9,139	50.7%	62.0%
#6 Oral Antiplatelet Therapy Prescribed for Patients with CAD	247,891	11,763	4.8%	6,167	52.4%	65.9%
#9 Antidepressant Meds During Acute Phase for Patients with New Episode of MD	255,953	1,022	0.4%	317	31.0%	47.3%
#10 CT or MRI Reports	33,431	10,518	31.5%	5,426	51.6%	68.4%
#12 Optic Nerve Evaluation	44,207	11,086	25.1%	6,585	59.4%	80.2%
#14 Dilated Macular Examination	72,977	11,655	16.0%	6,134	52.6%	77.6%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	45,957	8,653	18.8%	4,235	48.9%	71.6%
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	45,957	4,703	10.2%	2,097	44.6%	65.4%
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	97,429	8,309	8.5%	4,641	55.9%	69.3%
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	69,130	6,175	8.9%	3,415	55.3%	69.0%

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	89,867	4,611	5.1%	2,389	51.8%	66.6%
#23 VTE Prophylaxis	76,847	5,466	7.1%	2,952	54.0%	68.5%
#24 Communication with the Physician Managing Ongoing Care Post-Fracture	101,439	654	0.6%	282	43.1%	48.7%
#28 Aspirin at Arrival	31,658	16,539	52.2%	13,845	83.7%	87.1%
#30 Timing of Prophylactic Antibiotics - Administering Physician	81,075	35,515	43.8%	23,988	67.5%	78.8%
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	97,429	2,652	2.7%	1,389	52.4%	63.3%
#32 Discharged on Antiplatelet Therapy	101,738	3,290	3.2%	1,040	31.6%	52.8%
#35 Screening for Dysphagia	72,513	1,451	2.0%	711	49.0%	59.8%
#36 Consideration of Rehabilitation Services	80,971	2,543	3.1%	771	30.3%	52.4%
#39 Screening or Therapy for Women Aged 65 Years and Older	532,564	6,929	1.3%	2,600	37.5%	42.1%
#40 Management Following Fracture	101,439	844	0.8%	362	42.9%	43.1%
#41 Pharmacologic Therapy	179,738	3,602	2.0%	1,875	52.1%	56.2%
#43 Use of IMA in CABG Surgery	3,918	943	24.1%	733	77.7%	83.4%
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery	3,918	654	16.7%	499	76.3%	81.1%
#45 Discontinuation of Prophylactic Antibiotics	4,264	660	15.5%	438	66.4%	75.8%

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	498,249	376	0.1%	19	5.1%	17.5%
#47 Advance Care Plan	629,686	6,596	1.1%	2,146	32.5%	51.5%
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	539,410	5,658	1.1%	1,502	26.6%	37.8%
#49 Characterization of UI in Women Aged 65 Years and Older	125,261	2,027	1.6%	909	44.8%	66.9%
#50 Plan of Care for UI in Women Aged 65 Years and Older	125,261	1,947	1.6%	852	43.8%	65.5%
#51 Spirometry Evaluation	214,914	2,073	1.0%	752	36.3%	56.2%
#52 Bronchodilator Therapy	214,914	1,533	0.7%	579	37.8%	52.2%
#53 Pharmacologic Therapy	50,027	528	1.1%	396	75.0%	76.4%
#54 ECG Performed for Non-Traumatic Chest Pain	69,602	39,615	56.9%	32,241	81.4%	86.1%
#55 ECG Performed for Syncope	54,112	33,508	61.9%	28,430	84.9%	88.7%
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	203,038	34,228	16.9%	28,266	82.6%	87.0%
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	203,038	38,503	19.0%	32,331	84.0%	87.9%
#58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	203,038	34,690	17.1%	29,350	84.6%	87.7%
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	203,038	24,755	12.2%	19,456	78.6%	83.1%
#64 Asthma Assessment	50,027	309	0.6%	232	75.1%	77.9%

Measure	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#65 Appropriate Treatment for Children	166	1	0.6%	1	100.0%	100.0%
#66 Appropriate Testing for Children	134	1	0.8%	1	100.0%	100.0%
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	28,257	1,411	5.0%	722	51.2%	68.6%
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	22,967	1,172	5.1%	506	43.2%	61.6%
#69 Treatment with Bisphosphonates	35,473	1,775	5.0%	912	51.4%	65.8%
#70 Baseline Flow Cytometry	35,251	1,577	4.5%	898	56.9%	73.2%
#71 Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer	131,099	1,666	1.3%	655	39.3%	60.8%
#72 Chemotherapy for Stage III	89,295	1,466	1.6%	539	36.8%	60.8%
#76 Prevention of CRBSI - Central Venous Catheter Insertion Protocol	89,766	14,406	16.1%	9,574	66.5%	75.2%
#79 Influenza Vaccination in Patients with ESRD	9,206	171	1.9%	91	53.2%	62.4%
#84 Initial Hepatitis C RNA Testing	36,071	307	0.9%	151	49.2%	71.5%
#85 Genotype Testing Prior to Therapy	36,071	307	0.9%	149	48.5%	66.1%
#86 Consideration for Antiviral Therapy	36,071	203	0.6%	98	48.3%	63.9%
#87 RNA Testing at Week 12 of Therapy	36,071	172	0.5%	83	48.3%	62.1%
#89 Counseling Patients Regarding Use of Alcohol	67,332	397	0.6%	174	43.8%	55.6%

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#90 Counseling Patients Regarding Use of Contraception Prior to Starting Antiviral Therapy	25,963	82	0.3%	27	32.9%	49.3%
#91 AOE: Topical Therapy	87,079	403	0.5%	175	43.4%	62.1%
#92 AOE: Pain Assessment	87,079	266	0.3%	96	36.1%	55.4%
#93 AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	87,079	289	0.3%	130	45.0%	58.5%
#94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	30	0	0.0%	0	0.0%	0.0%
#99 Breast Cancer Patients with a pT and pN Category and Histologic Grade	7,294	4,541	62.3%	2,946	64.9%	78.8%
#100 CRC Patients with a pT and pN Category and Histologic Grade	6,852	4,323	63.1%	3,299	76.3%	85.3%
#102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate Cancer Patients	7,916	370	4.7%	148	40.0%	53.3%
#104 Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	4,037	343	8.5%	129	37.6%	53.9%
#105 Three-dimensional Radiotherapy for Patients with Prostate Cancer	3,953	457	11.6%	187	40.9%	56.4%
#106 Patients who have MD Disorder who meet DSM IV Criteria	108,484	569	0.5%	232	40.8%	55.5%
#107 Patients who have MD Disorder who are Assessed for Suicide Risks	108,484	661	0.6%	307	46.4%	63.3%

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#108 DMARD Therapy in Rheumatoid Arthritis	146,535	885	0.6%	326	36.8%	51.0%
#109 Patients with OA with an Assessment of Pain and Function	213,521	1,001	0.5%	279	27.9%	44.3%
#110 Vaccination for Patients ≥ 50 Years Old	574,356	7,775	1.4%	2,046	26.3%	36.1%
#111 Vaccination for Patients 65 years and Older	569,033	7,593	1.3%	2,343	30.9%	42.1%
#112 Screening Mammography	515,005	6,569	1.3%	2,245	34.2%	42.0%
#113 CRC Screening	557,922	7,425	1.3%	2,433	32.8%	38.6%
#114 Inquiry Regarding Tobacco Use	659,920	18,460	2.8%	7,408	40.1%	54.5%
#115 Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	659,920	12,072	1.8%	3,388	28.1%	43.8%
#116 Inappropriate Antibiotic Treatment for Adults	98,592	151	0.2%	47	31.1%	29.4%
#117 Dilated Eye Exam in Diabetic Patient	339,656	12,043	3.6%	4,678	38.8%	63.2%
#119 Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	324,650	4,483	1.4%	1,393	31.1%	42.9%
#121 Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile)	52,355	585	1.1%	225	38.5%	54.6%
#122 Blood Pressure Management	52,355	720	1.4%	241	33.5%	48.2%
#123 Plan of Care: Elevated Hemoglobin for Patients Receiving ESAs	52,355	511	1.0%	113	22.1%	43.1%

Measure	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#124 HIT - Adoption/Use of EHRs	760,531	34,722	4.6%	19,307	55.6%	62.8%
#126 Diabetic Foot and Ankle Care, Peripheral Neuropathy: Neurological Evaluation	338,883	2,693	0.8%	892	33.1%	44.3%
#127 Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear	338,883	1,709	0.5%	368	21.5%	41.3%
#128 Universal Weight Screening and Follow-Up	704,262	6,833	1.0%	1,661	24.3%	35.0%
#130 Documentation of Current Medications	690,768	16,885	2.4%	6,771	40.1%	51.7%
#131 Assessment Prior to Initiation of Patient Treatment	170,665	6,017	3.5%	3,403	56.6%	58.2%
#134 Screening for Clinical Depression	117,263	567	0.5%	320	56.4%	70.6%
#135 Chronic Kidney Disease (CKD): Influenza Immunization	52,355	376	0.7%	136	36.2%	46.9%
#139 Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	12,796	3,716	29.0%	2,876	77.4%	87.8%
#140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	72,517	7,022	9.7%	3,080	43.9%	70.3%
#141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	44,154	3,791	8.6%	1,493	39.4%	62.2%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or	213,521	1,093	0.5%	343	31.4%	41.0%

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
Analgesic Over-the-Counter (OTC) Medications						
#145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	125,133	10,426	8.3%	6,744	64.7%	74.5%
#146 Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	27,008	7,300	27.0%	5,464	74.9%	81.3%
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	19,241	6,173	32.1%	4,384	71.0%	78.9%
#153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	52,355	428	0.8%	160	37.4%	51.9%
#154 Falls: Risk Assessment	607,937	7,858	1.3%	3,145	40.0%	41.9%
#155 Falls: Plan of Care	6,516	3,866	59.3%	2,974	76.9%	87.4%
#156 Oncology: Radiation Dose Limits to Normal Tissues	3,661	296	8.1%	116	39.2%	59.9%
#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	3,104	40	1.3%	22	55.0%	70.8%
#158 Endarterectomy: Use of Patch During Conventional Endarterectomy	6,462	344	5.3%	237	68.9%	75.8%
#163 Diabetes Mellitus: Foot Exam	324,650	3,963	1.2%	822	20.7%	41.6%
#172 Hemodialysis Vascular Access Decision-Making by Surgeon to	4,823	173	3.6%	97	56.1%	67.9%

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
Maximize Placement of Autogenous Arterial Venous (AV) Fistula						
#173 Preventive Care and Screening: Unhealthy Alcohol Use - Screening	662,161	3,261	0.5%	483	14.8%	24.2%
#175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	298	0	0.0%	0	0.0%	0.0%
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	146,535	318	0.2%	47	14.8%	29.5%
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	146,535	367	0.3%	56	15.3%	33.2%
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	146,535	388	0.3%	82	21.1%	34.6%
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	146,535	285	0.2%	32	11.2%	28.8%
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	146,535	319	0.2%	43	13.5%	28.8%
#181 Elder Maltreatment Screen and Follow-Up Plan	66,876	28	0.0%	13	46.4%	51.8%
#182 Functional Outcome Assessment in Chiropractic Care	47,621	267	0.6%	87	32.6%	48.9%
#183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	67,332	244	0.4%	115	47.1%	51.9%
#184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	67,332	226	0.3%	108	47.8%	49.6%

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	17,191	755	4.4%	388	51.4%	72.4%
#186 Wound Care: Use of Compression System in Patients with Venous Ulcers	11,485	63	0.6%	23	36.5%	55.5%
#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	3,442	2	0.1%	0	0.0%	27.3%
#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	6,814	9	0.1%	3	33.3%	41.3%
#190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	14,519	33	0.2%	4	12.1%	36.5%
#193 Perioperative Temperature Management	85,758	14,699	17.1%	7,397	50.3%	65.8%
#194 Oncology: Cancer Stage Documented	164,221	1,006	0.6%	500	49.7%	72.3%
#195 Stenosis Measurement in Carotid Imaging Studies	65,391	10,686	16.3%	6,693	62.6%	70.3%
#201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	263,487	1,373	0.5%	516	37.6%	53.3%
#202 Ischemic Vascular Disease (IVD): Complete Lipid Profile	263,487	1,514	0.6%	635	41.9%	53.9%

Measure	Eligible Professionals	Eligible Professionals who Reported ≥ 1 Valid QDC	% of Eligible Professionals who Reported ≥ 1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
#203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	263,487	1,054	0.4%	322	30.6%	44.3%
#204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	263,487	1,507	0.6%	505	33.5%	48.7%

Notes for Table A13: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims reporting option only. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) Reporting at least 80% of eligible instances defined satisfactory reporting. (5) The reporting rate was the percent of eligible instances on which the eligible professional reported. (6) Eligible professionals who participated in the claims reporting option reported quality data codes (QDC) to indicate the quality action (i.e., the action was performed, not performed, or did not apply).

Table A14. Individual Measures Submitted through the Claims Reporting Option for the Physician Quality Reporting System Where More than 20% of Reported Instances did not Include the Necessary Diagnosis Code (2010).

Measure	QDCs Reported	QDCs without Necessary Diagnosis Code	
		Count	% of QDCs
#40 Management Following Fracture	95,208	85,244	89.5%
#122 Blood Pressure Management	172,544	126,133	73.1%
#55 ECG Performed for Syncope	1,593,958	918,004	57.6%
#121 Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile)	21,780	7,859	36.1%
#99 Breast Cancer Patients with a pT and pN Category and Histologic Grade	65,713	24,081	36.7%
#24 Communication with the Physician Managing Ongoing Care Post-Fracture	12,024	3,543	29.5%
#106 Patients who have MD Disorder who meet DSM IV Criteria	13,000	3,702	28.5%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	93,298	24,155	25.9%
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	261,182	67,147	25.7%
#107 Patients who have MD Disorder who are Assessed for Suicide Risks	45,263	11,354	25.1%
#153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	15,804	3,955	25.0%
#135 Chronic Kidney Disease (CKD): Influenza Immunization	31,436	7,427	23.6%
#54 ECG Performed for Non-Traumatic Chest Pain	1,624,931	365,846	22.5%
#186 Wound Care: Use of Compression System in Patients with Venous Ulcers	1,993	435	21.8%
#12 Optic Nerve Evaluation	1,054,364	211,053	20.0%

Notes for Table A14: Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims reporting option only. (3) Results were restricted to individual measures (i.e., excluded measures groups).

Table A15. Individual Measures Submitted through the Claims Reporting Option for the Physician Quality Reporting System Where More than 20% of Reported Instances did not Include the Necessary Procedure Code (2010).

Measure	QDCs Reported	QDCs without Necessary Procedure Code	
		Count	% of QDCs
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	3,880,851	3,561,548	91.8%
#45 Discontinuation of Prophylactic Antibiotics	219,567	154,148	70.2%
#181 Elder Maltreatment Screen and Follow-Up Plan	2,752	1,506	54.7%
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery	23,207	8,805	37.9%
#43 Use of IMA in CABG Surgery	33,102	12,183	36.8%
#112 Screening Mammography	183,150	55,165	30.1%
#102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate Cancer Patients	5,715	1,684	29.5%
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	246,968	70,958	28.7%
#134 Screening for Clinical Depression	23,452	6,672	28.5%
#113 CRC Screening	468,371	107,224	22.9%
#23 VTE Prophylaxis	198,225	41,355	20.9%
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	258,980	53,427	20.6%
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	20,465	4,209	20.6%
#30 Timing of Prophylactic Antibiotics - Administering Physician	3,830,516	774,026	20.2%

Notes for Table A15: Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims reporting option only. (3) Results were restricted to individual measures (i.e., excluded measures groups).

Table A16. Individual Measures Submitted through the Claims Reporting Option for the Physician Quality Reporting System Where More than 20% of Reported Instances were for a Patient that did not Meet the Necessary Age Range (2010).

Measure	QDCs Reported	QDCs with Patient Age Unsuitable for the Measure	
		Count	% of QDCs
#175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	6	6	100.0%
#66 Appropriate Testing for Children	1,714	1,711	99.8%
#65 Appropriate Treatment for Children	1,097	1,094	99.7%
#94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	354	352	99.4%
#64 Asthma Assessment	4,003	3,476	86.8%
#53 Pharmacologic Therapy	5,178	4,132	79.8%
#116 Inappropriate Antibiotic Treatment for Adults	1,098	750	68.3%
#117 Dilated Eye Exam in Diabetic Patient	749,200	249,253	33.3%
#112 Screening Mammography	183,150	50,375	27.5%
#163 Diabetes Mellitus: Foot Exam	120,487	31,852	26.4%
#113 CRC Screening	468,371	106,248	22.7%
#3 High Blood Pressure Control	575,525	116,414	20.2%

Notes for Table A16: Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims reporting option only. (3) Results were restricted to individual measures (i.e., excluded measures groups).

Table A17. Incentive Eligibility Information by Reporting Option for the Physician Quality Reporting System (2007 to 2010).

Reporting Methods	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Eligible Professionals	--	--	--	--	--	--	--	--
Claims	--	--	--	--	--	--	--	--
Individual Measures	55,244	53.3%	74,810	51.6%	92,147	49.8%	122,567	61.1%
Measures Groups	N/A	N/A	415	29.4%	603	16.53%	2,182	52.6%
Registry	--	--	--	--	--	--	--	--
Individual Measures	N/A	N/A	8,099	93.6%	20,447	89.9%	34,276	87.3%
Measures Groups	N/A	N/A	3,090	97.6%	9,790	94.53%	16,186	94.5%
EHR	N/A	N/A	N/A	N/A	N/A	N/A	13	92.9%
Total (Unduplicated)	55,244	53.3%	85,450	55.6%	120,665	57.3%	168,843	69.2%

Notes for Table A17: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options. (3) The measures groups reporting option was not available in the 2007 program year. (4) The EHR reporting option was not available before the 2010 program year.

Table A18. Eligible Professionals who Qualified for an Incentive from Individual Measures through the Claims Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
MD/DO	41,617	52.0%	55,189	50.3%	68,071	50.1%	89,198	61.5%
Allergy/Immunology	21	43.8%	35	34.7%	77	40.3%	115	49.6%
Anesthesiology	9,071	95.2%	10,338	80.0%	8,001	46.1%	12,743	63.6%
Cardiology	1,663	40.1%	1,651	33.4%	2,300	40.0%	2,600	48.8%
Colon/Rectal Surgery	44	34.4%	44	27.7%	61	31.8%	86	40.4%
Critical Care	47	25.0%	65	28.1%	103	32.3%	148	41.9%
Dermatology	647	41.8%	58	28.2%	637	33.9%	318	59.1%
Emergency Medicine	14,203	67.9%	21,492	74.8%	24,405	78.7%	27,411	85.6%
Endocrinology	218	42.4%	308	41.2%	399	44.4%	466	53.8%
Family Practice	3,595	43.3%	5,361	44.0%	6,889	47.3%	7,857	53.2%
Gastroenterology	345	31.9%	215	25.9%	437	30.9%	798	43.9%
General Practice	67	51.9%	108	49.3%	160	52.0%	206	55.7%
General Surgery	533	34.1%	740	34.2%	1,003	38.7%	1,393	48.4%
Geriatrics	128	34.5%	155	30.3%	208	37.0%	235	41.3%
Hand Surgery	25	37.9%	36	35.6%	52	37.4%	108	58.1%
Infectious Disease	28	28.9%	79	35.3%	148	38.6%	204	45.1%
Internal Medicine	3,335	38.1%	4,559	37.7%	5,721	40.2%	6,871	47.6%
Interventional Radiologist	59	36.9%	60	24.5%	156	36.0%	285	54.6%
Nephrology	319	29.0%	309	27.1%	440	38.0%	449	42.8%
Neurology	164	27.4%	218	24.1%	398	32.1%	703	47.4%
Neurosurgery	100	34.1%	197	41.5%	260	44.1%	379	59.8%

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Nuclear Medicine	14	42.4%	14	35.9%	48	43.6%	97	70.3%
Obstetrics/Gynecology	162	25.2%	254	24.2%	626	35.4%	880	39.3%
Oncology/Hematology	448	19.7%	499	21.7%	841	32.0%	1,116	42.1%
Ophthalmology	2,162	42.1%	1,558	26.9%	3,269	46.4%	4,374	57.9%
Oral/Maxillofacial Surgery	N/A	N/A	2	33.3%	5	38.5%	5	41.7%
Orthopedic Surgery	676	35.8%	926	39.1%	1,392	41.9%	2,041	55.4%
Other MD/DO	161	33.2%	252	34.9%	323	35.6%	519	50.1%
Otolaryngology	58	35.6%	83	24.1%	244	31.4%	400	44.2%
Pathology	3	42.9%	1,796	42.8%	2,604	57.5%	3,348	70.7%
Pediatrics	73	58.4%	118	57.3%	190	59.6%	212	70.2%
Physical Medicine	43	22.9%	77	20.6%	187	37.0%	281	50.8%
Plastic Surgery	37	48.7%	43	42.2%	80	39.6%	137	55.7%
Psychiatry	79	50.6%	110	38.6%	191	35.4%	310	46.0%
Pulmonary Disease	178	25.3%	300	31.1%	425	35.9%	609	42.5%
Radiation Oncology	139	26.8%	141	17.6%	182	23.1%	283	37.5%
Radiologist	1,814	32.8%	1,815	24.4%	4,065	34.7%	8,899	61.1%
Rheumatology	84	22.6%	135	26.7%	252	35.0%	311	39.4%
Thoracic/Cardiac Surgery	466	50.7%	546	48.8%	510	47.3%	615	59.3%
Urology	284	30.9%	323	24.2%	553	31.7%	996	44.2%
Vascular Surgery	124	32.5%	169	31.8%	229	35.4%	390	53.9%
Other Eligible Professionals	13,530	57.6%	19,546	55.6%	23,881	48.7%	33,312	60.2%
Agencies/Hospitals/Nursing and Treatment Facilities	44	40.0%	73	46.2%	89	43.8%	129	55.4%
Audiologist	0	0.0%	N/A	N/A	64	57.1%	107	62.6%

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Certified Nurse Midwives	4	40.0%	11	34.4%	35	52.2%	45	62.5%
Chiropractor	1	33.3%	10	3.5%	60	13.0%	208	38.1%
Clinical Nurse Specialists	26	44.1%	46	36.5%	72	45.9%	92	51.4%
Counselor/Psychologist	34	46.6%	60	24.0%	110	26.6%	235	51.0%
Dentist	2	50.0%	4	50.0%	6	37.5%	9	45.0%
Dietitian/Nutritionist	50	53.2%	43	32.3%	74	49.7%	88	64.7%
Nurse Anesthetist	4,895	97.4%	7,526	96.1%	6,319	53.6%	9,539	66.8%
Nurse Practitioner	1,545	53.9%	2,332	51.4%	3,326	54.9%	4,352	64.8%
Optometry	1,419	34.5%	1,050	21.7%	1,752	30.0%	2,864	41.2%
Other Eligible Professional	1,635	45.6%	2,115	43.8%	3,714	48.5%	4,486	59.1%
Physical/Occupational Therapy	1,171	35.4%	1,579	32.2%	1,864	32.7%	3,105	51.1%
Physician Assistant	2,533	65.0%	4,303	66.7%	5,806	67.3%	7,097	74.5%
Podiatrist	17	16.0%	47	16.9%	172	17.7%	349	23.3%
Registered Nurse	141	71.6%	310	79.7%	360	53.2%	476	67.3%
Social Worker	13	43.3%	37	32.5%	58	27.8%	131	63.9%
<i>Unknown/Missing</i>	97	51.9%	75	48.7%	195	67.2%	57	62.0%
Total (Unduplicated)	55,244	53.3%	74,810	51.6%	92,147	49.8%	122,567	61.1%

Notes for Table A18: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims reporting option only.

Table A19. Eligible Professionals who Qualified for an Incentive from Measures Groups through the Claims Reporting Option for the Physician Quality Reporting System, by Specialty (2007 to 2010).

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
MD/DO	N/A	N/A	381	29.1%	513	16.3%	1,950	55.9%
Allergy/Immunology	N/A	N/A	0	0.0%	1	25.0%	N/A	N/A
Anesthesiology	N/A	N/A	N/A	N/A	11	29.7%	25	65.8%
Cardiology	N/A	N/A	8	36.4%	7	16.7%	431	77.1%
Colon/Rectal Surgery	N/A	N/A	N/A	N/A	0	0.0%	0	0.0%
Critical Care	N/A	N/A	0	0.0%	1	11.1%	4	80.0%
Dermatology	N/A	N/A	2	40.0%	1	16.7%	5	41.7%
Emergency Medicine	N/A	N/A	0	0.0%	1	16.7%	19	40.4%
Endocrinology	N/A	N/A	9	24.3%	11	15.5%	33	66.0%
Family Practice	N/A	N/A	121	24.4%	110	11.9%	308	40.6%
Gastroenterology	N/A	N/A	2	13.3%	5	17.2%	9	50.0%
General Practice	N/A	N/A	0	0.0%	3	21.4%	6	50.0%
General Surgery	N/A	N/A	3	27.3%	9	6.2%	37	26.4%
Geriatrics	N/A	N/A	5	25.0%	5	16.1%	10	27.8%
Hand Surgery	N/A	N/A	N/A	N/A	0	0.0%	2	50.0%
Infectious Disease	N/A	N/A	0	0.0%	1	50.0%	0	0.0%
Internal Medicine	N/A	N/A	137	28.6%	151	15.2%	545	60.9%
Interventional Radiologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nephrology	N/A	N/A	59	67.8%	16	13.7%	48	52.8%
Neurology	N/A	N/A	2	13.3%	3	15.8%	5	50.0%
Neurosurgery	N/A	N/A	1	20.0%	15	25.4%	36	50.7%

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Nuclear Medicine	N/A	N/A	N/A	N/A	N/A	N/A	0	0.0%
Obstetrics/Gynecology	N/A	N/A	2	22.2%	2	4.9%	13	44.8%
Oncology/Hematology	N/A	N/A	9	52.9%	5	22.7%	6	25.0%
Ophthalmology	N/A	N/A	5	23.8%	2	12.5%	0	0.0%
Oral/Maxillofacial Surgery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Orthopedic Surgery	N/A	N/A	0	0.0%	91	37.1%	171	60.0%
Other MD/DO	N/A	N/A	1	25.0%	6	13.0%	21	51.2%
Otolaryngology	N/A	N/A	0	0.0%	2	33.3%	1	25.0%
Pathology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pediatrics	N/A	N/A	0	0.0%	0	0.0%	1	50.0%
Physical Medicine	N/A	N/A	3	27.3%	9	32.1%	24	53.3%
Plastic Surgery	N/A	N/A	N/A	N/A	2	66.7%	N/A	N/A
Psychiatry	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Pulmonary Disease	N/A	N/A	4	33.3%	6	25.0%	19	55.9%
Radiation Oncology	N/A	N/A	N/A	N/A	2	50.0%	N/A	N/A
Radiologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Rheumatology	N/A	N/A	2	40.0%	27	18.1%	138	67.7%
Thoracic/Cardiac Surgery	N/A	N/A	N/A	N/A	2	22.2%	3	33.3%
Urology	N/A	N/A	3	23.1%	4	23.5%	23	76.7%
Vascular Surgery	N/A	N/A	3	50.0%	2	12.5%	7	53.9%
Other Eligible Professionals	N/A	N/A	34	34.3%	90	18.4%	232	34.9%
Agencies/Hospitals/Nursing and Treatment Facilities	N/A	N/A	2	100.0%	1	50.0%	1	100.0%
Audiologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Certified Nurse Midwives	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Chiropractor	N/A	N/A	N/A	N/A	0	0.0%	N/A	N/A
Clinical Nurse Specialists	N/A	N/A	N/A	N/A	1	33.3%	4	44.4%
Counselor/Psychologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dentist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dietitian/Nutritionist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nurse Anesthetist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Nurse Practitioner	N/A	N/A	12	25.0%	39	23.8%	51	33.3%
Optometry	N/A	N/A	N/A	N/A	5	25.0%	N/A	N/A
Other Eligible Professional	N/A	N/A	15	45.5%	20	13.2%	120	54.1%
Physical/Occupational Therapy	N/A	N/A	N/A	N/A	N/A	N/A	13	8.2%
Physician Assistant	N/A	N/A	4	33.3%	23	20.4%	38	34.9%
Podiatrist	N/A	N/A	0	0.0%	0	0.0%	2	28.6%
Registered Nurse	N/A	N/A	1	33.3%	1	16.7%	3	60.0%
Social Worker	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>Unknown/Missing</i>	N/A	N/A	N/A	N/A	0	0.0%	N/A	N/A
Total (Unduplicated)	N/A	N/A	415	29.4%	603	16.5%	2,182	52.6%

Notes for Table A19: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims reporting option only. (3) The measures groups reporting option was not available in the 2007 program year.

Table A20. Eligible Professionals who Qualified for an Incentive from Individual Measures through the Registry Reporting Option by Specialty for the Physician Quality Reporting System (2007 to 2010).

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
MD/DO	N/A	N/A	6,709	94.7%	17,458	91.6%	28,961	89.0%
Allergy/Immunology	N/A	N/A	30	100.0%	75	92.6%	96	91.4%
Anesthesiology	N/A	N/A	13	68.4%	60	53.6%	136	79.1%
Cardiology	N/A	N/A	325	97.3%	1,303	96.0%	2,090	95.0%
Colon/Rectal Surgery	N/A	N/A	10	100.0%	23	85.2%	48	94.1%
Critical Care	N/A	N/A	21	91.3%	41	95.4%	66	79.5%
Dermatology	N/A	N/A	87	98.9%	240	93.4%	1,194	91.1%
Emergency Medicine	N/A	N/A	111	81.0%	336	91.8%	434	91.4%
Endocrinology	N/A	N/A	109	93.2%	365	95.3%	446	95.5%
Family Practice	N/A	N/A	2,193	96.9%	4,208	93.3%	6,549	92.8%
Gastroenterology	N/A	N/A	111	99.1%	327	97.0%	550	89.7%
General Practice	N/A	N/A	4	100.0%	46	92.0%	72	90.0%
General Surgery	N/A	N/A	179	96.8%	516	92.6%	804	91.3%
Geriatrics	N/A	N/A	55	91.7%	179	93.2%	232	86.6%
Hand Surgery	N/A	N/A	8	100.0%	18	78.3%	58	93.6%
Infectious Disease	N/A	N/A	42	97.7%	195	89.0%	312	90.2%
Internal Medicine	N/A	N/A	1,687	94.5%	4,154	92.2%	6,452	89.1%
Interventional Radiologist	N/A	N/A	7	100.0%	22	84.6%	41	82.0%
Nephrology	N/A	N/A	68	97.1%	253	94.1%	360	90.7%
Neurology	N/A	N/A	116	97.5%	362	93.5%	529	84.4%
Neurosurgery	N/A	N/A	47	94.0%	128	92.1%	189	93.1%

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Nuclear Medicine	N/A	N/A	1	50.0%	9	64.3%	14	53.9%
Obstetrics/Gynecology	N/A	N/A	289	93.5%	756	90.8%	1,102	86.4%
Oncology/Hematology	N/A	N/A	83	98.8%	311	94.8%	598	91.3%
Ophthalmology	N/A	N/A	135	91.2%	390	88.4%	988	93.1%
Oral/Maxillofacial Surgery	N/A	N/A	0	0.0%	N/A	N/A	1	50.0%
Orthopedic Surgery	N/A	N/A	277	97.5%	536	95.2%	780	92.6%
Other MD/DO	N/A	N/A	79	90.8%	119	85.0%	304	81.7%
Otolaryngology	N/A	N/A	78	95.1%	213	93.8%	450	91.8%
Pathology	N/A	N/A	4	57.1%	12	92.3%	7	24.1%
Pediatrics	N/A	N/A	26	40.6%	96	49.7%	145	41.7%
Physical Medicine	N/A	N/A	21	95.5%	93	94.9%	158	86.8%
Plastic Surgery	N/A	N/A	26	100.0%	81	90.0%	105	92.1%
Psychiatry	N/A	N/A	46	97.9%	128	72.7%	128	69.6%
Pulmonary Disease	N/A	N/A	96	97.0%	241	94.9%	435	92.4%
Radiation Oncology	N/A	N/A	22	95.7%	191	90.1%	303	92.7%
Radiologist	N/A	N/A	42	58.3%	322	84.1%	1,215	71.1%
Rheumatology	N/A	N/A	68	98.6%	202	92.7%	260	90.0%
Thoracic/Cardiac Surgery	N/A	N/A	34	100.0%	426	86.4%	550	85.0%
Urology	N/A	N/A	132	97.8%	360	90.2%	587	93.8%
Vascular Surgery	N/A	N/A	27	100.0%	121	87.1%	173	89.6%
Other Eligible Professionals	N/A	N/A	1,386	89.0%	2,974	81.3%	5,313	79.3%
Agencies/Hospitals/Nursing and Treatment Facilities	N/A	N/A	2	40.0%	7	50.0%	27	64.3%
Audiologist	N/A	N/A	2	15.4%	7	21.9%	23	38.3%
Certified Nurse Midwives	N/A	N/A	10	71.4%	17	50.0%	31	58.5%

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Chiropractor	N/A	N/A	2	66.7%	8	66.7%	7	63.6%
Clinical Nurse Specialists	N/A	N/A	20	100.0%	24	80.0%	44	93.6%
Counselor/Psychologist	N/A	N/A	13	52.0%	39	36.8%	40	40.8%
Dentist	N/A	N/A	1	100.0%	3	75.0%	7	63.6%
Dietitian/Nutritionist	N/A	N/A	9	81.8%	38	82.6%	44	81.5%
Nurse Anesthetist	N/A	N/A	N/A	N/A	19	100.0%	11	64.7%
Nurse Practitioner	N/A	N/A	520	90.1%	1,084	86.0%	1,821	81.4%
Optometry	N/A	N/A	46	100.0%	90	90.0%	205	95.4%
Other Eligible Professional	N/A	N/A	118	87.4%	522	82.6%	1,045	78.5%
Physical/Occupational Therapy	N/A	N/A	33	80.5%	55	38.7%	305	68.4%
Physician Assistant	N/A	N/A	512	92.3%	841	89.3%	1,403	81.9%
Podiatrist	N/A	N/A	53	94.6%	143	92.9%	244	93.9%
Registered Nurse	N/A	N/A	17	89.5%	35	74.5%	42	62.7%
Social Worker	N/A	N/A	28	75.7%	42	49.4%	14	40.0%
Unknown/Missing	N/A	N/A	4	50.0%	15	41.7%	2	8.3%
Total (Unduplicated)	N/A	N/A	8,099	93.6%	20,447	89.9%	34,276	87.3%

Notes for Table A20: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the registry reporting option only.

Table A21. Eligible Professionals who Qualified for an Incentive from Measures Groups through the Registry Reporting Option by Specialty for the Physician Quality Reporting System (2007 to 2010).

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
MD/DO	N/A	N/A	2,914	97.7%	8,701	95.3%	14,305	95.3%
Allergy/Immunology	N/A	N/A	41	100.0%	63	98.4%	69	98.6%
Anesthesiology	N/A	N/A	3	100.0%	26	76.5%	28	90.3%
Cardiology	N/A	N/A	91	98.9%	629	96.6%	2,184	95.8%
Colon/Rectal Surgery	N/A	N/A	2	100.0%	37	88.1%	24	77.4%
Critical Care	N/A	N/A	7	100.0%	14	87.5%	25	96.2%
Dermatology	N/A	N/A	4	100.0%	61	96.8%	46	95.8%
Emergency Medicine	N/A	N/A	11	84.6%	25	89.3%	59	96.7%
Endocrinology	N/A	N/A	42	97.7%	126	96.9%	179	98.4%
Family Practice	N/A	N/A	1,438	97.2%	2,746	95.0%	3,880	96.0%
Gastroenterology	N/A	N/A	28	100.0%	130	92.2%	319	93.8%
General Practice	N/A	N/A	17	100.0%	38	95.0%	72	93.5%
General Surgery	N/A	N/A	15	100.0%	146	93.6%	327	93.4%
Geriatrics	N/A	N/A	42	97.7%	89	89.9%	142	94.7%
Hand Surgery	N/A	N/A	1	100.0%	9	90.0%	20	83.3%
Infectious Disease	N/A	N/A	5	100.0%	46	97.9%	83	93.3%
Internal Medicine	N/A	N/A	772	98.2%	1,898	96.8%	2,938	96.5%
Interventional Radiologist	N/A	N/A	N/A	N/A	N/A	N/A	1	100.0%
Nephrology	N/A	N/A	145	100.0%	740	98.0%	1,125	96.7%
Neurology	N/A	N/A	19	95.0%	90	96.8%	81	95.3%
Neurosurgery	N/A	N/A	4	100.0%	34	100.0%	62	92.5%
Nuclear Medicine	N/A	N/A	N/A	N/A	1	100.0%	14	93.3%

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Obstetrics/Gynecology	N/A	N/A	29	93.6%	130	90.9%	212	93.8%
Oncology/Hematology	N/A	N/A	30	100.0%	239	98.8%	292	86.9%
Ophthalmology	N/A	N/A	17	100.0%	125	94.0%	162	84.8%
Oral/Maxillofacial Surgery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Orthopedic Surgery	N/A	N/A	14	93.3%	324	91.3%	556	97.4%
Other MD/DO	N/A	N/A	4	100.0%	45	88.2%	90	91.8%
Otolaryngology	N/A	N/A	21	100.0%	140	95.2%	222	95.3%
Pathology	N/A	N/A	N/A	N/A	1	100.0%	N/A	N/A
Pediatrics	N/A	N/A	N/A	N/A	13	92.9%	15	93.8%
Physical Medicine	N/A	N/A	3	100.0%	52	86.7%	72	97.3%
Plastic Surgery	N/A	N/A	0	0.0%	18	81.8%	16	88.9%
Psychiatry	N/A	N/A	N/A	N/A	6	75.0%	5	45.5%
Pulmonary Disease	N/A	N/A	50	96.2%	131	94.9%	213	95.1%
Radiation Oncology	N/A	N/A	N/A	N/A	28	93.3%	14	53.9%
Radiologist	N/A	N/A	0	0.0%	2	20.0%	2	100.0%
Rheumatology	N/A	N/A	14	100.0%	250	94.0%	350	94.6%
Thoracic/Cardiac Surgery	N/A	N/A	4	100.0%	29	100.0%	53	94.6%
Urology	N/A	N/A	30	100.0%	189	96.9%	283	93.4%
Vascular Surgery	N/A	N/A	11	100.0%	31	88.6%	70	94.6%
Other Eligible Professionals	N/A	N/A	176	96.2%	1,087	89.8%	1,877	89.0%
Agencies/Hospitals/Nursing and Treatment Facilities	N/A	N/A	N/A	N/A	6	40.0%	9	40.9%
Audiologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Certified Nurse Midwives	N/A	N/A	N/A	N/A	2	100.0%	4	100.0%
Chiropractor	N/A	N/A	N/A	N/A	2	50.0%	0	0.0%

Specialty	Eligible Professionals who Qualified for an Incentive							
	2007		2008		2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Clinical Nurse Specialists	N/A	N/A	1	100.0%	9	75.0%	7	100.0%
Counselor/Psychologist	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dentist	N/A	N/A	N/A	N/A	2	66.7%	N/A	N/A
Dietitian/Nutritionist	N/A	N/A	N/A	N/A	2	100.0%	5	100.0%
Nurse Anesthetist	N/A	N/A	N/A	N/A	N/A	N/A	0	0.0%
Nurse Practitioner	N/A	N/A	54	98.2%	304	88.4%	539	90.1%
Optometry	N/A	N/A	4	100.0%	39	88.6%	50	79.4%
Other Eligible Professional	N/A	N/A	78	96.3%	448	93.3%	807	93.2%
Physical/Occupational Therapy	N/A	N/A	N/A	N/A	4	80.0%	32	55.2%
Physician Assistant	N/A	N/A	34	94.4%	192	89.7%	280	90.0%
Podiatrist	N/A	N/A	3	75.0%	71	89.9%	135	93.8%
Registered Nurse	N/A	N/A	2	100.0%	6	100.0%	9	90.0%
Social Worker	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>Unknown/Missing</i>	N/A	N/A	0	0.0%	2	18.2%	4	21.1%
Total (Unduplicated)	N/A	N/A	3,090	97.6%	9,790	94.5%	16,186	94.5%

Notes for Table A21: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the registry reporting option only. (3) The measures groups reporting option was not available in the 2007 program year.

Table A22. Eligible Professional Eligibility and Participation Information by Individual Measure for the Physician Quality Reporting System (2007 to 2010).

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus ^c	229,938	296,552	312,211	326,935	6.3%	7.6%	9.8%	10.1%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	229,938	296,540	312,292	326,617	6.0%	7.3%	9.6%	9.4%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	229,938	296,493	312,122	326,669	6.1%	7.0%	9.0%	9.1%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	175,335	229,284	235,546	3,526	4.0%	4.3%	4.8%	100.0%
6	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	186,013	239,666	246,981	248,762	5.1%	5.4%	7.1%	7.2%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ^{a, b}	61,628	98,133	1,953	4,001	7.4%	6.4%	100.0%	100.0%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	155,671	203,665	207,870	2,081	3.9%	2.5%	3.7%	100.0%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	175,216	238,366	252,456	255,966	0.3%	0.3%	0.5%	0.5%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	25,524	34,262	34,248	33,449	21.1%	21.5%	26.6%	32.4%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	35,648	45,293	46,187	44,213	19.5%	19.4%	22.5%	25.7%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	45,967	68,311	70,802	72,984	13.9%	12.9%	14.8%	16.3%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	30,607	43,472	45,255	45,963	17.6%	16.5%	18.3%	19.3%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	30,607	43,473	45,253	45,974	18.6%	13.1%	9.3%	10.7%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	79,356	101,818	102,657	97,556	6.9%	7.2%	8.5%	9.6%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	68,910	90,892	73,278	69,187	5.9%	6.1%	8.8%	9.9%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	72,313	94,023	94,891	89,932	5.3%	5.5%	5.1%	5.9%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	60,729	78,090	78,336	76,922	5.3%	5.6%	6.9%	7.7%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	71,147	112,008	115,425	101,443	0.8%	0.8%	1.0%	0.9%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	25,099	30,090	30,422	31,663	27.3%	44.9%	49.2%	52.3%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	20,981	29,426	81,831	81,075	80.8%	81.7%	38.1%	43.8%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	53,594	90,981	96,238	97,565	1.5%	1.2%	2.1%	3.4%
32	Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	56,997	90,885	92,260	101,839	2.5%	2.6%	3.4%	4.4%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge ^{a, b}	11,768	23,956	46	687	2.4%	2.5%	100.0%	100.0%
35	Stroke and Stroke Rehabilitation: Screening for	42,265	70,552	73,653	72,588	1.4%	1.2%	1.4%	2.4%

Measures	Eligible Professionals				% of Eligible Professionals who Reported			
	2007	2008	2009	2010	2007	2008	2009	2010
Dysphagia								
36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	40,620	67,683	71,280	81,074	2.2%	2.0%	3.6%	4.5%
39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	428,071	509,352	522,054	532,859	1.0%	1.0%	2.3%	2.3%
40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	71,147	112,011	115,488	101,542	1.3%	1.1%	1.5%	1.4%
41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	134,197	179,241	182,957	180,391	2.4%	2.1%	3.0%	3.2%
43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	3,466	4,098	4,145	4,032	30.4%	31.4%	36.7%	37.6%
44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	3,466	4,098	4,145	4,031	21.2%	22.6%	29.9%	30.6%
45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	3,985	4,872	4,531	4,373	22.7%	23.2%	27.3%	28.7%
46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility ^b	340,794	428,889	283	498,294	0.4%	0.5%	100.0%	0.2%
47 Advance Care Plan	547,335	598,863	616,386	630,016	1.2%	0.9%	1.3%	1.6%
48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	428,071	509,330	527,926	539,520	0.5%	0.7%	1.3%	1.3%
49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	80,130	119,399	125,467	125,304	1.4%	1.4%	2.0%	2.0%
50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	80,130	119,399	125,346	125,324	1.5%	1.4%	1.8%	2.0%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	158,579	207,117	213,281	215,291	1.0%	1.0%	1.5%	1.7%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	158,579	207,115	213,095	215,192	0.8%	0.8%	1.0%	1.2%
53	Asthma: Pharmacologic Therapy	24,439	45,936	49,033	50,359	0.5%	0.8%	1.6%	2.3%
54	12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	54,108	64,069	65,574	69,637	42.7%	52.9%	57.6%	57.0%
55	12-Lead Electrocardiogram (ECG) Performed for Syncope	40,051	50,506	52,051	54,135	47.0%	56.4%	60.7%	62.0%
56	Community-Acquired Pneumonia (CAP): Vital Signs	140,930	197,524	203,661	203,053	11.0%	14.5%	16.1%	17.1%
57	Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	140,930	197,530	203,661	203,053	13.9%	16.5%	18.1%	19.2%
58	Community-Acquired Pneumonia (CAP): Assessment of Mental Status	140,930	197,524	203,661	203,049	10.2%	14.5%	16.1%	17.3%
59	Community-Acquired Pneumonia (CAP): Empiric Antibiotic	140,930	197,530	203,656	203,047	8.4%	10.1%	11.4%	12.4%
64	Asthma: Asthma Assessment	24,439	45,937	48,977	50,033	0.3%	0.5%	1.1%	0.8%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	72	176	187	172	1.4%	0%	1.6%	4.1%
66	Appropriate Testing for Children with Pharyngitis	36	135	144	134	0%	0%	0%	0.8%
67	Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	15,194	24,663	26,893	28,260	5.9%	4.3%	5.4%	5.7%
68	Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	12,356	19,621	21,624	22,970	6.2%	4.6%	6.1%	5.7%
69	Multiple Myeloma: Treatment with Bisphosphonates	19,818	31,967	34,305	35,479	6.7%	4.9%	5.7%	5.8%
70	Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	21,075	32,693	34,685	35,261	5.6%	4.4%	5.0%	5.1%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	83,954	101,354	104,123	131,106	2.9%	1.5%	1.8%	1.6%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	51,662	67,395	68,634	89,303	3.1%	1.8%	2.0%	1.9%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	N/A	87,907	91,087	89,790	N/A	4.9%	10.1%	16.3%
79	End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	N/A	9,004	9,264	9,206	N/A	5.2%	3.1%	2.1%
81	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients ^{a, b}	N/A	8,889	24	13	N/A	7.2%	100.0%	100.0%
82	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis ^{a, b}	N/A	6,666	10	10	N/A	6.5%	100.0%	100.0%
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia ^a	N/A	62,794	65,821	200	N/A	0.5%	0.8%	100.0%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	N/A	32,725	34,821	36,074	N/A	0.8%	1.0%	1.3%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	N/A	32,726	34,821	36,074	N/A	0.8%	1.0%	1.3%
86	Hepatitis C: Antiviral Treatment Prescribed	N/A	32,725	34,821	36,078	N/A	0.6%	0.8%	1.2%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	N/A	32,726	34,821	36,072	N/A	0.4%	0.6%	0.8%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	N/A	62,793	65,819	67,335	N/A	0.4%	0.6%	0.8%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	N/A	23,742	25,205	25,973	N/A	0.4%	0.5%	0.8%
91	Acute Otitis Externa (AOE): Topical Therapy	N/A	85,385	87,451	87,135	N/A	0.4%	0.6%	0.9%
92	Acute Otitis Externa (AOE): Pain Assessment	N/A	85,384	87,427	87,093	N/A	0.3%	0.5%	0.5%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	N/A	85,384	87,449	87,128	N/A	0.3%	0.5%	0.6%
94	Otitis Media with Effusion (OME): Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	N/A	27	21	30	N/A	0%	0%	0%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	N/A	7,491	7,241	7,295	N/A	54.4%	60.4%	62.4%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	N/A	7,117	6,843	6,855	N/A	54.7%	61.4%	63.2%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	N/A	8,747	8,140	7,926	N/A	3.1%	6.7%	6.7%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	N/A	4,475	4,118	4,057	N/A	5.3%	12.0%	12.7%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	N/A	4,405	4,025	3,996	N/A	10.7%	14.3%	15.0%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	N/A	158	104,994	108,495	N/A	100.0%	0.5%	0.7%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	N/A	258	104,994	108,497	N/A	100.0%	0.6%	0.8%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	N/A	140,370	144,593	146,592	N/A	0.4%	0.9%	0.9%
109	Osteoarthritis (OA): Function and Pain Assessment	N/A	208,994	213,195	213,654	N/A	0.3%	0.8%	0.8%
110	Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	N/A	543,704	562,152	575,225	N/A	1.3%	2.5%	3.1%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	N/A	555,840	568,943	569,814	N/A	1.1%	2.7%	3.1%
112	Preventive Care and Screening: Screening Mammography	N/A	504,608	516,596	515,658	N/A	0.9%	2.5%	2.8%
113	Preventive Care and Screening: Colorectal Cancer	N/A	552,107	564,578	558,452	N/A	0.6%	2.2%	2.7%

Measures	Eligible Professionals				% of Eligible Professionals who Reported				
	2007	2008	2009	2010	2007	2008	2009	2010	
Screening									
114	Preventive Care and Screening: Inquiry Regarding Tobacco Use	N/A	539,104	647,158	660,867	N/A	1.5%	3.2%	4.9%
115	Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	N/A	568,072	580,375	660,348	N/A	0.9%	2.1%	2.8%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	N/A	98,563	99,562	98,605	N/A	0.2%	0.3%	0.4%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	N/A	320,355	326,021	340,035	N/A	2.3%	4.0%	4.3%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) ^a	N/A	215,770	222,368	1,751	N/A	0.7%	1.7%	100.0%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	N/A	321,407	311,088	325,831	N/A	1.5%	3.0%	3.1%
121	Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	N/A	37,451	46,391	53,480	N/A	0.7%	3.2%	4.4%
122	Chronic Kidney Disease (CKD): Blood Pressure Management	N/A	37,452	46,294	53,335	N/A	1.2%	3.1%	4.3%
123	Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	N/A	37,450	46,026	52,359	N/A	0.9%	1.6%	1.2%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	N/A	735,245	758,029	761,872	N/A	1.7%	5.0%	6.9%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	N/A	317,190	357,885	338,908	N/A	0.4%	0.8%	1.0%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	N/A	317,155	357,845	338,899	N/A	0.2%	0.6%	0.7%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	N/A	732,278	782,405	704,404	N/A	0.3%	1.1%	1.3%
130	Documentation and Verification of Current Medications in the Medical Record	N/A	265,808	768,825	691,221	N/A	0.7%	2.1%	3.4%
131	Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	N/A	164,139	167,391	170,678	N/A	2.2%	3.3%	3.6%
134	Screening for Clinical Depression and Follow-Up Plan	N/A	96,875	116,337	117,265	N/A	0.2%	0.4%	0.5%
135	Chronic Kidney Disease (CKD): Influenza Immunization	N/A	N/A	46,108	52,367	N/A	N/A	1.6%	1.3%
136	Melanoma: Follow-Up Aspects of Care ^a	N/A	N/A	53,102	1,586	N/A	N/A	4.5%	100.0%
137	Melanoma: Continuity of Care – Recall System ^a	N/A	N/A	53,100	1,582	N/A	N/A	4.2%	100.0%
138	Melanoma: Coordination of Care ^a	N/A	N/A	44,934	1,235	N/A	N/A	2.3%	100.0%
139	Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	N/A	N/A	24,669	12,798	N/A	N/A	12.6%	30.6%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	N/A	N/A	70,379	72,524	N/A	N/A	7.8%	10.0%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	N/A	N/A	43,409	44,154	N/A	N/A	6.4%	8.7%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	N/A	N/A	213,059	213,553	N/A	N/A	0.5%	0.7%
143	Oncology: Medical and Radiation – Pain Intensity Quantified ^a	N/A	N/A	20,975	61	N/A	N/A	2.6%	100.0%
144	Oncology: Medical and Radiation – Plan of Care for Pain ^a	N/A	N/A	352	18	N/A	N/A	98.0%	100.0%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	N/A	N/A	127,892	125,166	N/A	N/A	6.1%	8.7%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening ^c	N/A	N/A	28,703	27,027	N/A	N/A	20.2%	28.4%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	N/A	N/A	19,233	19,251	N/A	N/A	22.8%	33.2%
153	Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	N/A	N/A	46,024	52,360	N/A	N/A	1.0%	1.0%
154	Falls: Risk Assessment	N/A	N/A	606,013	607,967	N/A	N/A	1.5%	1.4%
155	Falls: Plan of Care	N/A	N/A	6,848	6,688	N/A	N/A	47.6%	60.9%
156	Oncology: Radiation Dose Limits to Normal Tissues	N/A	N/A	3,706	3,661	N/A	N/A	8.3%	11.6%
157	Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	N/A	N/A	3,299	3,105	N/A	N/A	1.5%	1.5%
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	N/A	N/A	6,742	6,464	N/A	N/A	4.6%	6.0%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage ^{a, b}	N/A	N/A	92	96	N/A	N/A	100.0%	100.0%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis ^{a, b}	N/A	N/A	74	87	N/A	N/A	100.0%	100.0%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy ^{a, b}	N/A	N/A	60	61	N/A	N/A	100.0%	100.0%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy ^{a, b}	N/A	N/A	69	68	N/A	N/A	100.0%	100.0%
163	Diabetes Mellitus: Foot Exam	N/A	N/A	310,542	324,819	N/A	N/A	1.6%	1.7%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation) ^{a, b, c}	N/A	N/A	15	16	N/A	N/A	100.0%	100.0%
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate ^{a, b, c}	N/A	N/A	11	19	N/A	N/A	100.0%	100.0%

Measures	Eligible Professionals				% of Eligible Professionals who Reported			
	2007	2008	2009	2010	2007	2008	2009	2010
166 Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA) ^{a, b, c}	N/A	N/A	4	11	N/A	N/A	100.0%	100.0%
167 Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency ^{a, b, c}	N/A	N/A	4	7	N/A	N/A	100.0%	100.0%
168 Coronary Artery Bypass Graft (CABG): Surgical Re-exploration ^{a, b, c}	N/A	N/A	12	16	N/A	N/A	100.0%	100.0%
169 Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge ^{a, b}	N/A	N/A	14	16	N/A	N/A	100.0%	100.0%
170 Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge ^{a, b}	N/A	N/A	13	15	N/A	N/A	100.0%	100.0%
171 Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling ^{a, b}	N/A	N/A	13	14	N/A	N/A	100.0%	100.0%
172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	N/A	N/A	4,922	4,823	N/A	N/A	2.7%	3.7%
173 Preventive Care and Screening: Unhealthy Alcohol Use – Screening	N/A	N/A	625,600	662,216	N/A	N/A	0.3%	0.7%
175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	N/A	N/A	260	298	N/A	N/A	3.5%	0%
176 Rheumatoid Arthritis (RA): Tuberculosis Screening	N/A	N/A	130,424	146,538	N/A	N/A	0.4%	0.3%
177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	N/A	N/A	130,424	146,538	N/A	N/A	0.4%	0.4%
178 Rheumatoid Arthritis (RA): Functional Status Assessment	N/A	N/A	130,423	146,537	N/A	N/A	0.4%	0.4%
179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	N/A	N/A	130,423	146,537	N/A	N/A	0.3%	0.3%
180 Rheumatoid Arthritis (RA): Glucocorticoid Management	N/A	N/A	130,423	146,537	N/A	N/A	0.4%	0.4%
181 Elder Maltreatment Screen and Follow-Up Plan	N/A	N/A	65,240	66,877	N/A	N/A	0.1%	0.1%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
182	Functional Outcome Assessment in Chiropractic Care	N/A	N/A	47,529	47,621	N/A	N/A	0.3%	0.6%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	N/A	N/A	55,571	67,361	N/A	N/A	1.2%	0.7%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	N/A	N/A	55,570	67,359	N/A	N/A	1.2%	0.6%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	N/A	N/A	16,486	17,191	N/A	N/A	4.0%	4.8%
186	Wound Care: Use of Compression System in Patients with Venous Ulcers	N/A	N/A	7,851	11,493	N/A	N/A	1.1%	1.0%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy ^a	N/A	N/A	N/A	15	N/A	N/A	N/A	100.0%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	N/A	N/A	N/A	3,444	N/A	N/A	N/A	0.2%
189	Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	N/A	N/A	N/A	6,815	N/A	N/A	N/A	0.2%
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	N/A	N/A	N/A	14,519	N/A	N/A	N/A	0.3%
191	Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery ^a	N/A	N/A	N/A	170	N/A	N/A	N/A	100.0%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures ^{a, c}	N/A	N/A	N/A	148	N/A	N/A	N/A	100.0%
193	Perioperative Temperature Management	N/A	N/A	N/A	85,758	N/A	N/A	N/A	17.2%
194	Oncology: Cancer Stage Documented	N/A	N/A	N/A	164,231	N/A	N/A	N/A	0.7%
195	Stenosis Measurement in Carotid Imaging Studies	N/A	N/A	N/A	65,456	N/A	N/A	N/A	16.9%
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment ^a	N/A	N/A	N/A	596	N/A	N/A	N/A	100.0%
197	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol ^a	N/A	N/A	N/A	1,778	N/A	N/A	N/A	100.0%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
198	Heart Failure: Left Ventricular Function (LVF) Assessment ^a	N/A	N/A	N/A	927	N/A	N/A	N/A	100.0%
199	Heart Failure: Patient Education ^a	N/A	N/A	N/A	624	N/A	N/A	N/A	100.0%
200	Heart Failure: Warfarin Therapy Patients with Atrial Fibrillation ^a	N/A	N/A	N/A	814	N/A	N/A	N/A	100.0%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	N/A	N/A	N/A	264,191	N/A	N/A	N/A	1.7%
202	Ischemic Vascular Disease (IVD): Complete Lipid Profile	N/A	N/A	N/A	263,684	N/A	N/A	N/A	1.2%
203	Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	264,240	N/A	N/A	N/A	1.7%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	N/A	N/A	264,152	N/A	N/A	N/A	1.7%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea ^a	N/A	N/A	N/A	50	N/A	N/A	N/A	100.0%
206	HIV/AIDS: Screening for High Risk Sexual Behaviors ^a	N/A	N/A	N/A	22	N/A	N/A	N/A	100.0%
207	HIV/AIDS: Screening for Injection Drug Use ^a	N/A	N/A	N/A	23	N/A	N/A	N/A	100.0%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis ^a	N/A	N/A	N/A	70	N/A	N/A	N/A	100.0%
209	Functional Communication Measure - Spoken Language Comprehension ^a	N/A	N/A	N/A	10	N/A	N/A	N/A	100.0%
210	Functional Communication Measure - Attention ^a	N/A	N/A	N/A	6	N/A	N/A	N/A	100.0%
211	Functional Communication Measure - Memory ^a	N/A	N/A	N/A	10	N/A	N/A	N/A	100.0%
212	Functional Communication Measure - Motor Speech ^a	N/A	N/A	N/A	6	N/A	N/A	N/A	100.0%
213	Functional Communication Measure - Reading ^a	N/A	N/A	N/A	4	N/A	N/A	N/A	100.0%
214	Functional Communication Measure - Spoken Language Expression ^a	N/A	N/A	N/A	12	N/A	N/A	N/A	100.0%

Measures		Eligible Professionals				% of Eligible Professionals who Reported			
		2007	2008	2009	2010	2007	2008	2009	2010
215	Functional Communication Measure - Writing ^a	N/A	N/A	N/A	3	N/A	N/A	N/A	100.0%
216	Functional Communication Measure - Swallowing ^a	N/A	N/A	N/A	10	N/A	N/A	N/A	100.0%

Notes for Table A22: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting methods. (3) Results were restricted to individual measures (i.e., excluded measures groups). ^a Measure was not reportable via claims (e.g., registry only) during the 2010 program year (Measures 5, 7, 8, 33, 81, 82, 83, 118, 136, 137, 138, 143, 144, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 174, 187, 191, 192, 196, 197, 198, 199, 200, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and 216). ^b Measure was not reportable via claims (e.g., registry only) during the 2009 program year (Measures 7, 33, 46, 81, 82, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171 and 174). ^c Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 146, 164, 165, 166, 167, 168 and 192).

Table A23. Reporting and Performance Information by Individual Measure for the Physician Quality Reporting System (2007 to 2010).

Measures		Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
		2007	2008	2009	2010	2007	2008	2009	2010
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus ^c	66.3%	70.8%	78.8%	80.6%	11.5%	11.3%	12.3%	21.9%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	66.3%	70.6%	79.1%	80.6%	59.8%	66.4%	67.0%	57.0%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	66.6%	69.8%	78.2%	79.9%	53.4%	55.6%	59.3%	58.6%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	64.9%	63.7%	68.2%	91.0%	72.5%	71.9%	94.5%	85.6%
6	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	67.5%	69.8%	76.8%	77.1%	94.4%	90.9%	86.5%	85.3%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ^{a, b}	73.2%	73.7%	99.8%	95.6%	96.7%	93.4%	60.9%	71.4%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	67.6%	69.3%	74.2%	91.8%	66.5%	94.7%	95.0%	82.7%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	59.9%	61.3%	66.9%	62.9%	90.9%	75.0%	60.2%	68.6%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	66.2%	59.9%	66.1%	71.5%	62.5%	61.1%	65.4%	68.0%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	65.3%	61.4%	69.4%	74.5%	96.0%	95.9%	95.9%	95.2%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	61.0%	59.3%	67.9%	70.0%	97.0%	96.8%	96.1%	95.7%

Measures		Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
		2007	2008	2009	2010	2007	2008	2009	2010
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	67.1%	59.1%	66.5%	68.9%	98.5%	97.8%	96.8%	97.0%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	68.9%	56.4%	62.2%	65.8%	51.9%	34.4%	92.5%	91.5%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	66.3%	65.4%	70.9%	73.9%	95.8%	94.2%	92.4%	92.6%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	65.1%	64.9%	70.2%	73.4%	92.9%	90.9%	90.0%	89.4%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	64.1%	63.3%	69.7%	72.0%	55.9%	61.5%	94.5%	93.4%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	66.9%	66.6%	71.0%	72.7%	92.3%	91.0%	90.0%	91.2%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	49.5%	52.6%	66.2%	68.8%	70.8%	61.8%	49.0%	50.6%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	88.1%	86.7%	89.6%	91.4%	82.4%	81.6%	81.5%	83.5%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	96.1%	96.3%	71.8%	78.5%	93.4%	94.2%	91.4%	92.0%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	66.6%	65.3%	72.0%	77.8%	87.0%	79.9%	83.6%	78.6%
32	Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	63.6%	66.3%	70.6%	65.4%	88.3%	82.4%	85.1%	82.8%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge ^{a, b}	84.7%	77.8%	100.0%	85.3%	84.3%	73.3%	45.4%	79.4%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	62.6%	64.5%	67.1%	74.6%	44.8%	51.4%	76.7%	84.3%

Measures		Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
		2007	2008	2009	2010	2007	2008	2009	2010
36	Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	67.9%	66.2%	72.7%	63.1%	82.6%	76.4%	71.9%	69.7%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	46.0%	53.9%	71.3%	71.4%	85.4%	59.9%	56.1%	55.1%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	62.0%	60.1%	70.0%	76.2%	80.3%	71.4%	56.5%	46.8%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	57.9%	60.5%	76.1%	79.6%	94.2%	85.0%	74.7%	72.5%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	79.6%	76.7%	85.9%	90.1%	98.2%	97.9%	97.6%	97.9%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	76.8%	71.4%	86.4%	90.8%	91.1%	92.6%	91.0%	92.0%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	74.5%	69.6%	83.3%	87.8%	68.9%	73.8%	99.4%	99.4%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility ^b	43.7%	44.2%	100.0%	65.7%	65.1%	66.5%	91.6%	91.3%
47	Advance Care Plan	54.4%	56.7%	64.7%	68.2%	49.9%	48.9%	45.7%	50.7%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	49.5%	44.1%	51.5%	54.8%	84.4%	72.0%	57.3%	66.5%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	65.5%	63.3%	74.1%	71.4%	96.4%	85.7%	68.9%	82.5%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	65.9%	64.0%	71.6%	70.3%	94.9%	85.2%	76.4%	82.7%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	59.2%	63.9%	75.9%	74.0%	85.5%	73.0%	53.5%	56.0%

Measures		Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
		2007	2008	2009	2010	2007	2008	2009	2010
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	56.7%	60.1%	70.1%	74.2%	68.0%	67.7%	92.7%	89.7%
53	Asthma: Pharmacologic Therapy	89.2%	86.0%	91.8%	94.3%	78.9%	76.2%	83.4%	81.7%
54	12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	81.8%	82.5%	85.9%	87.7%	93.5%	94.1%	94.6%	95.1%
55	12-Lead Electrocardiogram (ECG) Performed for Syncope	85.4%	85.7%	88.9%	90.6%	94.3%	95.7%	96.1%	96.4%
56	Community-Acquired Pneumonia (CAP): Vital Signs	84.1%	84.0%	88.6%	89.2%	95.1%	94.0%	94.0%	95.0%
57	Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	85.9%	87.0%	89.0%	89.9%	88.7%	91.7%	92.7%	94.0%
58	Community-Acquired Pneumonia (CAP): Assessment of Mental Status	84.3%	85.8%	89.5%	90.1%	93.8%	94.7%	95.4%	96.5%
59	Community-Acquired Pneumonia (CAP): Empiric Antibiotic	83.1%	82.9%	86.1%	86.5%	91.0%	91.5%	92.2%	92.4%
64	Asthma: Asthma Assessment	87.1%	87.3%	92.5%	89.3%	96.9%	57.2%	34.2%	48.6%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	100.0%	N/A	100.0%	100.0%	100.0%	N/A	66.7%	85.7%
66	Appropriate Testing for Children with Pharyngitis	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	100.0%
67	Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	55.1%	57.2%	66.5%	73.7%	95.5%	93.9%	90.9%	88.8%
68	Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	52.7%	54.6%	64.5%	69.3%	72.2%	78.3%	97.7%	94.7%
69	Multiple Myeloma: Treatment with Bisphosphonates	66.1%	64.5%	71.3%	75.9%	93.9%	90.2%	86.1%	81.7%
70	Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	65.0%	66.2%	72.9%	77.9%	94.7%	95.1%	92.6%	88.3%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	49.8%	52.6%	61.5%	69.0%	93.0%	70.4%	96.4%	90.7%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	47.1%	53.4%	62.6%	67.6%	91.7%	73.6%	98.8%	93.2%

Measures	Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
	2007	2008	2009	2010	2007	2008	2009	2010
76 Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	N/A	63.3%	76.1%	80.4%	N/A	81.7%	77.2%	77.4%
79 End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	N/A	36.8%	62.6%	67.1%	N/A	73.2%	63.4%	68.4%
81 End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients ^{a, b}	N/A	56.8%	100.0%	100.0%	N/A	85.7%	16.0%	6.7%
82 End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis ^{a, b}	N/A	54.6%	100.0%	100.0%	N/A	37.2%	0.0%	10.0%
83 Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia ^a	N/A	68.3%	74.2%	98.7%	N/A	54.6%	70.6%	34.8%
84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	N/A	77.5%	76.3%	79.6%	N/A	64.6%	84.5%	86.1%
85 Hepatitis C: HCV Genotype Testing Prior to Treatment	N/A	71.2%	74.8%	77.7%	N/A	67.3%	88.4%	88.4%
86 Hepatitis C: Antiviral Treatment Prescribed	N/A	67.7%	77.6%	84.0%	N/A	61.0%	46.0%	41.3%
87 Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	N/A	70.6%	79.2%	80.2%	N/A	59.1%	74.5%	78.5%
89 Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	N/A	70.1%	72.4%	75.8%	N/A	63.9%	57.6%	59.4%
90 Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	N/A	83.6%	81.9%	83.2%	N/A	61.8%	50.8%	70.2%
91 Acute Otitis Externa (AOE): Topical Therapy	N/A	80.7%	81.3%	82.7%	N/A	62.0%	72.4%	73.8%
92 Acute Otitis Externa (AOE): Pain Assessment	N/A	80.6%	80.1%	76.3%	N/A	34.7%	40.3%	59.4%
93 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	N/A	78.9%	82.0%	81.3%	N/A	37.6%	45.5%	63.3%
94 Otitis Media with Effusion (OME): Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Measures	Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
	2007	2008	2009	2010	2007	2008	2009	2010
99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	N/A	72.6%	80.2%	80.7%	N/A	95.8%	96.6%	97.6%
100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	N/A	80.0%	87.2%	87.4%	N/A	96.9%	97.5%	98.5%
102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	N/A	61.7%	60.0%	72.9%	N/A	53.5%	65.5%	71.6%
104 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	N/A	52.2%	54.6%	72.6%	N/A	75.7%	75.8%	79.6%
105 Prostate Cancer: Three-Dimensional (3D) Radiotherapy	N/A	55.8%	62.5%	70.9%	N/A	83.3%	82.4%	94.7%
106 Major Depressive Disorder (MDD): Diagnostic Evaluation	N/A	100.0%	72.2%	69.6%	N/A	52.8%	68.0%	77.3%
107 Major Depressive Disorder (MDD): Suicide Risk Assessment	N/A	85.2%	66.2%	72.0%	N/A	61.8%	69.0%	80.8%
108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	N/A	76.4%	80.9%	70.2%	N/A	73.4%	66.5%	79.9%
109 Osteoarthritis (OA): Function and Pain Assessment	N/A	62.1%	73.6%	63.9%	N/A	59.3%	41.3%	51.7%
110 Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	N/A	65.7%	72.6%	72.2%	N/A	53.8%	50.9%	51.2%
111 Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	N/A	60.4%	76.7%	75.8%	N/A	56.2%	52.8%	54.5%
112 Preventive Care and Screening: Screening Mammography	N/A	66.9%	76.4%	76.6%	N/A	59.0%	56.1%	53.5%
113 Preventive Care and Screening: Colorectal Cancer Screening	N/A	50.7%	73.9%	73.0%	N/A	59.5%	50.5%	52.0%
114 Preventive Care and Screening: Inquiry Regarding Tobacco Use	N/A	61.0%	68.9%	73.9%	N/A	64.4%	76.2%	79.4%
115 Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	N/A	47.2%	56.8%	63.6%	N/A	46.9%	52.1%	50.5%
116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	N/A	88.9%	90.6%	81.7%	N/A	81.1%	55.3%	42.3%

Measures		Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
		2007	2008	2009	2010	2007	2008	2009	2010
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	N/A	54.6%	65.9%	66.9%	N/A	81.1%	73.0%	79.7%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) ^a	N/A	56.6%	72.4%	90.3%	N/A	82.0%	73.2%	67.2%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	N/A	74.1%	79.2%	78.5%	N/A	71.2%	72.7%	74.0%
121	Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	N/A	56.2%	84.7%	89.3%	N/A	75.4%	35.2%	40.0%
122	Chronic Kidney Disease (CKD): Blood Pressure Management	N/A	61.4%	78.9%	84.3%	N/A	83.0%	68.9%	58.2%
123	Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	N/A	56.0%	61.0%	54.1%	N/A	82.0%	96.0%	94.8%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	N/A	65.3%	74.9%	78.5%	N/A	100.0%	99.2%	99.2%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	N/A	58.3%	66.2%	59.5%	N/A	63.0%	52.8%	74.2%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	N/A	60.9%	67.3%	54.7%	N/A	48.0%	43.9%	66.9%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	N/A	49.8%	54.5%	55.0%	N/A	55.9%	49.6%	60.2%
130	Documentation and Verification of Current Medications in the Medical Record	N/A	56.3%	69.9%	69.2%	N/A	79.7%	68.4%	74.7%
131	Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	N/A	63.1%	65.6%	73.5%	N/A	98.1%	97.4%	97.3%
134	Screening for Clinical Depression and Follow-Up Plan	N/A	54.4%	64.3%	73.0%	N/A	83.4%	67.2%	84.2%
135	Chronic Kidney Disease (CKD): Influenza Immunization	N/A	N/A	75.7%	74.0%	N/A	N/A	49.6%	48.6%

Measures	Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
	2007	2008	2009	2010	2007	2008	2009	2010
136 Melanoma: Follow-Up Aspects of Care ^a	N/A	N/A	71.6%	99.9%	N/A	N/A	92.0%	71.1%
137 Melanoma: Continuity of Care – Recall System ^a	N/A	N/A	72.7%	99.9%	N/A	N/A	90.8%	78.2%
138 Melanoma: Coordination of Care ^a	N/A	N/A	65.7%	99.9%	N/A	N/A	87.2%	87.7%
139 Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	N/A	N/A	81.0%	85.0%	N/A	N/A	97.4%	97.5%
140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	N/A	N/A	60.1%	63.0%	N/A	N/A	92.0%	92.1%
141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	N/A	N/A	57.1%	58.6%	N/A	N/A	93.4%	94.2%
142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	N/A	N/A	71.3%	61.2%	N/A	N/A	41.9%	61.6%
143 Oncology: Medical and Radiation – Pain Intensity Quantified ^a	N/A	N/A	65.2%	99.9%	N/A	N/A	66.8%	31.8%
144 Oncology: Medical and Radiation – Plan of Care for Pain ^a	N/A	N/A	91.3%	100.0%	N/A	N/A	91.2%	90.0%
145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	N/A	N/A	65.4%	77.7%	N/A	N/A	41.6%	48.1%
146 Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening ^c	N/A	N/A	75.1%	83.3%	N/A	N/A	2.7%	1.1%
147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	N/A	N/A	77.3%	82.3%	N/A	N/A	57.3%	54.8%
153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	N/A	N/A	66.6%	66.9%	N/A	N/A	43.8%	51.1%
154 Falls: Risk Assessment	N/A	N/A	55.9%	62.7%	N/A	N/A	87.1%	91.9%
155 Falls: Plan of Care	N/A	N/A	83.4%	87.1%	N/A	N/A	86.6%	88.0%
156 Oncology: Radiation Dose Limits to Normal Tissues	N/A	N/A	70.6%	73.9%	N/A	N/A	89.2%	93.2%

Measures	Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
	2007	2008	2009	2010	2007	2008	2009	2010
157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	N/A	N/A	73.9%	80.9%	N/A	N/A	77.7%	81.6%
158 Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	N/A	N/A	75.1%	81.2%	N/A	N/A	91.5%	93.8%
159 HIV/AIDS: CD4+ Cell Count or CD4+ Percentage ^{a, b}	N/A	N/A	100.0%	99.6%	N/A	N/A	76.8%	83.9%
160 HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis ^{a, b}	N/A	N/A	100.0%	99.6%	N/A	N/A	61.5%	75.8%
161 HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy ^{a, b}	N/A	N/A	100.0%	97.7%	N/A	N/A	90.3%	97.2%
162 HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy ^{a, b}	N/A	N/A	100.0%	98.5%	N/A	N/A	76.7%	75.5%
163 Diabetes Mellitus: Foot Exam	N/A	N/A	68.8%	59.0%	N/A	N/A	51.7%	72.1%
164 Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation) ^{a, b, c}	N/A	N/A	100.0%	100.0%	N/A	N/A	73.9%	93.9%
165 Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate ^{a, b, c}	N/A	N/A	100.0%	99.8%	N/A	N/A	100.0%	79.0%
166 Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA) ^{a, b, c}	N/A	N/A	100.0%	99.7%	N/A	N/A	100.0%	63.6%
167 Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency ^{a, b, c}	N/A	N/A	100.0%	100.0%	N/A	N/A	100.0%	100.0%
168 Coronary Artery Bypass Graft (CABG): Surgical Re-exploration ^{a, b, c}	N/A	N/A	100.0%	100.0%	N/A	N/A	92.3%	94.1%
169 Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge ^{a, b}	N/A	N/A	100.0%	91.3%	N/A	N/A	7.1%	37.5%
170 Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge ^{a, b}	N/A	N/A	100.0%	88.3%	N/A	N/A	0.0%	33.2%

Measures	Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
	2007	2008	2009	2010	2007	2008	2009	2010
171 Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling ^{a, b}	N/A	N/A	100.0%	93.1%	N/A	N/A	0.0%	28.4%
172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	N/A	N/A	64.1%	71.2%	N/A	N/A	91.2%	94.6%
173 Preventive Care and Screening: Unhealthy Alcohol Use – Screening	N/A	N/A	78.4%	50.3%	N/A	N/A	31.0%	63.2%
175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	N/A	N/A	100.0%	N/A	N/A	N/A	1.6%	N/A
176 Rheumatoid Arthritis (RA): Tuberculosis Screening	N/A	N/A	74.8%	56.9%	N/A	N/A	90.0%	85.7%
177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	N/A	N/A	74.7%	59.7%	N/A	N/A	38.2%	61.6%
178 Rheumatoid Arthritis (RA): Functional Status Assessment	N/A	N/A	75.7%	60.9%	N/A	N/A	38.4%	62.2%
179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	N/A	N/A	75.2%	59.9%	N/A	N/A	33.2%	55.5%
180 Rheumatoid Arthritis (RA): Glucocorticoid Management	N/A	N/A	76.8%	60.8%	N/A	N/A	90.3%	95.9%
181 Elder Maltreatment Screen and Follow-Up Plan	N/A	N/A	75.4%	74.0%	N/A	N/A	50.9%	55.3%
182 Functional Outcome Assessment in Chiropractic Care	N/A	N/A	31.0%	50.2%	N/A	N/A	85.0%	76.6%
183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	N/A	N/A	90.1%	83.3%	N/A	N/A	39.4%	47.3%
184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	N/A	N/A	90.2%	83.4%	N/A	N/A	41.0%	51.6%
185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	N/A	N/A	72.0%	73.5%	N/A	N/A	87.0%	92.5%
186 Wound Care: Use of Compression System in Patients with Venous Ulcers	N/A	N/A	81.4%	80.0%	N/A	N/A	83.4%	80.4%
187 Stroke and Stroke Rehabilitation: Thrombolytic Therapy ^a	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	83.3%
188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	N/A	N/A	N/A	74.4%	N/A	N/A	N/A	100.0%

Measures		Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
		2007	2008	2009	2010	2007	2008	2009	2010
189	Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	N/A	N/A	N/A	70.3%	N/A	N/A	N/A	87.5%
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	N/A	N/A	N/A	40.3%	N/A	N/A	N/A	88.7%
191	Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery ^a	N/A	N/A	N/A	98.5%	N/A	N/A	N/A	90.6%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures ^{a,c}	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	3.4%
193	Perioperative Temperature Management	N/A	N/A	N/A	67.0%	N/A	N/A	N/A	85.3%
194	Oncology: Cancer Stage Documented	N/A	N/A	N/A	71.6%	N/A	N/A	N/A	85.6%
195	Stenosis Measurement in Carotid Imaging Studies	N/A	N/A	N/A	75.3%	N/A	N/A	N/A	59.5%
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment ^a	N/A	N/A	N/A	99.7%	N/A	N/A	N/A	47.1%
197	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol ^a	N/A	N/A	N/A	97.9%	N/A	N/A	N/A	75.3%
198	Heart Failure: Left Ventricular Function (LVF) Assessment ^a	N/A	N/A	N/A	99.1%	N/A	N/A	N/A	45.6%
199	Heart Failure: Patient Education ^a	N/A	N/A	N/A	99.8%	N/A	N/A	N/A	43.4%
200	Heart Failure: Warfarin Therapy Patients with Atrial Fibrillation ^a	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	72.1%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	N/A	N/A	N/A	86.1%	N/A	N/A	N/A	76.1%
202	Ischemic Vascular Disease (IVD): Complete Lipid Profile	N/A	N/A	N/A	79.9%	N/A	N/A	N/A	68.7%
203	Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	87.5%	N/A	N/A	N/A	53.2%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	N/A	N/A	83.7%	N/A	N/A	N/A	74.7%

Measures	Average % of Instances Reported per Eligible Professional				Average Performance Rate per Eligible Professional			
	2007	2008	2009	2010	2007	2008	2009	2010
205 HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea ^a	N/A	N/A	N/A	96.4%	N/A	N/A	N/A	32.4%
206 HIV/AIDS: Screening for High Risk Sexual Behaviors ^a	N/A	N/A	N/A	98.5%	N/A	N/A	N/A	28.6%
207 HIV/AIDS: Screening for Injection Drug Use ^a	N/A	N/A	N/A	96.8%	N/A	N/A	N/A	32.3%
208 HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis ^a	N/A	N/A	N/A	96.2%	N/A	N/A	N/A	50.3%
209 Functional Communication Measure - Spoken Language Comprehension ^a	N/A	N/A	N/A	80.8%	N/A	N/A	N/A	58.8%
210 Functional Communication Measure - Attention ^a	N/A	N/A	N/A	88.9%	N/A	N/A	N/A	58.3%
211 Functional Communication Measure - Memory ^a	N/A	N/A	N/A	83.0%	N/A	N/A	N/A	55.5%
212 Functional Communication Measure - Motor Speech ^a	N/A	N/A	N/A	81.5%	N/A	N/A	N/A	66.7%
213 Functional Communication Measure - Reading ^a	N/A	N/A	N/A	87.5%	N/A	N/A	N/A	58.3%
214 Functional Communication Measure - Spoken Language Expression ^a	N/A	N/A	N/A	77.6%	N/A	N/A	N/A	45.8%
215 Functional Communication Measure - Writing ^a	N/A	N/A	N/A	80.0%	N/A	N/A	N/A	16.7%
216 Functional Communication Measure - Swallowing ^a	N/A	N/A	N/A	84.7%	N/A	N/A	N/A	73.6%

Notes for Table A23: (1) Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an eligible professional participated in multiple options, we used reporting and performance information in accordance with the following hierarchy: EHR, claims, and then registry. ^a Measure was not reportable via claims (e.g., registry only) during the 2010 program year (Measures 5, 7, 8, 33, 81, 82, 83, 118, 136, 137, 138, 143, 144, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 174, 187, 191, 192, 196, 197, 198, 199, 200, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and 216). ^b Measure was not reportable via claims (e.g., registry only) during the 2009 program year (Measures 7, 33, 46, 81, 82, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171 and 174). ^c Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 146, 164, 165, 166, 167, 168 and 192).

Table A24. Eligible Professional Individual Measure Reporting Consistency Across Program Years for the Physician Quality Reporting System (2007 to 2010).

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
1 Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus ^c	6,292	5,528	8,079	12,059	2.19	1.14
2 Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	6,045	5,558	7,658	10,749	2.23	1.14
3 Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	5,840	5,033	7,064	10,815	2.21	1.15
5 Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	384	537	720	1,819	1.85	1.05
6 Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	3,778	1,972	4,790	6,933	2.15	1.16
7 Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ^{a, b}	100	160	667	2,622	1.36	0.70
8 Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	180	280	428	1,108	1.77	1.00
9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	103	97	399	738	1.67	0.91
10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	3,270	1,603	2,553	3,002	2.49	1.21
12 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	4,209	1,829	2,421	2,418	2.72	1.19

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	3,906	2,265	2,540	2,661	2.65	1.18
18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	2,802	1,669	1,848	1,983	2.64	1.18
19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	1,492	724	840	1,227	2.58	1.23
20 Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	2,914	1,506	2,060	2,533	2.53	1.21
21 Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	2,081	1,128	1,607	1,786	2.53	1.19
22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	1,433	848	1,249	1,569	2.42	1.19
23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	1,769	975	1,321	1,696	2.49	1.21
24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	159	203	222	246	2.33	1.09
28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	2,864	3,632	3,263	5,396	2.26	1.13
30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	9,937	5,193	10,557	9,248	2.45	1.16
31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	199	170	783	2,047	1.54	0.85
32 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	462	483	1,019	2,337	1.78	1.02

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
33 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge ^{a, b}	N/A	N/A	16	538	1.03	0.17
35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	119	112	372	1,032	1.58	0.90
36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	238	249	1,055	1,941	1.65	0.88
39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	482	1,326	4,776	5,376	1.74	0.81
40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	90	169	457	603	1.81	0.91
41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	573	512	2,010	2,505	1.85	0.96
43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	551	175	434	313	2.65	1.18
44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	351	145	437	259	2.49	1.13
45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	381	151	385	299	2.50	1.17
46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility ^b	N/A	N/A	168	476	1.26	0.44
47 Advance Care Plan	657	1,158	2,485	5,176	1.71	0.93
48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	727	976	2,337	2,935	1.93	0.99
49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	431	406	688	922	2.14	1.11

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	464	356	586	993	2.12	1.15
51 Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	467	425	951	1,702	1.90	1.06
52 Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	354	277	711	1,281	1.89	1.06
53 Asthma: Pharmacologic Therapy	17	45	310	788	1.39	0.64
54 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	12,525	6,869	8,362	10,762	2.55	1.21
55 12-Lead Electrocardiogram (ECG) Performed for Syncope	10,355	6,023	6,500	9,489	2.53	1.21
56 Community-Acquired Pneumonia (CAP): Vital Signs	8,451	8,057	7,401	10,040	2.44	1.16
57 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	10,783	7,639	8,072	11,515	2.47	1.19
58 Community-Acquired Pneumonia (CAP): Assessment of Mental Status	7,867	8,364	7,651	10,352	2.40	1.14
59 Community-Acquired Pneumonia (CAP): Empiric Antibiotic	6,237	5,018	5,532	7,618	2.40	1.17
64 Asthma: Asthma Assessment	13	37	113	213	1.60	0.80
65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	N/A	N/A	N/A	7	1.00	0.00
66 Appropriate Testing for Children with Pharyngitis	N/A	N/A	N/A	1	1.00	N/A
67 Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	374	197	445	523	2.27	1.17
68 Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	202	131	481	378	2.13	1.04

Measures		Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
		2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
69	Multiple Myeloma: Treatment with Bisphosphonates	450	288	607	601	2.30	1.14
70	Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	484	259	460	483	2.44	1.18
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	498	221	430	686	2.29	1.22
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	316	200	371	536	2.21	1.17
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	N/A	2,772	4,205	7,358	1.68	0.78
79	End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	N/A	99	46	40	2.32	0.81
81	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients ^{a, b}	N/A	6	2	5	2.08	0.95
82	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis ^{a, b}	N/A	3	3	4	1.90	0.88
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia ^a	N/A	26	26	145	1.40	0.71
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	N/A	94	74	260	1.61	0.82
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	N/A	96	83	248	1.64	0.82
86	Hepatitis C: Antiviral Treatment Prescribed	N/A	64	52	286	1.45	0.75
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	N/A	42	44	185	1.47	0.75
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	N/A	86	86	378	1.47	0.75
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	N/A	24	25	145	1.38	0.70

Measures		Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
		2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
91	Acute Otitis Externa (AOE): Topical Therapy	N/A	117	176	498	1.52	0.74
92	Acute Otitis Externa (AOE): Pain Assessment	N/A	109	76	268	1.65	0.84
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	N/A	93	134	311	1.59	0.77
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	N/A	2,935	717	756	2.49	0.77
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	N/A	2,698	694	771	2.46	0.79
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	N/A	106	228	182	1.85	0.73
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	N/A	89	242	174	1.83	0.70
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	N/A	181	158	229	1.92	0.85
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	N/A	66	259	376	1.56	0.66
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	N/A	99	284	421	1.60	0.70
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	N/A	185	441	688	1.62	0.72
109	Osteoarthritis (OA): Function and Pain Assessment	N/A	219	740	789	1.67	0.69
110	Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	N/A	2,535	5,072	9,890	1.58	0.73
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	N/A	2,360	5,845	9,523	1.60	0.71

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
112 Preventive Care and Screening: Screening Mammography	N/A	1,496	5,880	6,751	1.63	0.67
113 Preventive Care and Screening: Colorectal Cancer Screening	N/A	1,375	5,923	7,485	1.59	0.65
114 Preventive Care and Screening: Inquiry Regarding Tobacco Use	N/A	4,465	9,045	18,138	1.57	0.73
115 Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	N/A	2,287	5,681	10,518	1.55	0.70
116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	N/A	38	52	291	1.34	0.65
117 Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	N/A	4,150	4,540	5,707	1.89	0.82
118 Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) ^a	N/A	211	313	1,222	1.42	0.70
119 Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	N/A	1,977	3,443	4,728	1.73	0.77
121 Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	N/A	127	800	1,433	1.45	0.60
122 Chronic Kidney Disease (CKD): Blood Pressure Management	N/A	198	780	1,287	1.52	0.65
123 Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	N/A	100	285	238	1.78	0.70
124 Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	N/A	7,039	20,504	24,796	1.66	0.70
126 Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	N/A	357	1,056	1,862	1.54	0.68

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
127 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	N/A	216	841	1,185	1.57	0.66
128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	N/A	943	3,069	4,823	1.56	0.68
130 Documentation and Verification of Current Medications in the Medical Record	N/A	967	9,125	13,610	1.47	0.57
131 Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	N/A	1,942	2,142	2,022	1.99	0.81
134 Screening for Clinical Depression and Follow-Up Plan	N/A	62	207	315	1.57	0.68
135 Chronic Kidney Disease (CKD): Influenza Immunization	N/A	N/A	318	345	1.48	0.50
136 Melanoma: Follow-Up Aspects of Care ^a	N/A	N/A	847	739	1.53	0.50
137 Melanoma: Continuity of Care – Recall System ^a	N/A	N/A	832	750	1.53	0.50
138 Melanoma: Coordination of Care ^a	N/A	N/A	382	853	1.31	0.46
139 Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	N/A	N/A	2,765	1,154	1.71	0.46
140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	N/A	N/A	4,598	2,625	1.64	0.48
141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	N/A	N/A	2,265	1,575	1.59	0.49
142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	N/A	N/A	642	899	1.42	0.49
143 Oncology: Medical and Radiation – Pain Intensity Quantified ^a	N/A	N/A	37	24	1.61	0.49
144 Oncology: Medical and Radiation – Plan of Care for Pain ^a	N/A	N/A	9	9	1.50	0.51

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	N/A	N/A	6,523	4,348	1.60	0.49
146 Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening ^c	N/A	N/A	4,760	2,920	1.62	0.49
147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	N/A	N/A	3,713	2,677	1.58	0.49
153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	N/A	N/A	276	266	1.51	0.50
154 Falls: Risk Assessment	N/A	N/A	5,672	2,990	1.65	0.48
155 Falls: Plan of Care	N/A	N/A	2,308	1,765	1.57	0.50
156 Oncology: Radiation Dose Limits to Normal Tissues	N/A	N/A	234	189	1.55	0.50
157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	N/A	N/A	22	25	1.47	0.50
158 Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	N/A	N/A	211	176	1.55	0.50
159 HIV/AIDS: CD4+ Cell Count or CD4+ Percentage ^{a, b}	N/A	N/A	42	54	1.44	0.50
160 HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis ^{a, b}	N/A	N/A	38	49	1.44	0.50
161 HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy ^{a, b}	N/A	N/A	25	36	1.41	0.50
162 HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy ^{a, b}	N/A	N/A	39	29	1.57	0.50
163 Diabetes Mellitus: Foot Exam	N/A	N/A	2,247	3,187	1.41	0.49
164 Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation) ^{a, b, c}	N/A	N/A	9	7	1.56	0.51

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
165 Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate ^{a, b, c}	N/A	N/A	8	11	1.42	0.51
166 Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA) ^{a, b, c}	N/A	N/A	N/A	11	1.00	0.00
167 Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency ^{a, b, c}	N/A	N/A	N/A	7	1.00	0.00
168 Coronary Artery Bypass Graft (CABG): Surgical Re-exploration ^{a, b, c}	N/A	N/A	9	7	1.56	0.51
169 Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge ^{a, b}	N/A	N/A	9	7	1.56	0.51
170 Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge ^{a, b}	N/A	N/A	8	7	1.53	0.52
171 Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling ^{a, b}	N/A	N/A	8	6	1.57	0.51
172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	N/A	N/A	100	79	1.56	0.50
173 Preventive Care and Screening: Unhealthy Alcohol Use – Screening	N/A	N/A	959	3,681	1.21	0.40
176 Rheumatoid Arthritis (RA): Tuberculosis Screening	N/A	N/A	198	301	1.40	0.49
177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	N/A	N/A	203	385	1.35	0.48
178 Rheumatoid Arthritis (RA): Functional Status Assessment	N/A	N/A	230	371	1.38	0.49
179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	N/A	N/A	181	298	1.38	0.49

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
180 Rheumatoid Arthritis (RA): Glucocorticoid Management	N/A	N/A	190	373	1.34	0.47
181 Elder Maltreatment Screen and Follow-Up Plan	N/A	N/A	38	5	1.88	0.32
182 Functional Outcome Assessment in Chiropractic Care	N/A	N/A	113	156	1.42	0.49
183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	N/A	N/A	160	301	1.35	0.48
184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	N/A	N/A	166	268	1.38	0.49
185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	N/A	N/A	506	322	1.61	0.49
186 Wound Care: Use of Compression System in Patients with Venous Ulcers	N/A	N/A	31	81	1.28	0.45
187 Stroke and Stroke Rehabilitation: Thrombolytic Therapy ^a	N/A	N/A	N/A	15	1.00	0.00
188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	N/A	N/A	N/A	5	1.00	0.00
189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	N/A	N/A	N/A	16	1.00	0.00
190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	N/A	N/A	N/A	37	1.00	0.00
191 Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery ^a	N/A	N/A	N/A	170	1.00	0.00
192 Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures ^{a, c}	N/A	N/A	N/A	148	1.00	0.00
193 Perioperative Temperature Management	N/A	N/A	N/A	14,749	1.00	0.00
194 Oncology: Cancer Stage Documented	N/A	N/A	N/A	1,212	1.00	0.00
195 Stenosis Measurement in Carotid Imaging Studies	N/A	N/A	N/A	11,075	1.00	0.00

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
196 Coronary Artery Disease (CAD): Symptom and Activity Assessment ^a	N/A	N/A	N/A	596	1.00	0.00
197 Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol ^a	N/A	N/A	N/A	1,778	1.00	0.00
198 Heart Failure: Left Ventricular Function (LVF) Assessment ^a	N/A	N/A	N/A	927	1.00	0.00
199 Heart Failure: Patient Education ^a	N/A	N/A	N/A	624	1.00	0.00
200 Heart Failure: Warfarin Therapy Patients with Atrial Fibrillation ^a	N/A	N/A	N/A	814	1.00	0.00
201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	N/A	N/A	N/A	4,574	1.00	0.00
202 Ischemic Vascular Disease (IVD): Complete Lipid Profile	N/A	N/A	N/A	3,272	1.00	0.00
203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	4,442	1.00	0.00
204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	N/A	N/A	4,465	1.00	0.00
205 HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea ^a	N/A	N/A	N/A	50	1.00	0.00
206 HIV/AIDS: Screening for High Risk Sexual Behaviors ^a	N/A	N/A	N/A	22	1.00	0.00
207 HIV/AIDS: Screening for Injection Drug Use ^a	N/A	N/A	N/A	23	1.00	0.00
208 HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis ^a	N/A	N/A	N/A	70	1.00	0.00
209 Functional Communication Measure - Spoken Language Comprehension ^a	N/A	N/A	N/A	10	1.00	0.00
210 Functional Communication Measure - Attention ^a	N/A	N/A	N/A	6	1.00	0.00
211 Functional Communication Measure - Memory ^a	N/A	N/A	N/A	10	1.00	0.00

Measures	Eligible Professionals who Participated ^d				Number of Years Eligible Professional Reported the Measure ^e	
	2007 to 2010	2008 to 2010	2009 to 2010	2010 Only	Average	Standard Deviation
212 Functional Communication Measure - Motor Speech ^a	N/A	N/A	N/A	6	1.00	0.00
213 Functional Communication Measure - Reading ^a	N/A	N/A	N/A	4	1.00	0.00
214 Functional Communication Measure - Spoken Language Expression ^a	N/A	N/A	N/A	12	1.00	0.00
215 Functional Communication Measure - Writing ^a	N/A	N/A	N/A	3	1.00	0.00
216 Functional Communication Measure - Swallowing ^a	N/A	N/A	N/A	10	1.00	0.00
Total	56,106	39,200	63,742	77,838	2.31	1.16

Notes for Table A24: Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims and registry reporting options; EHR was not included because it was not available before the 2010 program year. (3) Results were restricted to individual measures (i.e., excluded measures groups). ^a Measure was not reportable via claims (e.g., registry only) during the 2010 program year (Measures 5, 7, 8, 33, 81, 82, 83, 118, 136, 137, 138, 143, 144, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 174, 187, 191, 192, 196, 197, 198, 199, 200, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and 216). ^b Measure was not reportable via claims (e.g., registry only) during the 2009 program year (Measures 7, 33, 46, 81, 82, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171 and 174). ^c Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 146, 164, 165, 166, 167, 168 and 192). ^d This section describes continuous participation. Therefore, if an EP participated in multiple years, but not continuously (e.g., 2008 and 2010, but not 2009) they were not included in this section. ^e This section describes all EPs who participated in the measure in program year 2010.

Table A25. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for 4 Years for the Physician Quality Reporting System (2007 to 2010).

Measures	Eligible Professionals who Reported the Measure 4- years Continuously	Average Performance Rate per Eligible Professional				Growth Rate
		2007	2008	2009	2010	
1 Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus ^c	6,292	11.2%	11.2%	10.8%	16.6%	13.9%
2 Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	6,045	61.4%	68.5%	69.1%	62.3%	0.5%
3 Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	5,840	54.3%	56.9%	60.0%	60.8%	3.8%
5 Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	384	84.1%	80.3%	96.8%	90.6%	2.5%
6 Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	3,778	95.0%	94.8%	95.4%	94.3%	-0.2%
7 Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ^{a, b}	100	96.4%	96.9%	84.2%	85.6%	-3.9%
8 Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	180	81.9%	97.9%	96.9%	95.4%	5.2%
9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	103	89.4%	89.0%	96.7%	94.4%	1.8%
10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	3,270	62.2%	62.4%	67.7%	70.6%	4.3%
12 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	4,209	96.6%	97.0%	97.0%	96.5%	0.0%

Measures	Eligible Professionals who Reported the Measure 4- years Continuously	Average Performance Rate per Eligible Professional				Growth Rate
		2007	2008	2009	2010	
14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	3,906	97.7%	97.8%	97.7%	97.0%	-0.3%
18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	2,802	98.7%	98.3%	98.4%	98.2%	-0.2%
19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	1,492	70.0%	50.2%	94.3%	93.9%	10.3%
20 Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	2,914	95.8%	96.4%	96.9%	97.3%	0.5%
21 Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	2,081	93.8%	94.0%	94.9%	94.6%	0.3%
22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	1,433	78.4%	84.4%	96.0%	95.4%	6.8%
23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	1,769	93.5%	94.0%	95.3%	95.9%	0.9%
24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	159	61.1%	63.0%	63.3%	61.3%	0.1%
28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	2,864	82.1%	83.0%	82.7%	83.3%	0.5%
30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	9,937	93.8%	94.8%	92.5%	92.9%	-0.3%
31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	199	88.2%	88.5%	90.6%	88.4%	0.1%
32 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	462	86.5%	84.3%	88.5%	87.1%	0.2%

Measures	Eligible Professionals who Reported the Measure 4- years Continuously	Average Performance Rate per Eligible Professional				Growth Rate
		2007	2008	2009	2010	
35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	119	46.5%	61.7%	85.7%	87.3%	23.4%
36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	238	80.0%	81.8%	79.9%	76.6%	-1.4%
39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	482	91.0%	78.7%	79.4%	79.5%	-4.4%
40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	90	80.1%	75.7%	68.2%	61.8%	-8.3%
41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	573	94.3%	94.5%	93.5%	91.4%	-1.0%
43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	551	98.7%	98.4%	98.5%	98.1%	-0.2%
44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	351	92.0%	93.3%	93.5%	93.4%	0.5%
45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	381	81.6%	84.2%	99.9%	99.6%	6.9%
47 Advance Care Plan	657	67.1%	70.6%	76.1%	74.5%	3.5%
48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	727	83.5%	84.2%	81.8%	82.9%	-0.2%
49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	431	96.8%	98.5%	97.5%	97.4%	0.2%
50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	464	94.9%	96.2%	96.4%	97.1%	0.8%
51 Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	467	93.7%	93.5%	92.4%	93.3%	-0.1%

Measures	Eligible Professionals who Reported the Measure 4- years Continuously	Average Performance Rate per Eligible Professional				Growth Rate
		2007	2008	2009	2010	
52 Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	354	78.4%	83.5%	99.1%	99.3%	8.2%
53 Asthma: Pharmacologic Therapy	17	100.0%	100.0%	100.0%	100.0%	0.0%
54 12-Lead Electrocardiogram (ECG) Performed for Non- Traumatic Chest Pain	12,525	94.1%	95.3%	95.5%	96.0%	0.7%
55 12-Lead Electrocardiogram (ECG) Performed for Syncope	10,355	94.6%	96.1%	96.4%	96.8%	0.8%
56 Community-Acquired Pneumonia (CAP): Vital Signs	8,451	95.5%	96.6%	97.2%	97.6%	0.7%
57 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	10,783	89.8%	93.2%	94.9%	95.8%	2.2%
58 Community-Acquired Pneumonia (CAP): Assessment of Mental Status	7,867	94.3%	96.4%	97.0%	97.4%	1.1%
59 Community-Acquired Pneumonia (CAP): Empiric Antibiotic	6,237	91.9%	94.1%	95.2%	95.0%	1.1%
64 Asthma: Asthma Assessment	13	100.0%	100.0%	100.0%	100.0%	0.0%
67 Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	374	94.0%	94.8%	95.5%	97.0%	1.1%
68 Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	202	78.0%	84.4%	99.2%	98.4%	8.1%
69 Multiple Myeloma: Treatment with Bisphosphonates	450	94.3%	92.0%	92.3%	92.0%	-0.8%
70 Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	484	95.0%	95.9%	96.3%	96.8%	0.6%
71 Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	498	96.4%	81.3%	98.9%	99.3%	1.0%
72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	316	93.4%	80.5%	98.8%	98.8%	1.9%

Notes for Table A25: (1) Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an eligible professional participated in multiple reporting options, we used performance information in accordance with the following hierarchy: EHR, claims, and then registry. (5) The “Growth Rate” is the compound annual growth rate (i.e., CAGR). ^a Measure was not reportable via claims (e.g., registry only) during the 2010 program year (Measures 5, 7, 8, 33, 81, 82, 83, 118, 136, 137, 138, 143, 144, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 174, 187, 191, 192, 196, 197, 198, 199, 200, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and 216). ^b Measure was not reportable via claims (e.g., registry only) during the 2009 program year (Measures 7, 33, 46, 81, 82, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171 and 174). ^c Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 146, 164, 165, 166, 167, 168 and 192).

Table A26. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for 3 Years for the Physician Quality Reporting System (2008 to 2010).

	Measures	Eligible Professionals who Reported the Measure <u>3-years</u> Continuously	Average Performance Rate per Eligible Professional			Growth Rate
			2008	2009	2010	
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus ^c	11,820	10.9%	10.5%	16.7%	24.0%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	11,603	67.0%	68.5%	61.0%	-4.6%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	10,873	57.4%	60.7%	61.7%	3.7%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	921	79.5%	97.2%	93.3%	8.3%
6	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	5,750	90.4%	91.3%	91.1%	0.4%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ^{a, b}	260	77.2%	70.5%	81.3%	2.6%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	460	95.5%	95.0%	93.7%	-0.9%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	200	77.2%	81.4%	81.5%	2.8%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	4,873	62.3%	68.0%	70.0%	6.0%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	6,038	96.2%	96.3%	95.8%	-0.2%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	6,171	97.4%	97.3%	96.7%	-0.4%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	4,471	98.1%	98.2%	98.0%	-0.1%

Measures	Eligible Professionals who Reported the Measure <u>3-years</u> Continuously	Average Performance Rate per Eligible Professional			Growth Rate
		2008	2009	2010	
19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	2,216	52.6%	92.7%	92.8%	32.8%
20 Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	4,420	94.2%	94.9%	95.1%	0.5%
21 Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	3,209	92.1%	93.1%	93.0%	0.5%
22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	2,281	84.4%	96.6%	96.1%	6.7%
23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	2,744	91.8%	93.2%	93.8%	1.1%
24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	362	58.0%	58.3%	54.3%	-3.2%
28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	6,496	81.4%	81.2%	82.9%	0.9%
30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	15,130	94.3%	92.4%	92.8%	-0.8%
31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	369	83.8%	84.5%	81.3%	-1.5%
32 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	945	82.8%	86.7%	85.5%	1.6%
35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	231	60.0%	84.9%	85.4%	19.4%
36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	487	77.6%	76.3%	73.6%	-2.6%
39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	1,808	55.7%	60.5%	64.2%	7.4%

	Measures	Eligible Professionals who Reported the Measure <u>3-years</u> Continuously	Average Performance Rate per Eligible Professional			Growth Rate
			2008	2009	2010	
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	259	59.9%	58.5%	51.4%	-7.3%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	1,085	83.3%	85.1%	86.6%	1.9%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	726	97.8%	98.0%	97.7%	0.0%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	496	92.5%	93.1%	93.1%	0.4%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	532	83.9%	99.9%	99.6%	9.0%
47	Advance Care Plan	1,815	52.0%	54.0%	53.9%	1.8%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	1,703	73.5%	72.5%	73.7%	0.2%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	837	87.9%	87.3%	87.4%	-0.3%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	820	86.6%	87.1%	87.4%	0.5%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	892	76.3%	77.7%	77.8%	1.0%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	631	79.1%	98.8%	99.0%	11.9%
53	Asthma: Pharmacologic Therapy	62	87.5%	87.0%	73.2%	-8.5%
54	12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	19,394	94.9%	95.4%	95.8%	0.5%
55	12-Lead Electrocardiogram (ECG) Performed for Syncope	16,378	96.0%	96.4%	96.8%	0.4%
56	Community-Acquired Pneumonia (CAP): Vital Signs	16,508	94.4%	95.4%	96.0%	0.8%

Measures	Eligible Professionals who Reported the Measure <u>3-years</u> Continuously	Average Performance Rate per Eligible Professional			Growth Rate
		2008	2009	2010	
57 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	18,422	92.5%	94.3%	95.4%	1.5%
58 Community-Acquired Pneumonia (CAP): Assessment of Mental Status	16,231	95.3%	96.2%	96.7%	0.7%
59 Community-Acquired Pneumonia (CAP): Empiric Antibiotic	11,255	92.7%	94.3%	94.4%	0.9%
64 Asthma: Asthma Assessment	50	69.3%	71.2%	69.6%	0.2%
67 Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	571	93.1%	93.7%	94.8%	0.9%
68 Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	333	83.8%	97.8%	96.3%	7.2%
69 Multiple Myeloma: Treatment with Bisphosphonates	738	90.0%	90.3%	90.3%	0.2%
70 Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	743	94.8%	95.1%	94.9%	0.0%
71 Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	719	78.3%	98.5%	98.5%	12.1%
72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	516	80.0%	99.2%	98.9%	11.2%
76 Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	2,772	82.5%	84.8%	86.9%	2.6%
79 End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	99	56.8%	67.9%	64.5%	6.6%
81 End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients ^{a, b}	6	0.0%	0.0%	0.0%	N/A
82 End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis ^{a, b}	3	0.0%	0.0%	0.0%	N/A
83 Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia ^a	26	0.0%	17.3%	31.5%	
84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	94	73.3%	75.7%	91.4%	11.7%

Measures	Eligible Professionals who Reported the Measure <u>3-years</u> Continuously	Average Performance Rate per Eligible Professional			Growth Rate
		2008	2009	2010	
85 Hepatitis C: HCV Genotype Testing Prior to Treatment	96	67.2%	84.5%	93.7%	18.1%
86 Hepatitis C: Antiviral Treatment Prescribed	64	49.3%	53.9%	50.9%	1.6%
87 Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	42	66.4%	67.2%	74.1%	5.6%
89 Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	86	63.4%	64.2%	62.2%	-1.0%
90 Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	24	33.3%	45.5%	64.3%	38.9%
91 Acute Otitis Externa (AOE): Topical Therapy	117	58.7%	71.0%	80.5%	17.1%
92 Acute Otitis Externa (AOE): Pain Assessment	109	36.8%	38.2%	39.8%	4.0%
93 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	93	37.3%	37.9%	38.4%	1.5%
99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,935	96.0%	96.8%	97.5%	0.8%
100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,698	97.0%	97.6%	98.4%	0.7%
102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	106	61.0%	79.5%	87.8%	20.0%
104 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	89	79.3%	87.1%	89.8%	6.4%
105 Prostate Cancer: Three-Dimensional (3D) Radiotherapy	181	87.9%	91.7%	98.4%	5.8%
106 Major Depressive Disorder (MDD): Diagnostic Evaluation	66	42.4%	43.6%	46.5%	4.7%
107 Major Depressive Disorder (MDD): Suicide Risk Assessment	99	59.6%	63.1%	64.7%	4.2%
108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	185	91.9%	91.1%	92.4%	0.3%
109 Osteoarthritis (OA): Function and Pain Assessment	219	59.4%	58.0%	58.1%	-1.2%

Measures	Eligible Professionals who Reported the Measure <u>3-years</u> Continuously	Average Performance Rate per Eligible Professional			Growth Rate
		2008	2009	2010	
110 Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	2,535	53.5%	51.3%	52.9%	-0.5%
111 Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	2,360	53.2%	54.6%	56.1%	2.7%
112 Preventive Care and Screening: Screening Mammography	1,496	54.8%	55.9%	58.3%	3.2%
113 Preventive Care and Screening: Colorectal Cancer Screening	1,375	58.8%	61.6%	63.3%	3.7%
114 Preventive Care and Screening: Inquiry Regarding Tobacco Use	4,465	66.6%	77.2%	79.5%	9.3%
115 Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	2,287	50.8%	65.1%	48.5%	-2.3%
116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	38	86.0%	56.3%	48.9%	-24.6%
117 Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	4,150	89.9%	90.2%	90.9%	0.6%
118 Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) ^a	211	47.3%	67.1%	74.5%	25.5%
119 Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	1,977	68.3%	74.7%	78.1%	6.9%
121 Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	127	77.0%	69.3%	68.6%	-5.6%
122 Chronic Kidney Disease (CKD): Blood Pressure Management	198	82.2%	87.7%	88.5%	3.7%
123 Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	100	81.7%	95.9%	95.8%	8.3%
124 Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	7,039	100.0%	100.0%	99.9%	-0.1%

Measures	Eligible Professionals who Reported the Measure <u>3-years</u> Continuously	Average Performance Rate per Eligible Professional			Growth Rate
		2008	2009	2010	
126 Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	357	48.1%	50.8%	50.3%	2.2%
127 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	216	39.7%	38.3%	36.5%	-4.1%
128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	943	55.7%	58.6%	62.1%	5.6%
130 Documentation and Verification of Current Medications in the Medical Record	967	81.4%	79.6%	81.9%	0.3%
131 Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	1,942	98.4%	98.0%	97.8%	-0.3%
134 Screening for Clinical Depression and Follow-Up Plan	62	93.4%	89.0%	87.1%	-3.4%

Notes for Table A26: (1) Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an eligible professional participated in multiple reporting options, we used performance information in accordance with the following hierarchy: EHR, claims, and then registry. (5) The “Growth Rate” is the compound annual growth rate (i.e., CAGR). ^a Measure was not reportable via claims (e.g., registry only) during the 2010 program year (Measures 5, 7, 8, 33, 81, 82, 83, 118, 136, 137, 138, 143, 144, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 174, 187, 191, 192, 196, 197, 198, 199, 200, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and 216). ^b Measure was not reportable via claims (e.g., registry only) during the 2009 program year (Measures 7, 33, 46, 81, 82, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171 and 174). ^c Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 146, 164, 165, 166, 167, 168 and 192).

Table A27. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for 2 Years for the Physician Quality Reporting System (2009 to 2010).

Measures	Eligible Professionals who Reported the Measure <u>2</u> -years Continuously	Average Performance Rate per Eligible Professional		Growth Rate
		2009	2010	
1 Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus ^c	19,899	11.2%	18.2%	61.8%
2 Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	19,261	67.9%	59.3%	-12.5%
3 Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	17,937	60.1%	60.3%	0.3%
5 Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	1,641	95.0%	91.9%	-3.3%
6 Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	10,540	86.4%	86.9%	0.5%
7 Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ^{a, b}	927	53.5%	61.5%	15.0%
8 Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	888	88.0%	87.6%	-0.5%
9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	599	67.4%	68.5%	1.6%
10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	7,426	65.9%	68.4%	3.8%
12 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	8,459	96.2%	95.9%	-0.3%
14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	8,711	97.1%	96.5%	-0.6%
18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	6,319	97.9%	97.9%	-0.1%

Measures	Eligible Professionals who Reported the Measure 2- years Continuously	Average Performance Rate per Eligible Professional		Growth Rate
		2009	2010	
19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	3,056	92.9%	92.7%	-0.2%
20 Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	6,480	93.7%	94.4%	0.8%
21 Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	4,816	91.9%	91.8%	0.0%
22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	3,530	95.6%	95.3%	-0.3%
23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	4,065	92.2%	92.8%	0.6%
24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	584	51.5%	48.3%	-6.2%
28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	9,759	81.4%	82.9%	1.9%
30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	25,687	91.6%	92.2%	0.7%
31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	1,152	85.0%	80.2%	-5.6%
32 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	1,964	86.2%	84.1%	-2.4%
33 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge ^{a, b}	16	85.7%	81.2%	-5.3%
35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	603	83.1%	83.7%	0.7%
36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	1,542	72.3%	69.9%	-3.4%
39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	6,584	56.2%	60.5%	7.6%

Measures	Eligible Professionals who Reported the Measure 2- years Continuously	Average Performance Rate per Eligible Professional		Growth Rate
		2009	2010	
40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	716	50.8%	43.9%	-13.5%
41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	3,095	74.0%	74.5%	0.7%
43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	1,160	97.8%	97.9%	0.1%
44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	933	91.1%	92.1%	1.2%
45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	917	99.3%	99.4%	0.1%
46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility ^b	168	92.3%	91.4%	-1.0%
47 Advance Care Plan	4,300	49.4%	49.3%	-0.2%
48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	4,040	62.5%	63.6%	1.8%
49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	1,525	81.6%	82.4%	0.9%
50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	1,406	83.9%	85.1%	1.4%
51 Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	1,843	59.7%	63.4%	6.2%
52 Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	1,342	91.6%	91.6%	0.0%
53 Asthma: Pharmacologic Therapy	372	84.3%	79.6%	-5.7%
54 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	27,756	95.1%	95.6%	0.6%
55 12-Lead Electrocardiogram (ECG) Performed for Syncope	22,878	96.2%	96.7%	0.5%
56 Community-Acquired Pneumonia (CAP): Vital Signs	23,909	94.6%	95.3%	0.7%

	Measures	Eligible Professionals who Reported the Measure 2- years Continuously	Average Performance Rate per Eligible Professional		Growth Rate
			2009	2010	
57	Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	26,494	93.6%	94.6%	1.1%
58	Community-Acquired Pneumonia (CAP): Assessment of Mental Status	23,882	96.1%	96.6%	0.6%
59	Community-Acquired Pneumonia (CAP): Empiric Antibiotic	16,787	93.0%	93.2%	0.2%
64	Asthma: Asthma Assessment	163	52.1%	51.1%	-1.9%
67	Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	1,016	91.5%	93.9%	2.6%
68	Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	814	97.4%	97.0%	-0.5%
69	Multiple Myeloma: Treatment with Bisphosphonates	1,345	86.8%	87.4%	0.7%
70	Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	1,203	93.6%	93.6%	0.0%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	1,149	98.0%	97.3%	-0.7%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	887	98.8%	98.6%	-0.2%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	6,977	78.6%	81.3%	3.5%
79	End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	145	71.3%	68.9%	-3.3%
81	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients ^{a, b}	8	0.0%	0.0%	N/A
82	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis ^{a, b}	6	0.0%	0.0%	N/A
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia ^a	52	20.7%	36.3%	75.0%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	168	84.2%	93.9%	11.5%

Measures	Eligible Professionals who Reported the Measure 2- years Continuously	Average Performance Rate per Eligible Professional		Growth Rate
		2009	2010	
85 Hepatitis C: HCV Genotype Testing Prior to Treatment	179	90.2%	93.7%	3.8%
86 Hepatitis C: Antiviral Treatment Prescribed	116	54.5%	54.4%	-0.3%
87 Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	86	73.3%	75.2%	2.6%
89 Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	172	64.0%	63.7%	-0.4%
90 Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	49	43.2%	55.2%	27.8%
91 Acute Otitis Externa (AOE): Topical Therapy	293	72.7%	77.4%	6.5%
92 Acute Otitis Externa (AOE): Pain Assessment	185	49.1%	49.0%	-0.3%
93 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	227	59.4%	58.1%	-2.3%
99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	3,652	96.8%	97.6%	0.8%
100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	3,392	97.7%	98.5%	0.8%
102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	334	69.7%	71.1%	2.1%
104 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	331	76.6%	77.3%	0.9%
105 Prostate Cancer: Three-Dimensional (3D) Radiotherapy	339	83.9%	96.7%	15.3%
106 Major Depressive Disorder (MDD): Diagnostic Evaluation	325	77.5%	77.3%	-0.3%
107 Major Depressive Disorder (MDD): Suicide Risk Assessment	383	79.4%	82.0%	3.3%
108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	626	73.1%	79.6%	8.9%
109 Osteoarthritis (OA): Function and Pain Assessment	959	48.2%	48.7%	0.9%

Measures	Eligible Professionals who Reported the Measure 2- years Continuously	Average Performance Rate per Eligible Professional		Growth Rate
		2009	2010	
110 Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	7,607	52.1%	53.5%	2.6%
111 Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	8,205	55.2%	58.2%	5.3%
112 Preventive Care and Screening: Screening Mammography	7,376	56.9%	55.9%	-1.8%
113 Preventive Care and Screening: Colorectal Cancer Screening	7,298	53.8%	52.8%	-1.9%
114 Preventive Care and Screening: Inquiry Regarding Tobacco Use	13,510	77.8%	81.6%	5.0%
115 Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	7,968	53.7%	49.4%	-8.0%
116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	90	52.7%	51.8%	-1.6%
117 Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	8,690	85.4%	86.1%	0.9%
118 Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) ^a	524	68.9%	71.2%	3.2%
119 Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	5,420	71.6%	75.5%	5.5%
121 Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	927	37.9%	48.9%	29.1%
122 Chronic Kidney Disease (CKD): Blood Pressure Management	978	66.5%	67.9%	2.2%
123 Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	385	96.2%	95.9%	-0.4%
124 Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	27,543	99.4%	99.6%	0.2%

Measures	Eligible Professionals who Reported the Measure 2- years Continuously	Average Performance Rate per Eligible Professional		Growth Rate
		2009	2010	
126 Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	1,413	66.8%	66.8%	0.1%
127 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	1,057	57.2%	58.1%	1.4%
128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	4,012	58.9%	62.2%	5.6%
130 Documentation and Verification of Current Medications in the Medical Record	10,092	71.8%	73.1%	1.9%
131 Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	4,084	97.9%	97.7%	-0.2%
134 Screening for Clinical Depression and Follow-Up Plan	269	81.1%	82.9%	2.3%
135 Chronic Kidney Disease (CKD): Influenza Immunization	318	54.1%	57.0%	5.5%
136 Melanoma: Follow-Up Aspects of Care ^a	847	89.1%	80.4%	-9.7%
137 Melanoma: Continuity of Care – Recall System ^a	832	89.4%	85.9%	-3.8%
138 Melanoma: Coordination of Care ^a	382	98.0%	92.6%	-5.5%
139 Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	2,765	97.6%	97.9%	0.3%
140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	4,598	93.6%	93.4%	-0.2%
141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	2,265	93.7%	94.2%	0.6%
142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	642	49.0%	51.2%	4.6%
143 Oncology: Medical and Radiation – Pain Intensity Quantified ^a	37	27.7%	28.7%	3.5%
144 Oncology: Medical and Radiation – Plan of Care for Pain ^a	9	88.7%	98.1%	10.6%
145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	6,523	43.7%	52.4%	20.0%

Measures	Eligible Professionals who Reported the Measure 2-years Continuously	Average Performance Rate per Eligible Professional		Growth Rate	
		2009	2010		
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening ^c	4,760	2.2%	1.2%	-48.6%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	3,713	58.0%	57.7%	-0.4%
153	Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	276	53.4%	56.5%	5.9%
154	Falls: Risk Assessment	5,672	92.1%	91.9%	-0.2%
155	Falls: Plan of Care	2,308	86.8%	86.6%	-0.3%
156	Oncology: Radiation Dose Limits to Normal Tissues	234	89.2%	94.0%	5.4%
157	Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	22	83.7%	85.0%	1.6%
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	211	91.9%	92.7%	0.8%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage ^{a,b}	42	82.2%	82.5%	0.3%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis ^{a,b}	38	66.1%	84.1%	27.3%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy ^{a,b}	25	100.0%	98.7%	-1.3%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy ^{a,b}	39	79.3%	76.2%	-3.9%
163	Diabetes Mellitus: Foot Exam	2,247	67.4%	70.2%	4.1%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation) ^{a,b,c}	9	89.7%	89.1%	-0.7%
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate ^{a,b,c}	8	100.0%	100.0%	0.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration ^{a,b,c}	9	89.7%	89.5%	-0.2%

Measures	Eligible Professionals who Reported the Measure 2- years Continuously	Average Performance Rate per Eligible Professional		Growth Rate
		2009	2010	
169 Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge ^{a, b}	9	11.1%	11.1%	0.0%
170 Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge ^{a, b}	8	0.0%	0.0%	N/A
171 Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling ^{a, b}	8	0.0%	0.0%	N/A
172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	100	96.2%	97.2%	0.9%
173 Preventive Care and Screening: Unhealthy Alcohol Use – Screening	959	40.3%	42.4%	5.3%
176 Rheumatoid Arthritis (RA): Tuberculosis Screening	198	88.6%	87.8%	-0.9%
177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	203	44.3%	47.1%	6.2%
178 Rheumatoid Arthritis (RA): Functional Status Assessment	230	48.0%	51.1%	6.4%
179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	181	42.1%	42.0%	-0.2%
180 Rheumatoid Arthritis (RA): Glucocorticoid Management	190	92.5%	95.5%	3.2%
181 Elder Maltreatment Screen and Follow-Up Plan	38	52.5%	53.2%	1.3%
182 Functional Outcome Assessment in Chiropractic Care	113	83.1%	82.5%	-0.7%
183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	160	62.3%	63.4%	1.8%
184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	166	64.1%	66.4%	3.6%
185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	506	91.9%	92.2%	0.3%
186 Wound Care: Use of Compression System in Patients with Venous Ulcers	31	81.5%	81.6%	0.1%

Notes for Table A27: (1) Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an eligible professional participated in multiple options, we used performance information in accordance with the following hierarchy: EHR, claims, and then

registry. (5) The “Growth Rate” is the compound annual growth rate (i.e., CAGR). ^a Measure was not reportable via claims (e.g., registry only) during the 2010 program year (Measures 5, 7, 8, 33, 81, 82, 83, 118, 136, 137, 138, 143, 144, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 174, 187, 191, 192, 196, 197, 198, 199, 200, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and 216). ^b Measure was not reportable via claims (e.g., registry only) during the 2009 program year (Measures 7, 33, 46, 81, 82, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171 and 174). ^c Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 146, 164, 165, 166, 167, 168 and 192).

Table A28. Percent of Eligible Professionals who had at Least a 90% Performance Rate for Individual Measures in the Physician Quality Reporting System (2010).

Measure	% of Eligible Professionals who had at least a 90% Performance Rate
1 Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus ^c	43.2%
2 Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	11.7%
3 Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	13.2%
5 Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	47.9%
6 Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	64.0%
7 Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) ^{a, b}	49.0%
8 Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) ^a	45.8%
9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	56.4%
10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	36.6%
12 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	89.0%
14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	91.7%
18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	94.4%
19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	83.4%
20 Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	88.0%
21 Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	81.8%
22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	83.3%
23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	85.7%
24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	43.7%
28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	65.5%

Measure	% of Eligible Professionals who had at least a 90% Performance Rate
30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	78.9%
31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	67.8%
32 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	70.1%
33 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge ^{a, b}	64.5%
35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	51.9%
36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	50.4%
39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	25.1%
40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	34.5%
41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	45.8%
43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	96.2%
44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	79.7%
45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	96.3%
46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility ^b	77.9%
47 Advance Care Plan	33.9%
48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	55.4%
49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	76.3%
50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	76.1%
51 Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	45.4%
52 Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	51.2%
53 Asthma: Pharmacologic Therapy	64.6%
54 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	88.2%
55 12-Lead Electrocardiogram (ECG) Performed for Syncope	90.1%

Measure	% of Eligible Professionals who had at least a 90% Performance Rate
56 Community-Acquired Pneumonia (CAP): Vital Signs	90.4%
57 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	87.0%
58 Community-Acquired Pneumonia (CAP): Assessment of Mental Status	92.4%
59 Community-Acquired Pneumonia (CAP): Empiric Antibiotic	81.8%
64 Asthma: Asthma Assessment	46.2%
65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	85.7%
66 Appropriate Testing for Children with Pharyngitis	100.0%
67 Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	80.9%
68 Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	78.0%
69 Multiple Myeloma: Treatment with Bisphosphonates	66.7%
70 Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	79.6%
71 Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	67.7%
72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	69.2%
76 Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	67.6%
79 End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	46.4%
82 End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis ^{a, b}	10.0%
83 Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia ^a	19.5%
84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	24.6%
85 Hepatitis C: HCV Genotype Testing Prior to Treatment	30.2%
86 Hepatitis C: Antiviral Treatment Prescribed	30.6%
87 Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	15.6%
89 Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	52.1%
90 Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	21.3%

Measure	% of Eligible Professionals who had at least a 90% Performance Rate
91 Acute Otitis Externa (AOE): Topical Therapy	55.3%
92 Acute Otitis Externa (AOE): Pain Assessment	51.7%
93 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	56.0%
99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	90.2%
100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	93.7%
102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	41.8%
104 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	51.5%
105 Prostate Cancer: Three-Dimensional (3D) Radiotherapy	88.9%
106 Major Depressive Disorder (MDD): Diagnostic Evaluation	73.2%
107 Major Depressive Disorder (MDD): Suicide Risk Assessment	75.3%
108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	66.8%
109 Osteoarthritis (OA): Function and Pain Assessment	43.2%
110 Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	22.5%
111 Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	23.9%
112 Preventive Care and Screening: Screening Mammography	22.6%
113 Preventive Care and Screening: Colorectal Cancer Screening	25.0%
114 Preventive Care and Screening: Inquiry Regarding Tobacco Use	63.6%
115 Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	28.8%
116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	26.9%
117 Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	70.7%
118 Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) ^a	24.7%

Measure	% of Eligible Professionals who had at least a 90% Performance Rate
119 Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	43.7%
121 Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	27.3%
122 Chronic Kidney Disease (CKD): Blood Pressure Management	34.3%
123 Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	73.7%
124 Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	98.6%
126 Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	67.9%
127 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	60.6%
128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	39.0%
130 Documentation and Verification of Current Medications in the Medical Record	60.8%
131 Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	94.8%
134 Screening for Clinical Depression and Follow-Up Plan	71.4%
135 Chronic Kidney Disease (CKD): Influenza Immunization	34.8%
136 Melanoma: Follow-Up Aspects of Care ^a	58.1%
137 Melanoma: Continuity of Care – Recall System ^a	73.1%
138 Melanoma: Coordination of Care ^a	73.0%
139 Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	96.5%
140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	84.6%
141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	91.2%
142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	53.9%
143 Oncology: Medical and Radiation – Pain Intensity Quantified ^a	24.6%
144 Oncology: Medical and Radiation – Plan of Care for Pain ^a	83.3%

Measure	% of Eligible Professionals who had at least a 90% Performance Rate
145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	28.1%
146 Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening ^c	98.8%
147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	27.1%
153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	35.8%
154 Falls: Risk Assessment	44.0%
155 Falls: Plan of Care	82.3%
156 Oncology: Radiation Dose Limits to Normal Tissues	87.9%
157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	61.7%
158 Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	84.5%
159 HIV/AIDS: CD4+ Cell Count or CD4+ Percentage ^{a, b}	71.9%
160 HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis ^{a, b}	48.3%
161 HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy ^{a, b}	73.8%
162 HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy ^{a, b}	63.2%
163 Diabetes Mellitus: Foot Exam	58.6%
164 Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation) ^{a, b, c}	6.3%
165 Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate ^{a, b, c}	21.1%
166 Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA) ^{a, b, c}	36.4%
168 Coronary Artery Bypass Graft (CABG): Surgical Re-exploration ^{a, b, c}	6.3%
169 Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge ^{a, b}	37.5%
170 Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge ^{a, b}	33.3%
171 Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling ^{a, b}	28.6%
172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	83.8%

Measure	% of Eligible Professionals who had at least a 90% Performance Rate
173 Preventive Care and Screening: Unhealthy Alcohol Use – Screening	55.0%
176 Rheumatoid Arthritis (RA): Tuberculosis Screening	36.9%
177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	57.8%
178 Rheumatoid Arthritis (RA): Functional Status Assessment	56.1%
179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	52.4%
180 Rheumatoid Arthritis (RA): Glucocorticoid Management	88.8%
181 Elder Maltreatment Screen and Follow-Up Plan	48.8%
182 Functional Outcome Assessment in Chiropractic Care	66.5%
183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	36.7%
184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	38.5%
185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	87.1%
186 Wound Care: Use of Compression System in Patients with Venous Ulcers	73.2%
187 Stroke and Stroke Rehabilitation: Thrombolytic Therapy ^a	66.7%
188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	80.0%
189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	43.8%
190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	40.5%
191 Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery ^a	70.0%
192 Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures ^{a, c}	97.3%
193 Perioperative Temperature Management	58.0%
194 Oncology: Cancer Stage Documented	80.0%
195 Stenosis Measurement in Carotid Imaging Studies	39.8%
196 Coronary Artery Disease (CAD): Symptom and Activity Assessment ^a	28.9%

Measure	% of Eligible Professionals who had at least a 90% Performance Rate
197 Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol ^a	26.3%
198 Heart Failure: Left Ventricular Function (LVF) Assessment ^a	24.8%
199 Heart Failure: Patient Education ^a	24.5%
200 Heart Failure: Warfarin Therapy Patients with Atrial Fibrillation ^a	30.8%
201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	24.3%
202 Ischemic Vascular Disease (IVD): Complete Lipid Profile	30.4%
203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	9.3%
204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	33.4%
205 HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea ^a	22.0%
206 HIV/AIDS: Screening for High Risk Sexual Behaviors ^a	13.6%
207 HIV/AIDS: Screening for Injection Drug Use ^a	21.7%
208 HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis ^a	35.7%
209 Functional Communication Measure - Spoken Language Comprehension ^a	40.0%
210 Functional Communication Measure - Attention ^a	50.0%
211 Functional Communication Measure - Memory ^a	40.0%
212 Functional Communication Measure - Motor Speech ^a	66.7%
213 Functional Communication Measure - Reading ^a	50.0%
214 Functional Communication Measure - Spoken Language Expression ^a	33.3%
216 Functional Communication Measure - Swallowing ^a	60.0%

Notes for Table A28: (1) Results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options. (3) Results were restricted to individual measures (i.e., excluded measures groups). (4) If an eligible professional participated in multiple options, we used performance information in accordance with the following hierarchy: EHR, claims, and then

registry. ^a Measure was not reportable via claims (e.g., registry only) during the 2010 program year (Measures 5, 7, 8, 33, 81, 82, 83, 118, 136, 137, 138, 143, 144, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171, 174, 187, 191, 192, 196, 197, 198, 199, 200, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215 and 216). ^b Measure was not reportable via claims (e.g., registry only) during the 2009 program year (Measures 7, 33, 46, 81, 82, 159, 160, 161, 162, 164, 165, 166, 167, 168, 169, 170, 171 and 174). ^c Measure was an inverse measure where a lower performance rate indicates better performance (Measures 1, 146, 164, 165, 166, 167, 168 and 192).

Table A29. Performance Information for Measures Reported by Practices Participating in the Group Practice Reporting Option for the Physician Quality Reporting System (2010).

GPRO Measures		GPRO Performance Rate					Average Performance Rate
		GPRO Count	Denominator Instances		Numerator Instances		
			Total	Average per GPRO	Total	Average per GPRO	
Coronary Artery Disease		--	--	--	--	--	--
CAD-1	Oral Antiplatelet Therapy Prescribed for Patients with CAD	35	15,718	449	15,460	442	84.9%
CAD-2	Drug Therapy for Lowering LDL-Cholesterol	35	15,718	449	15,003	429	89.6%
CAD-3	Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)	35	5,247	150	5,063	145	86.8%
CAD-7	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	35	7,558	216	7,179	205	82.7%
Diabetes Mellitus		--	--	--	--	--	--
DM-1	Hemoglobin A1c Testing	35	16,205	463	16,205	463	93.4%
DM-2	Hemoglobin A1c Poor Control in Diabetes Mellitus ^a	35	16,205	463	16,205	463	22.3%
DM-3	High Blood Pressure Control in Diabetes Mellitus	35	16,205	463	16,205	463	57.4%
DM-5	Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	35	16,205	463	16,205	463	54.6%
DM-6	Urine Screening for Microalbumin or Medical Attention for Nephropathy	35	16,205	463	16,205	463	89.2%
DM-7	Dilated Eye Exam in Diabetic Patient	35	16,205	463	16,205	463	60.6%
DM-8	Foot Exam	34	16,205	463	16,038	458	62.6%
DM-9	Lipid Profile	35	16,205	463	16,205	463	84.3%
Heart Failure		--	--	--	--	--	--
HF-1	Left Ventricular Function (LVF) Assessment	35	12,830	367	12,830	367	86.3%
HF-2	Left Ventricular Function (LVF) Testing	35	3,958	113	3,910	112	86.2%

GPRO Measures		GPRO Performance Rate					
		GPRO Count	Denominator Instances		Numerator Instances		Average Performance Rate
			Total	Average per GPRO	Total	Average per GPRO	
HF-3	Weight Measurement	35	109,981	3,142	109,337	3,124	86.4%
HF-5	Patient Education	34	12,830	367	12,830	367	79.6%
HF-6	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	35	4,216	120	3,994	114	92.3%
HF-7	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	35	4,216	120	3,858	110	89.9%
HF-8	Warfarin Therapy for Patients with Atrial Fibrillation	35	6,487	185	5,731	164	79.2%
Hypertension		--	--	--	--	--	--
HTN-1	Blood Pressure Measurement	35	94,222	2,692	94,222	2,692	92.5%
HTN-2	Blood Pressure Control	35	15,905	454	15,760	450	68.0%
HTN-3	Plan of Care	34	28,081	802	28,081	802	57.7%
Preventive Care		--	--	--	--	--	--
Prev-5	Screening Mammography	35	17,297	494	17,170	491	74.5%
Prev-6	Colorectal Cancer Screening	35	17,318	495	17,179	491	59.9%
Prev-7	Influenza Immunization for Patients ≥ 50 Years Old	35	17,376	496	16,925	484	66.7%
Prev-8	Pneumonia Vaccination for Patients 65 Years and Older	35	17,463	499	17,412	497	62.3%

Notes for Table A29: (1) Results in this table were restricted to GPRO measures. ^a Measure that was an inverse measure where a lower performance rate indicates better performance (DM-2).

2010 ERX INCENTIVE PROGRAM APPENDIX TABLES

Table A30. Distribution of Incentive Amounts by Specialty for the eRx Incentive Program (2010).

Specialty	Eligible Professionals who Qualified for an Incentive	Incentive Amount					Percent of National Total
		Minimum	Maximum	Mean	Median	Total	
MD/DO	56,050	\$0.50	\$81,073.27	\$4,066.22	\$2,669.10	\$227,911,648.01	90.2%
Allergy/Immunology	328	\$122.58	\$16,096.96	\$1,751.66	\$1,188.12	\$574,543.73	0.2%
Anesthesiology	103	\$113.14	\$18,290.89	\$3,935.80	\$2,952.10	\$405,387.17	0.2%
Cardiology	5,331	\$16.10	\$62,655.15	\$7,931.24	\$6,901.83	\$42,281,428.52	16.7%
Colon/Rectal Surgery	36	\$331.45	\$6,563.27	\$3,366.73	\$3,197.60	\$121,202.24	0.0%
Critical Care	141	\$207.51	\$24,745.11	\$4,599.36	\$3,752.12	\$648,509.15	0.3%
Dermatology	1,322	\$82.71	\$60,369.00	\$6,343.22	\$4,471.80	\$8,385,731.50	3.3%
Emergency Medicine	235	\$28.62	\$17,788.66	\$1,595.79	\$810.81	\$375,010.22	0.1%
Endocrinology	845	\$71.52	\$17,609.26	\$2,510.44	\$2,001.77	\$2,121,322.24	0.8%
Family Practice	15,656	\$1.49	\$36,539.40	\$1,779.80	\$1,285.34	\$27,864,519.26	11.0%
Gastroenterology	1,359	\$3.35	\$25,528.70	\$3,873.56	\$3,435.94	\$5,264,174.29	2.1%
General Practice	248	\$152.21	\$16,404.17	\$2,660.00	\$1,752.51	\$659,681.03	0.3%
General Surgery	228	\$359.22	\$15,815.30	\$3,752.47	\$3,345.61	\$855,562.78	0.3%
Geriatrics	477	\$132.52	\$40,245.69	\$3,770.45	\$2,965.99	\$1,798,505.47	0.7%
Hand Surgery	47	\$591.93	\$17,007.73	\$3,933.91	\$3,297.81	\$184,893.84	0.1%
Infectious Disease	265	\$117.08	\$26,147.22	\$3,551.52	\$2,601.77	\$941,154.05	0.4%
Internal Medicine	13,793	\$35.11	\$51,957.30	\$3,048.62	\$2,294.37	\$42,049,661.89	16.6%
Interventional Radiologist	0	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	0.0%
Nephrology	983	\$138.80	\$32,803.10	\$6,367.71	\$6,212.16	\$6,259,460.36	2.5%
Neurology	1,184	\$1.51	\$30,662.23	\$3,332.65	\$2,683.80	\$3,945,857.21	1.6%
Neurosurgery	70	\$138.03	\$15,893.61	\$4,253.76	\$4,125.31	\$297,763.54	0.1%
Nuclear Medicine	25	\$2,853.95	\$32,622.99	\$9,044.94	\$8,323.44	\$226,123.58	0.1%
Obstetrics/Gynecology	834	\$4.31	\$14,233.74	\$1,093.79	\$605.96	\$912,220.73	0.4%
Oncology/Hematology	1,410	\$186.98	\$53,016.15	\$7,010.21	\$5,838.70	\$9,884,399.23	3.9%
Ophthalmology	4,026	\$139.08	\$81,073.27	\$9,784.41	\$8,206.22	\$39,392,044.18	15.6%
Oral/Maxillofacial Surgery	0	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	0.0%

Specialty	Eligible Professionals who Qualified for an Incentive	Incentive Amount					Percent of National Total
		Minimum	Maximum	Mean	Median	Total	
Orthopedic Surgery	921	\$158.48	\$42,382.26	\$5,545.76	\$4,554.35	\$5,107,640.37	2.0%
Other MD/DO	198	\$165.45	\$45,316.08	\$5,339.89	\$4,114.20	\$1,057,298.50	0.4%
Otolaryngology	946	\$213.96	\$25,958.43	\$2,966.26	\$2,397.66	\$2,806,079.59	1.1%
Pathology	2	\$1,510.30	\$4,704.77	\$3,107.53	\$3,107.53	\$6,215.06	0.0%
Pediatrics	100	\$0.50	\$5,477.48	\$1,030.10	\$487.65	\$103,009.89	0.0%
Physical Medicine	346	\$115.49	\$21,759.44	\$3,848.08	\$2,945.26	\$1,331,437.19	0.5%
Plastic Surgery	29	\$683.13	\$23,925.57	\$5,031.76	\$3,169.82	\$145,921.00	0.1%
Psychiatry	502	\$30.03	\$17,145.61	\$1,548.62	\$861.15	\$777,408.53	0.3%
Pulmonary Disease	1,254	\$91.40	\$27,413.39	\$5,623.12	\$4,807.40	\$7,051,396.37	2.8%
Radiation Oncology	4	\$5,040.83	\$6,843.55	\$5,551.42	\$5,160.65	\$22,205.69	0.0%
Radiologist	1	\$1,507.51	\$1,507.51	\$1,507.51	\$1,507.51	\$1,507.51	0.0%
Rheumatology	969	\$95.49	\$52,826.61	\$3,903.91	\$3,037.71	\$3,782,890.97	1.5%
Thoracic/Cardiac Surgery	2	\$7,679.10	\$15,461.13	\$11,570.12	\$11,570.12	\$23,140.23	0.0%
Urology	1,786	\$26.68	\$52,245.10	\$5,490.50	\$4,792.86	\$9,806,024.77	3.9%
Vascular Surgery	44	\$593.69	\$25,059.30	\$10,007.19	\$8,426.81	\$440,316.14	0.2%
Other Eligible Professionals	9,797	\$1.10	\$56,742.14	\$2,519.97	\$1,038.80	\$24,688,099.48	9.8%
Agencies/Hospitals/Nursing and Treatment Facilities	34	\$157.92	\$11,440.73	\$3,641.14	\$3,028.90	\$123,798.85	0.0%
Audiologist	0	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	0.0%
Certified Nurse Midwives	9	\$2.87	\$137.92	\$37.38	\$7.08	\$336.44	0.0%
Chiropractor	6	\$275.86	\$4,011.95	\$2,493.89	\$2,591.36	\$14,963.36	0.0%
Clinical Nurse Specialists	76	\$66.37	\$3,080.00	\$786.17	\$597.78	\$59,748.60	0.0%
Counselor/Psychologist	8	\$67.56	\$3,845.69	\$1,377.15	\$872.92	\$11,017.23	0.0%
Dentist	0	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	0.0%
Dietitian/Nutritionist	4	\$95.26	\$1,844.73	\$562.51	\$155.02	\$2,250.02	0.0%
Nurse Anesthetist	1	\$440.87	\$440.87	\$440.87	\$440.87	\$440.87	0.0%
Nurse Practitioner	3,060	\$1.11	\$9,150.94	\$680.47	\$467.79	\$2,082,253.41	0.8%
Optometry	936	\$96.99	\$23,277.04	\$2,462.40	\$1,859.56	\$2,304,808.70	0.9%

Specialty	Eligible Professionals who Qualified for an Incentive	Incentive Amount					Percent of National Total
		Minimum	Maximum	Mean	Median	Total	
Other Eligible Professional	2,950	\$2.61	\$56,742.14	\$5,552.88	\$4,153.65	\$16,381,002.08	6.5%
Physical/Occupational Therapy	6	\$412.10	\$4,882.22	\$2,949.95	\$2,965.81	\$17,699.70	0.0%
Physician Assistant	2,002	\$1.10	\$12,152.36	\$749.35	\$480.40	\$1,500,190.49	0.6%
Podiatrist	628	\$184.59	\$17,359.29	\$3,403.15	\$2,898.94	\$2,137,180.96	0.8%
Registered Nurse	71	\$63.29	\$11,124.86	\$719.07	\$327.89	\$51,054.09	0.0%
Social Worker	6	\$51.23	\$480.77	\$225.78	\$205.79	\$1,354.68	0.0%
<i>Unknown/Missing</i>	10	\$120.02	\$12,549.88	\$3,692.18	\$1,879.25	\$36,921.76	0.0%
Total (Unduplicated)	65,857	\$0.50	\$81,073.27	\$3,836.14	\$2,419.24	\$252,636,669.26	100.0%

Notes for Table A30: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A31. Potential Incentives and Participation Information by Specialty for the eRx Incentive Program (2010).

Specialty	Average Potential Incentive per Eligible Professional	% of Eligible Professionals who Participated
MD/DO	\$2,367.43	19.1%
Allergy/Immunology	\$1,080.41	19.5%
Anesthesiology	\$1,775.99	3.8%
Cardiology	\$5,584.43	35.4%
Colon/Rectal Surgery	\$2,244.06	11.9%
Critical Care	\$3,242.40	21.5%
Dermatology	\$4,725.90	20.9%
Emergency Medicine	\$855.98	6.7%
Endocrinology	\$1,655.14	25.7%
Family Practice	\$1,252.39	25.9%
Gastroenterology	\$2,803.34	22.5%
General Practice	\$1,206.65	7.1%
General Surgery	\$1,923.84	6.6%
Geriatrics	\$2,387.22	17.9%
Hand Surgery	\$2,032.52	12.7%
Infectious Disease	\$2,511.91	15.4%
Internal Medicine	\$2,205.70	23.5%
Interventional Radiologist	\$5,174.75	2.1%
Nephrology	\$5,249.04	24.0%
Neurology	\$2,032.49	16.8%
Neurosurgery	\$2,701.93	7.4%
Nuclear Medicine	\$4,840.19	17.3%
Obstetrics/Gynecology	\$392.94	11.1%
Oncology/Hematology	\$3,378.87	23.8%
Ophthalmology	\$5,340.22	33.8%
Oral/Maxillofacial Surgery	\$316.33	0.5%
Orthopedic Surgery	\$2,983.91	14.5%
Other MD/DO	\$2,068.59	5.8%
Otolaryngology	\$2,022.73	19.3%
Pathology	\$1,738.92	2.6%
Pediatrics	\$193.54	6.2%
Physical Medicine	\$2,348.11	10.3%
Plastic Surgery	\$1,246.64	3.5%
Psychiatry	\$721.10	3.2%
Pulmonary Disease	\$3,811.11	24.5%

Specialty	Average Potential Incentive per Eligible Professional	% of Eligible Professionals who Participated
Radiation Oncology	\$8,158.44	2.2%
Radiologist	\$4,367.70	0.5%
Rheumatology	\$2,420.66	31.7%
Thoracic/Cardiac Surgery	\$3,645.34	3.5%
Urology	\$3,836.57	29.6%
Vascular Surgery	\$5,022.12	9.4%
Other Eligible Professionals	\$938.50	10.2%
Agencies/Hospitals/Nursing and Treatment Facilities	\$1,308.10	5.8%
Audiologist	\$381.24	2.2%
Certified Nurse Midwives	\$20.70	9.0%
Chiropractor	\$1,103.04	8.5%
Clinical Nurse Specialists	\$435.46	9.5%
Counselor/Psychologist	\$420.35	0.2%
Dentist	\$193.34	0.1%
Dietitian/Nutritionist	\$157.94	4.4%
Nurse Anesthetist	\$1,086.44	0.9%
Nurse Practitioner	\$423.17	17.3%
Optometry	\$609.60	9.9%
Other Eligible Professional	\$3,022.96	15.4%
Physical/Occupational Therapy	\$2,866.50	9.1%
Physician Assistant	\$425.04	16.9%
Podiatrist	\$2,091.74	9.5%
Registered Nurse	\$428.94	8.5%
Social Worker	\$197.18	0.2%
<i>Unknown/Missing</i>	\$757.33	7.1%
Total (Unduplicated)	\$1,905.78	16.2%

Notes for Table A31: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A32. Eligible Professional Information by Specialty for the eRx Incentive Program (2009 to 2010).

Specialty	Eligible Professionals		Eligible Professionals who Participated		% of Eligible Professionals who Participated	
	2009	2010	2009	2010	2009	2010
MD/DO	457,604	471,684	69,633	90,174	15.2%	19.1%
Allergy/Immunology	3,457	3,454	517	674	15.0%	19.5%
Anesthesiology	6,928	6,808	225	261	3.3%	3.8%
Cardiology	21,952	22,606	6,057	7,994	27.6%	35.4%
Colon/Rectal Surgery	1,048	1,092	124	130	11.8%	11.9%
Critical Care	1,476	1,301	235	279	15.9%	21.5%
Dermatology	10,390	10,426	1,422	2,176	13.7%	20.9%
Emergency Medicine	7,328	7,108	426	479	5.8%	6.7%
Endocrinology	4,939	5,071	886	1,305	17.9%	25.7%
Family Practice	81,807	85,251	15,698	22,059	19.2%	25.9%
Gastroenterology	11,535	11,846	1,855	2,668	16.1%	22.5%
General Practice	4,868	5,311	264	375	5.4%	7.1%
General Surgery	20,047	19,900	1,550	1,309	7.7%	6.6%
Geriatrics	2,974	3,853	460	690	15.5%	17.9%
Hand Surgery	1,421	1,542	190	196	13.4%	12.7%
Infectious Disease	4,311	4,470	521	687	12.1%	15.4%
Internal Medicine	77,145	80,389	13,888	18,916	18.0%	23.5%
Interventional Radiologist	677	677	31	14	4.6%	2.1%
Nephrology	7,025	7,386	1,220	1,770	17.4%	24.0%
Neurology	11,806	11,882	1,568	2,001	13.3%	16.8%
Neurosurgery	4,378	4,367	438	324	10.0%	7.4%
Nuclear Medicine	257	260	35	45	13.6%	17.3%
Obstetrics/Gynecology	29,341	29,565	2,795	3,282	9.5%	11.1%
Oncology/Hematology	10,499	10,623	2,150	2,530	20.5%	23.8%
Ophthalmology	18,879	18,903	5,584	6,386	29.6%	33.8%
Oral/Maxillofacial Surgery	367	371	7	2	1.9%	0.5%
Orthopedic Surgery	20,313	20,506	3,053	2,965	15.0%	14.5%
Other MD/DO	6,423	7,319	408	422	6.4%	5.8%
Otolaryngology	8,406	8,381	1,302	1,621	15.5%	19.3%
Pathology	402	389	11	10	2.7%	2.6%
Pediatrics	5,284	5,401	242	337	4.6%	6.2%
Physical Medicine	6,547	7,026	644	723	9.8%	10.3%
Plastic Surgery	4,180	4,280	219	148	5.2%	3.5%
Psychiatry	26,255	28,458	644	907	2.5%	3.2%
Pulmonary Disease	7,796	8,303	1,372	2,030	17.6%	24.5%
Radiation Oncology	4,297	4,310	166	94	3.9%	2.2%

Specialty	Eligible Professionals		Eligible Professionals who Participated		% of Eligible Professionals who Participated	
	2009	2010	2009	2010	2009	2010
Radiologist	3,765	3,610	57	18	1.5%	0.5%
Rheumatology	4,171	4,174	958	1,322	23.0%	31.7%
Thoracic/Cardiac Surgery	3,293	3,281	225	114	6.8%	3.5%
Urology	8,901	8,924	1,881	2,642	21.1%	29.6%
Vascular Surgery	2,716	2,860	305	269	11.2%	9.4%
Other Eligible Professionals	211,056	224,261	20,010	22,849	9.5%	10.2%
Agencies/Hospitals/Nursing and Treatment Facilities	1,132	1,256	60	73	5.3%	5.8%
Audiologist	116	182	4	4	3.5%	2.2%
Certified Nurse Midwives	1,144	1,211	115	109	10.1%	9.0%
Chiropractor	78	71	4	6	5.1%	8.5%
Clinical Nurse Specialists	1,605	1,909	127	182	7.9%	9.5%
Counselor/Psychologist	30,779	31,017	194	52	0.6%	0.2%
Dentist	3,299	3,221	23	3	0.7%	0.1%
Dietitian/Nutritionist	448	454	47	20	10.5%	4.4%
Nurse Anesthetist	120	108	2	1	1.7%	0.9%
Nurse Practitioner	35,271	43,423	6,130	7,523	17.4%	17.3%
Optometry	29,914	31,106	2,773	3,084	9.3%	9.9%
Other Eligible Professional	35,375	33,392	4,498	5,144	12.7%	15.4%
Physical/Occupational Therapy	316	319	24	29	7.6%	9.1%
Physician Assistant	25,133	28,056	4,399	4,747	17.5%	16.9%
Podiatrist	16,287	17,312	1,236	1,651	7.6%	9.5%
Registered Nurse	1,965	2,085	182	177	9.3%	8.5%
Social Worker	28,068	29,139	191	44	0.7%	0.2%
<i>Unknown/Missing</i>	1,031	718	109	51	10.6%	7.1%
Total (Unduplicated)	669,691	696,663	89,752	113,074	13.4%	16.2%

Notes for Table A32: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A33. Eligible Professionals who Qualified for an Incentive from the eRx Incentive Program (2009 to 2010).

Specialty	Eligible Professionals who Qualified for an Incentive			
	2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
MD/DO	37,133	53.3%	56,050	62.2%
Allergy/Immunology	247	47.8%	328	48.7%
Anesthesiology	102	45.3%	103	39.5%
Cardiology	3,299	54.5%	5,331	66.7%
Colon/Rectal Surgery	60	48.4%	36	27.7%
Critical Care	113	48.1%	141	50.5%
Dermatology	784	55.1%	1,322	60.8%
Emergency Medicine	220	51.6%	235	49.1%
Endocrinology	450	50.8%	845	64.8%
Family Practice	8,225	52.4%	15,656	71.0%
Gastroenterology	886	47.8%	1,359	50.9%
General Practice	98	37.1%	248	66.1%
General Surgery	723	46.7%	228	17.4%
Geriatrics	217	47.2%	477	69.1%
Hand Surgery	99	52.1%	47	24.0%
Infectious Disease	181	34.7%	265	38.6%
Internal Medicine	7,318	52.7%	13,793	72.9%
Interventional Radiologist	9	29.0%	0	0.0%
Nephrology	539	44.2%	983	55.5%
Neurology	868	55.4%	1,184	59.2%
Neurosurgery	188	42.9%	70	21.6%
Nuclear Medicine	20	57.1%	25	55.6%
Obstetrics/Gynecology	1,250	44.7%	834	25.4%
Oncology/Hematology	1,384	64.4%	1,410	55.7%
Ophthalmology	3,941	70.6%	4,026	63.0%
Oral/Maxillofacial Surgery	3	42.9%	0	0.0%
Orthopedic Surgery	1,653	54.1%	921	31.1%
Other MD/DO	193	47.3%	198	46.9%
Otolaryngology	679	52.2%	946	58.4%
Pathology	3	27.3%	2	20.0%
Pediatrics	150	62.0%	100	29.7%
Physical Medicine	310	48.1%	346	47.9%
Plastic Surgery	97	44.3%	29	19.6%
Psychiatry	292	45.3%	502	55.4%

Specialty	Eligible Professionals who Qualified for an Incentive			
	2009		2010	
	Count	% of Eligible Professionals who Participated	Count	% of Eligible Professionals who Participated
Pulmonary Disease	708	51.6%	1,254	61.8%
Radiation Oncology	31	18.7%	4	4.3%
Radiologist	7	12.3%	1	5.6%
Rheumatology	523	54.6%	969	73.3%
Thoracic/Cardiac Surgery	52	23.1%	2	1.8%
Urology	1,073	57.0%	1,786	67.6%
Vascular Surgery	138	45.3%	44	16.4%
Other Eligible Professionals	11,129	55.6%	9,797	42.9%
Agencies/Hospitals/Nursing and Treatment Facilities	28	46.7%	34	46.6%
Audiologist	0	0.0%	0	0.0%
Certified Nurse Midwives	73	63.5%	9	8.3%
Chiropractor	2	50.0%	6	100.0%
Clinical Nurse Specialists	73	57.5%	76	41.8%
Counselor/Psychologist	90	46.4%	8	15.4%
Dentist	11	47.8%	0	0.0%
Dietitian/Nutritionist	19	40.4%	4	20.0%
Nurse Anesthetist	1	50.0%	1	100.0%
Nurse Practitioner	3,828	62.5%	3,060	40.7%
Optometry	1,562	56.3%	936	30.4%
Other Eligible Professional	2,239	49.8%	2,950	57.4%
Physical/Occupational Therapy	6	25.0%	6	20.7%
Physician Assistant	2,508	57.0%	2,002	42.2%
Podiatrist	511	41.3%	628	38.0%
Registered Nurse	114	62.6%	71	40.1%
Social Worker	63	33.0%	6	13.6%
<i>Unknown/Missing</i>	92	84.4%	10	19.6%
Total (Unduplicated)	48,354	53.9%	65,857	58.2%

Notes for Table A33: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A34. Eligible Professional Characteristics for the eRx Incentive Program (2010).

Characteristics	Eligible Professionals	Eligible Professionals who Participated		Eligible Professionals who Qualified for an Incentive	
		Count	% of Eligible Professionals	Count	% of Eligible Professionals who Participated
Reporting Option	--	--	--	--	--
Claims	696,663	102,659	14.7%	56,022	54.6%
Registry	696,663	16,811	2.4%	13,301	79.1%
EHR	696,663	14	0.0%	8	57.1%
Geography (Regions)	--	--	--	--	--
West	130,008	16,612	12.8%	9,562	57.6%
South	227,369	37,682	16.6%	22,565	59.9%
Midwest	165,210	31,519	19.1%	17,758	56.3%
Northeast	162,736	26,692	16.4%	15,655	58.7%
Other	10,622	518	4.9%	307	59.3%
Unknown	718	51	7.1%	10	19.6%
Practice Size (# of NPIs)	--	--	--	--	--
1	171,352	13,366	7.8%	8,504	63.6%
2-4	103,264	16,417	15.9%	9,342	56.9%
5-10	86,727	15,817	18.2%	9,062	57.3%
>10	335,320	67,474	20.1%	38,949	57.7%
Beneficiary Volume	--	--	--	--	--
≤ 25	213,248	6,046	2.8%	294	4.9%
26 - 100	156,383	17,548	11.2%	6,106	34.8%
101 - 200	116,276	22,756	19.6%	13,076	57.5%
> 200	210,079	66,047	31.4%	46,381	70.2%
Missing Data	677	677	100.0%	0	0.0%

Characteristics	Eligible Professionals	Eligible Professionals who Participated		Eligible Professionals who Qualified for an Incentive	
		Count	% of Eligible Professionals	Count	% of Eligible Professionals who Participated
Specialty	--	--	--	--	--
MD/DO	--	--	--	--	--
Primary Care	176,352	41,687	23.6%	29,797	71.5%
Surgery	58,199	5,457	9.4%	1,377	25.2%
Other Specialties	237,133	43,030	18.2%	24,876	57.8%
Other Eligible Professionals	--	--	--	--	--
Physicians	51,710	4,744	9.2%	1,570	33.1%
Physician Assistant	28,056	4,747	16.9%	2,002	42.2%
Nurses	48,736	7,992	16.4%	3,217	40.3%
Other Eligible Professionals	96,477	5,417	5.6%	3,018	55.7%
Unknown/Missing	718	51	7.1%	10	19.6%
Total (Unduplicated)	696,663	113,074	16.2%	65,857	58.2%

Notes for Table A34: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A35. Eligible Professional Information by State for the eRx Incentive Program (2010).

State or Territory	Eligible Professionals	Eligible Professionals who Participated	% of Eligible Professionals	Eligible Professionals who Qualified for an Incentive	% of Eligible Professionals who Participated that Qualified for an Incentive
Alaska	1,722	98	5.7%	38	38.8%
Alabama	8,397	1,325	15.8%	832	62.8%
Arkansas	5,413	1,017	18.8%	609	59.9%
Arizona	12,964	1,415	10.9%	818	57.8%
California	58,197	8,015	13.8%	4,724	58.9%
Colorado	10,481	1,339	12.8%	753	56.2%
Connecticut	11,259	1,874	16.6%	1,185	63.2%
<i>District of Columbia</i>	2,331	451	19.4%	229	50.8%
Delaware	2,233	459	20.6%	292	63.6%
Florida	40,578	7,729	19.1%	4,725	61.1%
Georgia	16,660	2,678	16.1%	1,737	64.9%
Hawaii	2,695	265	9.8%	166	62.6%
Iowa	6,305	1,632	25.9%	1,063	65.1%
Idaho	3,163	373	11.8%	201	53.9%
Illinois	27,791	4,606	16.6%	2,812	61.1%
Indiana	15,297	3,112	20.3%	1,746	56.1%
Kansas	6,955	1,165	16.8%	577	49.5%
Kentucky	10,150	1,338	13.2%	767	57.3%
Louisiana	9,014	879	9.8%	489	55.6%
Massachusetts	26,549	5,389	20.3%	3,150	58.5%
Maryland	14,825	2,015	13.6%	1,201	59.6%
Maine	5,359	874	16.3%	525	60.1%
Michigan	25,304	5,415	21.4%	3,293	60.8%
Minnesota	16,905	3,968	23.5%	1,829	46.1%
Missouri	13,397	2,707	20.2%	1,399	51.7%
Mississippi	4,921	635	12.9%	380	59.8%
Montana	2,410	290	12.0%	167	57.6%
North Carolina	21,589	4,302	19.9%	2,669	62.0%
North Dakota	1,763	88	5.0%	47	53.4%
Nebraska	4,770	656	13.8%	403	61.4%
New Hampshire	4,651	466	10.0%	288	61.8%
New Jersey	22,228	3,752	16.9%	2,276	60.7%
New Mexico	4,189	532	12.7%	306	57.5%
Nevada	4,227	427	10.1%	237	55.5%

State or Territory	Eligible Professionals	Eligible Professionals who Participated	% of Eligible Professionals	Eligible Professionals who Qualified for an Incentive	% of Eligible Professionals who Participated that Qualified for an Incentive
New York	58,848	7,599	12.9%	4,430	58.3%
Ohio	29,186	4,197	14.4%	2,274	54.2%
Oklahoma	7,266	901	12.4%	542	60.2%
Oregon	8,479	1,627	19.2%	862	53.0%
Pennsylvania	33,068	6,481	19.6%	3,664	56.5%
Rhode Island	3,342	510	15.3%	309	60.6%
South Carolina	8,672	1,191	13.7%	747	62.7%
South Dakota	2,240	398	17.8%	246	61.8%
Tennessee	14,903	2,611	17.5%	1,549	59.3%
Texas	39,898	5,976	15.0%	3,436	57.5%
Utah	5,133	498	9.7%	255	51.2%
Virginia	16,376	3,389	20.7%	1,958	57.8%
Vermont	2,083	213	10.2%	116	54.5%
Washington	15,184	1,609	10.6%	969	60.2%
Wisconsin	15,297	3,575	23.4%	2,069	57.9%
West Virginia	4,143	786	19.0%	403	51.3%
Wyoming	1,164	124	10.7%	66	53.2%
Other	5,971	52	0.9%	19	36.5%
<i>Unknown/Missing</i>	718	51	7.1%	10	19.6%
Total (Unduplicated)	696,663	113,074	16.2%	65,857	58.2%

Notes for Table A35: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting options.

Table A36. Eligible Professionals who Successfully met Reporting Criteria but did not Qualify for an Incentive Because they did not have at Least 10% of their PFS Charges from Instances for the eRx Measure (i.e., Incentive Eligibility Threshold) for the eRx Incentive Program (2009 to 2010).

Specialty	Not Meeting Incentive Eligibility Threshold			
	2009		2010	
	Count	% of Eligible Professionals who Successfully met Reporting Criteria	Count	% of Eligible Professionals who Successfully met Reporting Criteria
MD/DO	1,946	5.0%	971	1.7%
Allergy/Immunology	0	0.0%	3	0.9%
Anesthesiology	26	20.3%	4	3.7%
Cardiology	310	8.6%	175	3.2%
Colon/Rectal Surgery	2	3.2%	0	0.0%
Critical Care	22	16.3%	6	4.1%
Dermatology	85	9.8%	105	7.4%
Emergency Medicine	37	14.4%	5	2.1%
Endocrinology	2	0.4%	2	0.2%
Family Practice	55	0.7%	122	0.8%
Gastroenterology	61	6.4%	30	2.2%
General Practice	1	1.0%	2	0.8%
General Surgery	126	14.8%	17	6.9%
Geriatrics	11	4.8%	4	0.8%
Hand Surgery	2	2.0%	0	0.0%
Infectious Disease	64	26.1%	22	7.7%
Internal Medicine	291	3.8%	99	0.7%
Interventional Radiologist	14	60.9%	1	100.0%
Nephrology	162	23.1%	137	12.2%
Neurology	29	3.2%	11	0.9%
Neurosurgery	50	21.0%	11	13.6%
Nuclear Medicine	8	28.6%	2	7.4%
Obstetrics/Gynecology	13	1.0%	18	2.1%
Oncology/Hematology	9	0.7%	2	0.1%
Ophthalmology	45	1.1%	14	0.4%
Oral/Maxillofacial Surgery	1	25.0%	0	0.0%
Orthopedic Surgery	76	4.4%	11	1.2%
Other MD/DO	46	19.3%	23	10.4%
Otolaryngology	8	1.2%	5	0.5%
Pathology	7	70.0%	0	0.0%

Specialty	Not Meeting Incentive Eligibility Threshold			
	2009		2010	
	Count	% of Eligible Professionals who Successfully met Reporting Criteria	Count	% of Eligible Professionals who Successfully met Reporting Criteria
Pediatrics	3	2.0%	53	34.6%
Physical Medicine	38	10.9%	3	0.9%
Plastic Surgery	16	14.2%	0	0.0%
Psychiatry	26	8.2%	3	0.6%
Pulmonary Disease	41	5.5%	48	3.7%
Radiation Oncology	81	72.3%	8	66.7%
Radiologist	33	82.5%	1	50.0%
Rheumatology	1	0.2%	3	0.3%
Thoracic/Cardiac Surgery	91	63.6%	5	71.4%
Urology	9	0.8%	6	0.3%
Vascular Surgery	44	24.2%	10	18.5%
Other Eligible Professionals	623	5.3%	219	2.2%
Agencies/Hospitals/Nursing and Treatment Facilities	4	12.5%	4	10.5%
Audiologist	3	100.0%	0	0.0%
Certified Nurse Midwives	2	2.7%	2	18.2%
Chiropractor	0	0.0%	0	0.0%
Clinical Nurse Specialists	5	6.4%	0	0.0%
Counselor/Psychologist	5	5.3%	0	0.0%
Dentist	1	8.3%	0	0.0%
Dietitian/Nutritionist	4	17.4%	0	0.0%
Nurse Anesthetist	0	0.0%	0	0.0%
Nurse Practitioner	153	3.8%	74	2.4%
Optometry	0	0.0%	0	0.0%
Other Eligible Professional	147	6.2%	65	2.2%
Physical/Occupational Therapy	1	14.3%	1	14.3%
Physician Assistant	272	9.8%	66	3.2%
Podiatrist	17	3.2%	6	1.0%
Registered Nurse	9	7.3%	1	1.4%
Social Worker	0	0.0%	0	0.0%
Unknown/Missing	1	1.1%	11	52.4%
Total (Unduplicated)	2,570	5.1%	1,201	1.8%

Notes for Table A36: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry and EHR reporting option